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Tissue transglutaminase (tTG) is a protein-crosslinking enzyme whose 
expression is up-regulated in several human cancers. Here I show that tTG is a key 
participant in a novel EGFR/Src-signaling pathway and a potential target for inhibiting 
EGFR-promoted tumor progression. Specifically, EGF up-regulates tTG expression in 
human breast cancer cells, and knock-downs of tTG expression or the treatment of 
breast cancer cells with a tTG-specific inhibitor, blocks EGF-stimulated anchorage-
independent growth. The combined actions of Ras and Cdc42, lead to the activation of 
PI 3-kinase and NFκB, mediating the EGF-dependent up-regulation of tTG in breast 
cancer cells. Moreover, overexpression of wild-type tTG in these cancer cells, but not 
its enzymatically-defective counterpart, fully mimics the actions of EGF. Surprisingly, 
the tTG-promoted growth of breast cancer cells is dependent on its ability to activate 
Src, as an outcome of a complex formed between tTG and the breast cancer marker 
and intermediate filament protein keratin-19.  
Microvesicles (MVs) derived from human cancer cells are receiving a good 
deal of attention because of their ability to participate in the transfer of signaling 
proteins between cancer cells and to contribute to their invasive activity. Here I show 
that MVs may play another important role in promoting oncogenesis, as MVs shed by 
 two different human cancer cells, MDAMB231 breast cancer cells and U87 
glioblastoma cells, are capable of conferring transformed characteristics onto normal 
cells. I further show that tTG crosslinks fibronectin in MVs derived from cancer cells 
and that the ensuing MV-mediated transfer of both crosslinked-fibronectin and tTG to 
recipient cells function cooperatively to induce their transformation. This new role for 
MVs in cancer progression led to my investigating the signaling pathways that induce 
MV formation in cancer cells. These efforts resulted in the identification of a RhoA-
ROCK-LIMK signaling pathway that plays a critical role in directing the biogenesis of 
MVs in cancer cells. 
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CHAPTER 1 
 
Overview 
 
Introduction 
Tissue transglutaminase, or tTG, is a Ca2+-dependent acyltransferase that 
catalyzes the formation of new amide bonds between the -carboxamide of glutamine 
and the -amino group of lysine or another primary amine (i.e. transamidation) (1, 2). 
This protein crosslinking capability has been implicated in a wide range of cellular 
processes including neuronal growth and regeneration, bone development, wound 
healing, angiogenesis, cellular differentiation, and apoptosis (3-20). Interestingly, 
there is a growing appreciation of the roles played by tTG in the growth, survival, and 
migration of cancer cells, and it has been suggested that loss of the normal regulation 
of tTG may have significant consequences for the development of the malignant state 
(21-25). 
To better understand the multifaceted functions of tTG, we began by 
considering its structural features. What makes this protein particularly interesting 
from a structure-function perspective is the fact that it is not only capable of acyl-
transferase activity, but that it also exhibits GTP-binding and GTP-hydrolytic activity  
(26) and that there is a reciprocal relationship between its “G-protein-like functions” 
and its ability to catalyze protein crosslinking reactions (27). Indeed, the three-
dimensional structures for guanine nucleotide-bound tTG, and for tTG that has its 
transamidation active site accessible and capable of binding substrates, are 
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dramatically different (28, 29). This likely explains some of the marked differences in 
the cellular effects caused by GTP-binding-defective tTG mutants versus mutants that 
are defective for transamidation activity (4, 23, 30-34).  
With this structure-function perspective as a back drop, we will then describe 
some of the initial lines of study that have implicated tTG in cell survival, and then 
show how these findings have led to a growing appreciation that tTG has interesting 
and important roles in cancer cell biology. In particular, previous work from our 
laboratory suggested that tTG helps ensure that cells remain viable during their 
differentiation (19, 20). This is a potentially important function because factors that 
normally cause cell-cycle arrest and differentiation can also trigger apoptotic programs 
and so it is necessary that these factors induce the expression and activation of 
additional gene products that can provide protection against apoptotic stresses (35). 
tTG appears to be one such protein, so that when cells receive signals triggering 
growth-arrest, the up-regulation of tTG expression occurs in order to help to tip the 
balance toward differentiation rather than cell death (19). From these initial results, we 
then went on to discover that the ability of tTG to confer a survival response in cells 
extends beyond those conditions leading to cellular differentiation and in fact 
contributes to the ability of mitogenic stimuli such as EGF to provide a survival 
advantage to human breast cancer cells (36-38). Moreover, we went on to find that 
tTG also plays roles in stimulating the ability of human breast cancer cells to grow in 
the absence of a substratum (i.e. anchorage-independent growth) (39) and that it plays 
an important role in the EGF-stimulated migration and invasive activity of cancer cells 
(40). These various studies will be elaborated upon further in the sections below.  
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 Catalytic mechanism of tTG 
tTG catalyzes the transamidation reaction between two substrates, a glutamine-
containing protein substrate 1 and a lysine-containing protein substrate 2 or a 
polyamine, through the cooperation of a protease-like catalytic triad Cys277, His335 
and Asp358 (41). Similar to the cysteine protease family (42), the catalytic process is 
comprised of two steps: the transient acylation of Cys277 by its nucleophilic attack on 
the glutamine side-chain of substrate 1 to form an acyl-thiolate intermediate, and the 
subsequent deacylation of Cys277 by the nucleophilic attack from the amino group of 
substrate 2, leading to the release of cross-linked products from the catalytic site (1, 43, 
44). Specifically, as the first step, His335 attacks Cys277 to create a thiolate–
imidazolium ion pair, with the help of Asp358 to counterbalance the positive change 
on His335 through its carboxylate group formed under conditions of physiological pH 
(44). The glutamine side-chain of substrate 1 approaches the vicinity of Cys277 and is 
attacked by the thiolate ion, resulting in the formation of an acyl-thiolate intermediate, 
accompanied by the release of an ammonia molecule (1, 43, 45). Because of the high-
energy consumption required to produce the tetrahedral adduct, the formation of an 
acyl-thiolate intermediate is the rate-limiting step of the transamidation reaction (2). 
The amino group of the second substrate then generates the amide ion by its 
interaction with the nearby His335 and Asp358 through the same mechanism as in the 
first step, and then participates in a nucleophilic attack on the acyl-thiolate 
intermediate (1, 43). The formation of the tetrahedral adduct in this step involves a  
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 Figure 1.1 Mechanism of tTG-catalyzed transamidation reaction. First, a 
thiolate anion is formed at the side chain of Cys277, which then attacks the 
glutamine group of substrate 1. Release of ammonia occurs after the proton 
donation from His335, which creates an acyl-thiolate intermediate. Next, the lysine 
side chain of substrate 2 approaches the catalytic site and undergoes a nucleophilic 
attack upon the intermediate, leading to the formation of a tetrahedral adduct and 
the subsequent release of the cross-linked product. As a result, substrates 1 and 2 
are covalently linked to each other through a newly-formed peptide bond. 
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low-energy barrier, therefore the specificity of the attacking amino group is not high 
(45). It either comes from a protein-bound lysine residue or a small polyamine 
compound (2). Finally, the break-down of the tetrahedral adduct leads to the release of 
the cross-linked product, while restoring the catalytic triad and completing the 
transamidation reaction (44, 45). The detailed mechanism is illustrated in Figure 1.1. 
 
A comparison between the active and inactive conformation of tTG 
Although the catalytic mechanism of tTG was clarified several years ago, how 
the non-core residues cooperate to facilitate and regulate the transamidation activity 
has been less clear. Efforts to address this issue led to the sequence alignment between 
tTG and Human factor XIIIA, a hetero-tetrameric transglutaminase-family member 
implicated in blood coagulation (46). The X-ray crystal structure of the human 
recombinant, dimeric fXIIIA2 was determined in 1994 (47), and sequence homology 
between XIIIA and tTG predicted that tTG probably folded into four sequential 
domains: an N-terminal -sandwich domain, the central catalytic core domain, and 
two -barrel domains at the C-terminal end of this protein (48). This result was 
confirmed by the first tTG structure that was solved in 2002 at 2.8 Å resolution, which 
showed that tTG was folded as a “closed” or inactive conformation (28). In this 
structure, the carboxylic group of Asp358 formed a hydrogen bond with the imidazole 
ring of His335, and the hydroxyl group of Cys277 was positioned close to His335, 
waiting to generate the thiolate–imidazolium ion pair through the resonant cooperation 
of the catalytic triad. This structure was thought to be catalytically inactive because of 
the inaccessibility of its catalytic core to the outer environment (28). The proposed  
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Figure 1.2 The structural superimposing and comparison of inactive tTG to 
active tTG. The overall structure of inactive tTG (PDB ID: 1KV3) is shown in 
dark grey color and the overall structure of active tTG (PDB ID: 2Q3Z) is shown 
in light grey color. Both of them have a -sandwich domain, a catalytic core 
domain and two -barrel domains arranged from the N-terminal end to the C-
terminal end. The N-terminal -sandwich domains of these two structures are 
superimposed, highlighting the conformational change at the C-terminal end. The 
arrow indicates the 120° swing angle of the C-terminal -barrel domains when 
tTG changes from its inactive conformation to its active conformation. 
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substrate entrance was blocked by two loops within the first -barrel domain at the C-
terminal end of tTG. Most importantly, Tyr516, which is located within this loop 
region, formed a tight hydrogen bond with the hydroxyl group of Cys277, thus 
negating the catalytic activity (28). As a result, a plausible hypothesis for tTG 
activation involves the withdrawal of the two loops from the catalytic core, and the 
concomitant disruption of the hydrogen bond between Cys277 and Tyr516 (28). This 
hypothesis was confirmed by the more recently determined tTG structure in its “open” 
state, where the active conformation of tTG was, in effect, trapped by incubating this 
enzyme with an inhibitor that mimicked its gluten peptide substrate (29). Surprisingly, 
the inhibitor stabilized tTG in a conformation that significantly differed from its 
“closed” state (Figure 1.2). The N-terminal superimposition of the “open” and 
“closed” tTG structures revealed that the loops containing Tyr516 move away from 
the catalytic core region when the enzyme is in an active conformation, but with an 
unexpected swing angle of 120 degrees. How tTG achieves these dramatic structure 
changes is not yet fully understood.  
Another significant finding associated with the “open” structure of tTG was the 
visualization of the “tryptophan tunnel” (29). Based on the comparison of the active 
sites between tTG and the structurally related cysteine proteases, Trp241 of tTG was 
proposed to be a critical residue for catalyzing the transamidation reaction through its 
ability to stabilize the first transition-state intermediate (49, 50). Consistent with this 
idea, Cys277 was found to be located within a hydrophobic tunnel bridged by Trp241 
and Trp332, where the glutamine-containing substrate was proposed to enter from one  
9 
 Figure 1.3 The “tryptophan tunnel” Trp241 and Trp332 bridges the access of 
the two substrates to the catalytic site of tTG. Trp241 and Trp332, as well as the 
catalytic triad Cys277, His335, and Asp358 of tTG, are displayed in stick mode, 
and all the other residues are drawn in opaque ribbon mode. Inactive tTG is 
presented in dark grey while active tTG is presented in light grey, which are 
superimposed through the alignment of respective N-terminal -sandwich domain. 
The two arrows within the figure point out the approaching track of the glutamine-
containing substrate and the lysine-containing substrate to tTG’s catalytic site, 
respectively. 
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side, while the lysine-containing substrate entered from the opposite side (Figure 1.3). 
Substitution of Trp241 with Ala or Gly caused a more than 300-fold decrease in the 
catalytic rate constant (50), demonstrating the critical role of this tryptophan tunnel for 
transamidation activity.  
 
Function of tTG as a G-protein 
In 1992, Graham and his co-workers made the unexpected finding that rat tTG 
was involved in receptor-coupled signal transduction by functioning as a classical 
GTP-binding protein (G-protein), specifically, through its ability to mediate agonist-
induced signaling events from the 1B/D-adrenergic receptor to its downstream effector 
phospholipase C 1 (PLC1) (26). Subsequently, tTG was shown to mediate the 
activation of Ca2+-activated K+ channels in vascular smooth muscle cells (51). What 
made these findings particularly surprising was that the primary sequence of tTG did 
not contain any of the conventional guanine nucleotide-interacting motifs featured in 
the small or large G-proteins (52). However, the intrinsic ability of tTG to bind 
GDP/GTP and hydrolyze GTP to GDP argues that it contains a unique guanine 
nucleotide-interacting pocket which lacks obvious sequence similarity with those of 
the classical G-proteins. This was confirmed when the three dimensional structure for 
the “closed” conformation of tTG was determined, where one molecule of GDP was 
found to bind and co-crystalize with the inactive form of tTG (28). In large G-proteins, 
the G subunit often contains a helical domain adjacent to its guanine nucleotide-
binding region to ensure the high affinity binding of guanine nucleotides, whereas 
small G-proteins lack the helical domain and instead use a bound Mg2+ ion to  
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Figure 1.4 The interaction of GDP with four positive-charged residues from 
tTG. Lys173, Arg476, Arg478, and Arg580 from inactive tTG and the bound-
GDP are shown in stick mode. The remaining residues are shown in opaque ribbon 
mode. The four positive-charged residues are displayed in light grey while GDP is 
drawn in dark grey. The hydrogen bonds are shown as dashed lines. 
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 strengthen nucleotide-binding (53, 54). However, neither of these classical features 
was present in the tTG structure. Instead, surrounding the bound GDP molecule was a 
sequence of positive-charged residues (28), which were assumed to contribute to 
nucleotide-binding (Figure 1.4). These residues were located within the first -strand 
and the following loop region of the first C-terminal -barrel domain. Perhaps the 
most important of these residues was Arg580, which formed three hydrogen bonds 
with the guanine ring, the -phosphate, and the -phosphate of the GDP molecule, 
respectively (28). Substitutions at the corresponding position in rat tTG (Arg579) 
resulted in as much as a 100-fold reduction in GTP-binding affinity, as determined by 
isothermal titration calorimetry (55). In addition to Arg580, two other residues, 
Arg476 and Arg478, also helped properly position the GDP molecule in the pocket, 
through the formation of two hydrogen bonds between Arg478 and the -phosphate 
group, and a single hydrogen bond contributed by Arg476 to the -phosphate (28). 
The Arg476Ala and Arg478Ala substitutions attenuated the photo-affinity labeling of 
tTG with radioactive GTP, thus indicating that these residues contributed to the 
binding of guanine nucleotides (55). In addition to these three arginine residues that 
made direct contact with GDP, Lys173 was another positive-charged residue that drew 
significant attention. Changing Lys173 to asparagine did not alter the ability of tTG to 
bind guanine nucleotides, but it greatly impaired its GTP-hydrolytic capability (56). A 
plausible mechanism underlying this effect was that Lys173 plays an essential role in 
catalyzing GTP hydrolysis. Specifically, the fact that the -phosphate group of GDP 
interacts with Arg476, Arg478 and Arg580 led to the prediction that the -phosphate 
group of GTP needed to point away from the arginine pocket in order to avoid steric 
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clash. Lys173 would presumably function to stabilize the transition-state for the GTP-
hydrolytic reaction, because it is located close to the predicted position of the -
phosphate group. An examination of the GTP hydrolysis-deficient Lys173Asn mutant 
in cells resulted in an interesting finding, namely, that the ability of tTG to mediate 
signals from the -adrenergic receptor to PLC was independent of its GTP-
hydrolysis capability (26, 56). This conclusion was demonstrated by the fact that the 
tTG Lys173Asn mutant stimulated the production of similar levels of inositol 
phosphate (i.e. the product of PLC) as wild-type tTG in COS-1 cells co-transfected 
with 1B-adrenergic receptor (26, 56). On the other hand, the Ser171Glu mutation in 
tTG, which disrupted the GTP-binding capability, as well as the Arg580Lys mutation 
seriously impaired the production of inositol phosphates in COS-1 cells, indicating 
that the guanine nucleotide-binding activity of tTG was necessary for mediating the 
signals from the -adrenergic receptor (56).  
 
The role of tTG as a protective factor in cellular differentiation 
While there is now a growing appreciation for tTG in the progression of 
various types of human cancer (22-24, 39, 40, 57-59), as little as nine years ago this 
was far from the case. In fact, at that time tTG was widely considered as a protein that 
was important for either triggering the induction of apoptosis (18, 60-65) or for 
promoting cellular differentiation (14, 66-68), two cellular processes that are 
paradoxical with the development of the oncogenic state. The evidence implicating 
tTG as a regulator of cell death stemmed largely from a line of research being 
conducted at that time aimed at understanding the molecular mechanisms that underlie 
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the onset/progression of a class of neurodegenerative disorders, in particular 
Alzheimer’s disease (AD), Huntington’s disease (HD), and Parkinson’s disease (PD), 
that are characterized by the presence of insoluble protein aggregates (69). In each of 
these disease states, the size and number of protein aggregates detected in the brains of 
affected individuals tend to increase with the severity of the disease, and protein 
aggregation has been suggested to directly contribute to neuronal cell dysfunction and 
death (70, 71). Interestingly, high levels of tTG expression and its enzymatic 
transamidation activity have been identified as hallmarks of AD, HD, and PD (72-76). 
Moreover, tTG was shown to cross-link components of the protein aggregates 
associated with each of these diseases (73, 75, 77-79). These findings, when coupled 
with the fact that inhibiting tTG-catalyzed transamidation activity suppresses protein 
aggregation and extends the lifespan of mouse models of HD and PD (77, 79, 80), 
provided some of the earliest and most intriguing data suggesting that tTG participated 
in the induction of cell death through the aberrant cross-linking of substrate proteins. 
In addition to tTG being up-regulated in response to a variety of apoptosis-
inducing cellular stresses (i.e. stressful conditions encountered by cells in 
neurodegenerative diseases), increases in its expression and activation were also 
shown to accompany cellular differentiation. For example, treatment of the human 
neuroblastoma cell line SH-SY5Y with the differentiation agent retinoic acid (RA) 
arrests their growth and stimulates the formation of neurite extensions (81, 82), 
making them a useful cell type to identify proteins which are important for neuronal 
differentiation. tTG was identified as one such protein (14, 66, 83). Not only was tTG 
expression and transamidation activity found to be significantly enhanced in SH-
17 
SY5Y cells by RA stimulation, but inhibiting RA-induced tTG expression using an 
anti-sense construct blocked the ability of RA to arrest cell cycle progression, as well 
as to promote neurite extension (66). The study then went on to show that the ectopic 
expression of wild-type tTG in SH-SY5Y cells, but not a transamidation-defective 
form in which a cysteine residue within the catalytic triad of the enzyme active site 
was changed to a valine (tTG C277V), was sufficient to cause these cells to 
spontaneously undergo differentiation. Thus, these findings demonstrated that 
induction of tTG expression and activity in cells does not invariably result in cell 
death, but rather tTG may in certain contexts also promote cellular differentiation.   
Our laboratory’s interest in the functional consequences of tTG expression and 
activation started at about the same time that accumulating evidence, like those 
findings described above, were leading to the general belief that tTG participated in 
biological processes that resulted in apoptosis, and in a few instances limited cell 
growth through arresting the cell cycle. We were investigating the effects that the 
naturally occurring retinoid RA, as well as other synthetic retinoid analogs had on cell 
fate decisions. This question was particularly relevant at that time, since the growth 
inhibitory and differentiation activities associated with RA were prompting several 
research groups to examine the use of RA or RA-like synthetic derivatives as potential 
treatments for different types of human cancers ranging from prostate cancer to 
leukemia (84-87). Our laboratory, as well as other groups, was able to show that 
treatment of the human leukemia cell line HL60 with RA did indeed inhibit their 
growth (19, 88, 89). However, when the same cell line was cultured in the presence of 
a synthetically-derived analog that differs from RA by only the addition of a phenol 
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ring to its carbon backbone, and is referred to as N-(4-hydroxyphenol) retinamide 
(HPR or fenretinide), instead of inducing cell cycle arrest as is the case for RA, HPR 
elicited a potent apoptotic response in these cells (19, 90-92). Likewise, HPR was also 
found to be much more effective than RA at inducing cell death in NIH3T3 mouse 
fibroblasts (19), indicating that the abilities of these retinoids to differently influence 
cell fate decisions were not unique to a specific cell lineage.  
How the highly related retinoid analogs RA and HPR gave rise to opposing 
cellular outcomes, such that RA promotes cell survival whereas HPR induces 
apoptosis, was puzzling and led us to consider possible mechanisms that could account 
for these effects. We obtained a clue as to how this may occur when we examined the 
effectiveness of HPR at inducing apoptosis in both HL60 leukemia cells and NIH3T3 
fibroblasts that had first been stimulated with RA for different lengths of time (19). 
While short-term RA pre-treatments (up to 6 hours) caused little, if any, change in the 
ability of HPR to induce apoptosis in these cells, longer pre-treatments with RA did 
have effects. For example, HL60 and NIH3T3 cells that had been pre-incubated with 
RA for two days prior to being challenged with HPR became highly resistant to the 
apoptotic-inducing actions of HPR. Since pre-treating the cells with RA for extended 
lengths of time (on the order of days) was required in order to see the protective 
effects against HPR-induced apoptosis afforded by RA treatment, we began to favor 
the idea that RA-signaling might induce the expression of a distinct gene or set of 
genes that is crucial for ensuring cell viability during cellular differentiation.  
While searching for potential candidate genes that were selectively up-
regulated by RA, we considered tTG since the induction of its expression was already 
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known to be tightly coupled to the effects of RA-signaling in HL60 cells (88, 89), as 
well as some other cell types (i.e. SH-SY5Y cells) (14, 66, 83). In un-stimulated HL60 
leukemia cells and NIH3T3 mouse fibroblasts, tTG is expressed at very low or almost 
undetectable levels (19, 62, 93). However, following the addition of RA to the cells, 
there was a progressive increase in the levels of tTG expression, with maximal 
expression being reached in both cell lines between 2-3 days after RA treatment (19). 
We then questioned how treating cells with HPR would influence tTG expression. In 
contrast to RA, HPR was found to be completely ineffective at increasing tTG 
expression levels beyond the nearly undetectable levels measured in un-stimulated 
HL60 or NIH3T3 cells. These findings not only identified the induction of tTG 
expression as a distinguishing feature between the signaling capabilities of RA and 
HPR, but they also opened the door to the possibility that tTG may be important for 
mediating the ability of RA to protect cells from HPR-induced apoptosis. This indeed 
appears to be the case, as ectopically expressing tTG in NIH3T3 cells was as effective 
as RA treatment at protecting the cells from challenges with HPR. Perhaps even more 
telling of the potential significance that tTG has in promoting cell survival came from 
another experiment in which its transamidation activity was blocked using 
monodansylcadaverine (MDC), a competitive inhibitor of the transamidation reaction, 
during the RA-induced differentiation of HL60 cells. Rather than undergoing cell 
cycle arrest and stimulating the formation of neurite extensions as occurs with RA 
treatment alone, RA treated HL60 cells cultured in the presence of MDC instead 
underwent apoptosis. These findings suggested for the first time that tTG can serve as 
a protective factor, particularly in cells that are undergoing differentiation. In these 
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instances, tTG expression and its corresponding transamidation activity are induced by 
RA to ensure that cells that are exiting the cell cycle as part of the cellular 
differentiation process survive without undergoing apoptosis. 
 
tTG and chemotherapy-resistance 
In addition to establishing a novel and unexpected role for tTG in maintaining 
the viability of HL60 leukemia cells and NIH3T3 fibroblasts undergoing RA-induced 
cellular differentiation (19), these initial findings also laid the foundation for 
subsequent investigations into whether tTG might provide a protective effect to cells 
under a number of other conditions. One area of study that has been developing 
rapidly over the last few years is the relationship between tTG and drug resistance in 
human cancer cells. Screening several different types of primary human tumor 
samples by immunohistochemistry for tTG expression has revealed that its expression 
levels are increased in a significant percentage of breast, pancreatic, ovarian, and brain 
tumors (19, 22, 24, 59, 94-96). Moreover, breast and pancreatic cancer cell lines that 
are resistant to chemotherapies also tend to have the highest levels of tTG expression 
and transamidation activity (38, 57, 59, 97, 98), suggesting that tTG may contribute to 
the drug-resistant phenotypes exhibited by some cancer cells. A case in point is the 
highly aggressive and chemotherapy-insensitive human breast carcinoma cell line 
MDAMB231. These cells constitutively express high levels of tTG, and when extracts 
from the cells were assayed for transamidation activity, it was determined that tTG 
was active (23, 38). Knocking-down tTG expression in these cancer cells using small 
interfering-RNAs (siRNAs) was found to be sufficient to sensitize them to the 
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chemotherapeutic agent doxorubicin (23). Likewise, treating MDAMB231 cells with 
the transamidation inhibitor MDC also made the cells susceptible to doxorubicin-
induced apoptosis (38), indicating that the cross-linking activity of tTG is likely 
responsible for mediating its protective effects.  
The notion that tTG provides a survival advantage to human cancer cells was 
further strengthened by demonstrating that the pro-survival signaling capabilities of 
the epidermal growth factor (EGF)-receptor are dependent on tTG in some cancer cell 
lines (38, 39). The EGF-receptor (EGFR) is a cell surface receptor tyrosine kinase that 
has been extensively investigated for its roles in promoting tumorigenesis (99-101). 
Upon binding EGF, the EGFR becomes activated and initiates the activation of 
numerous intracellular signal transduction pathways that work in concert to directly 
influence cellular processes, as well as to induce the expression of a specific set of 
genes that promote cancer cell growth and survival (99-101). The interplay that exists 
between EGFR-signaling and tTG in cancer cells was discovered when it was shown 
that the levels of tTG expression and its corresponding transamidation activity were 
markedly enhanced in the human breast cancer cell line SKBR3 after EGF stimulation 
(38). Consistent with the findings that RA-induced tTG activation protects HL60 
leukemia cells and NIH3T3 fibroblasts from apoptotic challenges (19), inhibiting the 
EGF-stimulated transamidation activity of tTG using MDC also abolishes the ability 
of the EGFR to protect cells from doxorubicin-induced apoptosis, as well as from 
serum-deprivation-induced apoptosis (38, 39). Although it is currently unclear how 
often and in which cancer cell types the EGFR elicits a survival response by up-
regulating tTG expression and activation, two additional pieces of evidence suggest 
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that this signaling mechanism is not limited to just SKBR3 breast cancer cells. First, it 
was shown that EGF stimulation was capable of potently inducing the expression and 
activation of tTG in two additional breast cancer cell lines, namely BT20 and 
MDAMB468 cells (38). Second, tTG was identified in a screen as one of the most 
highly up-regulated genes in a U87 brain tumor cell line that exogenously expresses a 
constitutively active mutant form of the EGFR (102). Thus, the coupling of EGFR-
signaling to the induction of tTG expression and activation may be a common 
occurrence in human cancers, particularly in those cancer cells whose oncogenic 
potential is dependent on EGFR-signaling activities. Taken together, these findings 
suggest that the up-regulation of tTG expression and activation in human tumors 
represent a critical step during cancer progression where tumor cells are transitioning 
to a high grade, drug-resistant phenotype.  
 
How does tTG promote cell survival? 
In those cases where tTG has been implicated as a protective factor in both 
normal and cancer cells, its enzymatic transamidation activity has been shown to be 
essential (19, 24, 38, 39, 57, 97, 102). As a result of these findings, it should come as 
no surprise to learn that an important emphasis in the field has been to determine the 
identities of those proteins that are cross-linked by tTG to elicit survival responses in 
cancer cells. While virtually hundreds of proteins have been shown to serve as 
putative substrates for the transamidation activity of tTG using in vitro and high-
throughput screening approaches (103, 104), determining which, if any, of these 
proteins are physiologically relevant substrates in different cellular contexts has 
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proven to be far more challenging. However, recent results have highlighted two 
proteins, that when covalently modified by tTG, can have significant implications on 
cell viability. The first is caspase-3 (also referred to as CPP32, YAMA, and apopain) 
(105), an important component of the apoptotic-inducing machinery in cells (106). 
Caspase-3, as well as the other members of the caspase family, is a cysteine protease 
that is expressed in cells as an inactive, proto-form of the enzyme. However, when a 
cell commits to undergoing programmed cell death or apoptosis, it initiates an 
irreversible activation of the caspase pathway which involves a series of cleavages that 
result in the conversion of inactive pro-caspases to active, functional caspases. Once 
activated, caspase-3 catalyzes the specific cleavage of several key proteins that are 
essential for maintaining cell viability, which results in cell death.  
The findings showing that tTG can cross-link caspase-3 as a way to promote 
cell survival came from a study that was investigating how a HCT-116 colon 
carcinoma cell line that lacked Bax expression was insensitive to the apoptotic-
inducing effects of thapsigargin (THG), an inhibitor of the endoplasmic reticulum 
Ca2+-ATPase (105). The authors found by Western blot analysis that exposing Bax-
deficient HCT-116 cells to THG for increasing lengths of time resulted in the 
progressive appearance of unusually high molecular weight forms of pro-caspase-3. 
Since the catalytic activity of tTG has been shown to induce the oligomerization of 
several different proteins (73, 75, 77, 79, 107), the ability of tTG to induce the 
oligomerization of pro-caspase-3 was examined as a possible explanation for the 
higher molecular weight forms of pro-caspase-3 detected in the cells treated with THG. 
Not only was it shown that THG potently induced tTG expression and activation in the 
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Bax-deficient HCT-116 colon carcinoma cells, but a recombinant form of pro-capase-
3 could also be cross-linked by tTG in vitro (105). This raised the question of whether 
blocking the ability of tTG to cross-link proteins in THG-treated HCT-116 cells would 
influence the formation of the higher molecular weight species of pro-caspase-3, as 
well as sensitize these cells to THG. Indeed, knocking-down tTG expression using 
siRNA approaches or incubating HCT-116 cells with the tTG inhibitor MDC caused a 
significant reduction in the ability of THG to induce the formation of the larger forms 
of pro-caspase-3 (105). Coinciding with this effect, MDC treatment also made the 
cells susceptible to THG-induced apoptosis, indicating that tTG affords a protective 
effect to HCT-116 colon carcinoma cells from THG-induced apoptosis by cross-
linking an important component of the cell death machinery, namely caspase-3, into 
non-functional oligomers (105).  
The inhibitor of B (IB), a regulatory protein in the Rel/nuclear factor 
(NF)B survival pathway, is the second example of a protein that can be cross-linked 
by tTG to potentiate cell survival (22). The central player in the NFB survival 
pathway is NFB itself, a transcription factor that can be rapidly and transiently 
activated by a variety of growth factors, and especially in response to harmful cellular 
stresses, to induce the expression of specific genes that promote cell survival, as well 
as cell growth (108, 109). The transcriptional activity of NFB in un-stimulated cells 
is normally kept in check because NFB is sequestered in the cytoplasm where it is 
found in a complex with its negative regulator IB (109). For NFB to become 
activated by extracellular stimuli, a complex sequence of events must take place that 
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results in the phosphorylation of IB on two serine residues contained within its 
regulatory domain. This phosphorylated form of IB is then ubiquitinated and 
targeted for degradation in the proteosome. Once IB is degraded, NFB is free to 
translocate from the cytoplasm to the nucleus where it functions to regulate the 
expression of various genes (109). While many of the genes up-regulated by NFB 
promote cell survival and cell growth responses, NFB also rapidly induces the 
expression of its own negative regulator IB, ensuring that NFB activity is tightly 
controlled in normal cells (109).  
Aberrant activation of the NFB survival pathway has emerged as a hallmark 
of human cancers (109-112). Moreover, inactivating NFB by siRNA knockdown or 
using NFB inhibitors has been shown to block the growth and survival advantages 
associated with numerous cancer cell lines (109, 113), suggesting that de-regulation of 
the NFB pathway may represent an important step during cancer progression. While 
searching for the mechanisms used by cancer cells to excessively stimulate NFB 
activation, a connection with tTG emerged. It was noted that a strong correlation 
existed between the levels of tTG expression and the amount of constitutive NFB 
activity detected in aggressive and drug-resistant forms of breast cancer cells (i.e. 
MDAMB231 cells), malignant melanoma cells (i.e. A375 cells), and pancreatic cancer 
cells (i.e. Panc-28 cells), as well as in primary pancreatic tumors (22). When the 
transamidation activity of tTG, associated with the Panc-28 pancreatic cancer cells, 
was inhibited by knocking-down tTG using siRNAs or treating the cells with MDC, 
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there was a corresponding reduction in NFB activity, indicating that NFB activation 
in Panc-28 cells is dependent on the catalytic function of tTG (22) . 
So how does the transamidation activity of tTG stimulate NFB activity?  It 
appears to most likely involve the ability of tTG to cross-link IB, the critical 
negative regulator of NFB activity. In support of this idea, tTG was found to induce 
the covalent oligomerization of IB both in vitro and within the Panc-28 cell line (22, 
114). Interestingly, the recombinant form IB that was cross-linked by tTG was 
shown to bind NFB more weakly than its non-cross-linked counterpart, suggesting 
that this tTG-induced modification of IB in cells functionally inactivates IB, 
resulting in the constitutive activation of NFB (114). In line with these findings, a 
separate study looking at how tTG provides a protective effect to ovarian cancer cells 
challenged with the chemotherapeutic agent cisplatin also concluded that the tTG-
stimulated chemo-resistance seen in these cancer cells was dependent on its ability to 
stimulate the activation of the NFB survival pathway (97). Thus, it appears that the 
survival effects of tTG are coupled to NFB activation in a number of cancer types.  
Determining the mechanisms that give rise to drug-resistance in cancer cells is 
extremely important for the development of more effective strategies to treat patients 
with advanced forms of cancer. The increasing amounts of evidence showing that tTG 
expression and activation is frequently up-regulated in human cancers as a means of 
protecting cells from harmful cellular stresses (24, 38, 57, 59, 97, 98), has provided 
significant insights into how cancer cells become insensitive to chemotherapies. Thus, 
targeting tTG itself or its associated effects may prove to be an important strategy to 
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treat cancer patients with advanced and/or chemotherapy-insensitive forms of the 
disease. 
 
The role of tTG in cancer cell migration and invasion 
Directional cell migration is a fundamental cellular process that is required for 
proper embryonic development, tissue homeostasis, and immune responses in animals 
(115, 116). In order for a cell to efficiently migrate it must coordinate the activation 
and distribution of signaling molecules with changes in its actin-cytoskeleton network 
and plasma membrane. Although directional cell migration is a highly complicated, 
cyclic process that is still far from being completely understood, the general principles 
underlying cell migration are known (116). To migrate, a cell must first take on a 
polarized morphology, such that it has a front or leading edge (for forward movement) 
and a back (for retraction). Actin polymerization-dependent protrusions are then 
extended from the leading edge and make contact with the extracellular matrix. These 
newly formed sites of cell adhesion function to anchor the protrusions, allowing the 
body of the cell to shift forward. Cell contraction at the back end of the cell, as an 
outcome of actin bundling and de-polymerization, completes one cycle of the cell 
migration process. By repeating this sequence of events, a cell moves from one site to 
another (116). 
Aside from its physiological relevance, cell migration is also a major factor in 
the development or progression of several different human pathologies, ranging from 
cardiovascular disease to cancer (115). For example, during tumor progression a 
subset of the cancer cells found within the primary tumor mass often acquire the 
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ability to move into or invade neighboring normal tissue. Tumors that exhibit this type 
of invasive behavior tend to be more aggressive in nature and correlate with a poor 
patient prognosis (115). Interestingly, tTG has recently been implicated as an 
important contributor to the migratory and invasive phenotype of human cancer cells 
(23, 25, 40, 58, 59, 96, 117).   
One of the earliest indications that tTG is associated with cancer cell migration 
and tumor dissemination came from proteomic screens performed on primary and 
metastatic human lung and breast tumors, where tTG was identified as one of only 
eleven proteins that were consistently up-regulated in metastatic tumors (118). These 
findings were then followed up with a study that investigated the possible link 
between the constitutively expressed and activated tTG found in the human breast 
cancer cell line MDAMB231 and the excessive migration and invasive activity 
exhibited by these cells (23). Experiments performed comparing the migration and 
invasive capability of the parental MDAMB231 cells to a sub-line that was selected 
for its greatly reduced levels of tTG expression, revealed that tTG was required for 
MDAMB231 cells to exhibit these aggressive properties. The authors then went on to 
show that tTG was present at the plasma membrane of MDAMB231 cells where it was 
bound to 1, 4, and 5 integrins, members of a family of cell surface receptors that 
primarily function to attach cells to specific components in the extracellular matrix (i.e. 
fibronectin) and to promote cell migration (119, 120). tTG has been shown to interact 
with specific members of the integrin family in a variety of normal and cancer cell 
types (31, 96, 121), suggesting that its ability to interact with proteins that function in 
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cell attachment may likely contribute to its ability to stimulate cancer cell migration 
and invasion. 
Signals that originate outside of the cell can play critical roles in directional 
cell motility. For example, simply adding growth factors like EGF to the culturing 
medium of normal fibroblasts or to HeLa cervical carcinoma cells can induce or 
enhance the ability of these cells to migrate (122, 123). These findings, combined with 
the fact that accumulating evidence suggests that the EGFR contributes to tumor 
invasion and metastasis (124-126), has generated a considerable amount of interest in 
determining the molecular mechanisms that link EGFR activation to the changes that 
cells must undergo in order to allow them to migrate and invade. 
Our laboratory has recently implicated tTG as an important mediator of EGF-
stimulated cancer cell migration and invasive activity (40). These studies stemmed 
from our long-standing interest in understanding how activation of the EGFR both 
initiates and orchestrates intracellular signaling events that give rise to cellular 
phenotypes that are characteristic of the oncogenic or transformed state. In this 
particular case, we set out to identify proteins that coupled the ability of the activated 
EGFR to give rise to an enhanced migratory and invasive capability in the human 
cervical carcinoma cell line HeLa. HeLa cell cultures exposed to EGF acquire the 
distinctive polarized cell morphology associated with actively migrating cells; with 
each cell having formed both a front or leading edge and a back. Since proteins that 
are localized to leading edges have consistently been shown to contribute to cell 
motility (115, 116), we began to look for proteins that accumulated at the leading 
edges of EGF-stimulated HeLa cells as a means to identify novel participants in cell 
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migration. Due to the earlier findings showing that tTG was vital for the aggressive 
phenotype exhibited by MDAMB231 breast cancer cells (23), we considered tTG as a 
possible candidate protein. Immunofluorescent studies carried-out on untreated HeLa 
cells revealed that tTG was primarily expressed throughout the cytoplasm of these 
cells (40). However, EGF treatment caused a dramatic change in the sub-cellular 
localization of tTG, such that it could be readily detectable in the leading edges of 
cells. Moreover, we found that EGF promotes the activation of tTG in HeLa cells, 
without having a significant effect on its expression, suggesting that tTG might play 
an important role in EGF-promoted cell migration (40). Indeed, treating HeLa cells 
with the tTG inhibitor MDC, or knocking-down tTG expression by siRNA, potently 
inhibited the migration- and invasion-promoting effects of EGF (40). Interestingly, 
however, MDC treatment appeared to have no effect on serum-induced HeLa cell 
migration, raising the possibility that tTG may not play a general role in cell migration, 
but rather is a specific component of the EGF-signaling pathway that promotes the 
motility of these cancer cells. 
While these findings identify tTG as a crucial regulator of EGF-stimulated cell 
migration and invasion, they also raise a number of additional questions. The foremost 
of these being, what are the proteins that are covalently modified by tTG to promote 
cell migration and/or invasion? It is especially tempting to speculate that tTG is 
recruited to the leading edges of cells in order to cross-link another protein or specific 
set of proteins that are also present at the leading edge during cell migration. The 
cross-linking of these proteins by tTG would most likely affect their function in such a 
way as to allow EGF-stimulated cell migration to occur. However, we also recognize 
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the possibility that tTG might contribute to the development of the invasive/metastatic 
phenotype in cancer cells through additional mechanisms. In support of this idea, the 
aggressive nature of ovarian cancers was found to be coupled to the ability of tTG to 
regulate gene expression (25). More specifically, it was shown that tTG stimulated the 
expression of the transcriptional repressor Zeb1 through an NFB-dependent 
mechanism. Since Zeb1 functions to limit the expression of proteins that are important 
for maintaining tissue homeostasis (i.e. E-cadherin) (127), ovarian tumors that over-
express Zeb1 tend to disrupt tissue integrity, increasing the invasive and metastatic 
potential of these tumors. 
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 CHAPTER 2 
 
*EGF potentiated oncogenesis requires a tissue transglutaminase-dependent 
signaling pathway leading to Src activation 
 
Introduction 
The EGFR is expressed on the surface of various types of human cancer cells 
where the ligand-dependent induction of its kinase activity triggers signaling pathways 
that promote cancer cell growth, motility, and chemo-resistance (1). Moreover, the 
EGFR or one of its ligands is often found overexpressed or mutated in tumors, with 
these events being linked to enhanced tumorigenicity (2, 3). The close connection 
between excessive EGFR-signaling activities and cancer progression has led to the 
development of EGFR-targeted therapeutic strategies that are currently being used to 
treat patients with lung, colon, and pancreatic cancer (1, 4). However, many of these 
patients either fail to respond or develop resistance to these treatments, suggesting that 
alternative strategies that target EGFR-signaling activities are needed and could be 
therapeutically beneficial in these cases (5).  
Determining the molecular mechanisms that underlie the ability of the EGFR 
to stimulate malignant transformation represents a crucial step in the development of 
more effective and/or alternative cancer treatments. Indeed, several of the signaling 
proteins that have been shown to function downstream of the EGFR, including Ras, 
PI3K, and Src, have been extensively investigated for their roles in mediating 
oncogenic transformation and are now considered as viable targets for intervention 
*Published previously as Li B & Antonyak MA, et al. (2010) PNAS 107:1408-1413. 
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Figure 2.1 tTG is required for EGF-stimulated growth of human breast 
cancer cells. (A) Equal numbers of SKBR3 cells were plated and maintained in 
medium containing 2% FBS, supplemented without or with EGF. The cell cultures 
were counted every other day for a week and their growth rates recorded. Error 
bars represents standard deviation from two repeated experiemts. (B) Anchorage-
independent growth assays were performed on SKBR3 cells treated without or 
with EGF. Shown are images of the resulting colonies that formed. (C) Graph 
quantifying the number of colonies that SKBR3 cells formed in these assays. All 
of the assays were performed 3 times and the results were averaged together and 
plotted. (D and E) Serum-starved SKBR3 cells (D) and BT20 cells (E) were 
treated without or with EGF for 2 days and then were lysed. The cell extracts were 
immunoblotted with tTG and actin antibodies (insets) and assayed for 
transamidation activity as read-out by the incorporation of BPA into lysate 
proteins. The results from 3 separate assays were quantified using ImageJ 
software, averaged together, and graphed (graphs). (F) Serum-starved SKBR3 
cells were treated without or with 150 ng/mL heregulin for 2 days and then were 
lysed. The cell extracts were immunoblotted with tTG and actin antibodies (insets) 
and assayed for transamidation activity by the incorporation of BPA into lysate 
proteins. The results from 3 separate assays were quantified using ImageJ 
software, averaged together, and graphed (graph). (G and H) Two sets each of 
SKBR3 cells (G) or BT20 cells (H) transfected with control siRNA or tTG 
siRNAs (denoted tTG-1 or tTG-2), or incubated without or with MDC, were 
stimulated without or with EGF as indicated. One set of cells was lysed and 
immunoblotted with tTG and actin antibodies (insets). Anchorage-independent 
growth assays were performed on the second set of cells. The results from 3 
separate assays were averaged together and graphed (graphs). (I) Equal numbers 
of SKBR3 cells transfected with control siRNA or tTG siRNAs, or incubated 
without or with MDC, were plated and then maintained in medium containing 2% 
FBS supplemented without or with EGF. The cell cultures were counted at the 
indicated times and their growth rates recorded. Experiemts were repeated twice. 
All the error bars shown from (C) to (I) represent standard deviation. 
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Figure 2.1 (Continued)
  against various types of human cancer (3, 6, 7). In addition, the EGFR regulates the 
expression of a number of proteins likely to contribute to cell growth control and to 
malignant transformation, and these proteins offer an additional group of potential 
therapeutic targets. Here I show that tTG, which is capable of GTP-binding/GTPase 
activity and acyl-transferase activity (8, 9), represents one such protein whose 
expression is strongly stimulated by EGF in human breast cancer cells. I go on to 
demonstrate how tTG expression is up-regulated by EGFR-signaling activities and 
that it plays an essential role through a novel mechanism in EGFR-driven oncogenic 
transformation. 
 
Results 
tTG mediates the growth-promoting effects of EGF in human breast cancer cells  
The human breast cancer cell line, SKBR3, when grown in medium containing 
EGF shows enhanced proliferation compared to control cells (Figure 2.1A), and an 
increased ability to form colonies in soft agar (Figure 2.1B and 2.1C), an in vitro 
measure of tumorigenicity. Efforts to identify proteins in these breast cancer cells 
whose expression was up-regulated by EGF and therefore potentially contribute to its 
growth-promoting activity, led me to tTG, a dual function enzyme that couples an 
ability to bind and hydrolyze GTP with a transamidation activity that cross-links 
proteins via glutamine-lysine or glutamine-polyamine linkages. While there have been 
suggestions that chronic tTG expression and/or activation associated with some human 
cancers is linked to their malignant transformation (10-16), an understanding of how 
tTG is regulated in cancer cells and whether there is a functional relationship between 
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Figure 2.2 EGFR and ErbB2 expression levels are correlated to tTG 
expression levels in human mammary tumor tissues. Human breast cancer 
tissue arrays (catalog # BR1921, U.S. Biomax) containing 80 cases of invasive 
ductal breast cancer tissue and 16 normal ductal mammary tissues were subjected 
to immunohistochemical analysis with tTG, EGFR, and ErbB2 antibodies 
according to the manufacturer’s protocol. The resulting staining obtained with 
each antibody was quantified using ImageJ software. (A) The expression levels of 
tTG detected in the normal mammary tissues and mammary tumor tissues were 
plotted. Each circle represents a normal mammary tissue, whereas each square 
represents a mammary tumor tissue. (B) Representative immunohistochemical 
images of a normal mammary tissue and a mammary tumor tissue stained for tTG 
(magnification: ×20). (C) Chart summarizing the numbers and percentages of 
ductal mammary tumors that were screened and exhibited tTG overexpression 
(column 2, designated positive) or showed no overexpression of tTG (column 2, 
designated negative) versus the overexpression of EGFR or ErbB2 (column 3). 
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Tumor type and Grading
Human Ductal Mammary 
Carcinoma (80 Cases*)
*Grade 1: 3/80 (4%) ; Grade 2: 63/80 (78%) ; Grade 3: 14/80 (18%)
tTG Status
Positive: 64/80 (80%)
Negative:16/80 (20%)
EGFR and ErbB2 Status
EGFR Positive: 44/64 (69%)
ErbB2 Positive: 44/64 (69%)
EGFR Positive:  5/16  (31%)
ErbB2 Positive:  6/16  (39%)
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  this protein and EGF-promoted tumor growth has been lacking.  Figure 2.1D, inset 
shows that EGF induced a strong up-regulation of tTG expression in SKBR3 cells, 
compared to the nearly undetectable amounts in untreated cells, as well as stimulated 
its enzymatic activity as assayed by the incorporation of biotinylated pentylamine 
(BPA) into lysate proteins (Figure 2.1D, graph). Similarly, EGF caused the up-
regulation and activation of tTG in other breast cancer cell lines such as BT20 cells 
(Figure 2.1E, inset and graph).  
I further established a link between growth factor signaling and tTG in human 
breast cancer cells by providing two additional pieces of evidence. First, I found that 
heregulin, a ligand that activates the EGFR family member ErbB2, which has been 
implicated in breast cancer progression (1), was nearly as effective as EGF at inducing 
tTG expression and activation in SKBR3 cells (Figure 2.1F). Second, 
immunohistochemical analysis of a human breast cancer tissue array shows that the 
expression levels of both the EGFR and ErbB2 correlate significantly to tTG 
expression (Figure 2.2A-C). Taken together, these findings suggest that tTG may be a 
critical mediator of EGF- and heregulin-promoted oncogenic processes.  
I then asked whether knocking-down tTG expression by siRNA (Figure 2.1G 
and 2.1H, insets) or the addition of monodansylcadaverine (MDC), an inhibitor of 
tTG-catalyzed transamidation, affected the growth-promoting characteristics of EGF. 
Soft agar assays showed that the EGF-stimulated colony formation of SKBR3 and 
BT20 cells was reduced to essentially basal levels (i.e. the number of colonies that 
form in the absence of EGF stimulation) by either the introduction of siRNAs 
targeting tTG or by treatment with MDC (Figure 2.1G and 2.1H, graphs). In addition, 
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Figure 2.3 Ras- and Cdc42-dependent signaling stimulate tTG expression. (A) 
Extracts of serum-starved SKBR3 cells ectopically expressing either the vector-
only (treated without or with EGF) or one of the activated forms of the indicated 
signaling proteins for 2 days were immunoblotted with tTG, HA, and actin 
antibodies as indicated. (B) Serum-deprived cells expressing the vector-only 
(treated without or with EGF) or various combinations of the activated forms of 
Ras (Ras G12V) and Cdc42 (Cdc42 F28L) were lysed and then immunoblotted 
with the indicated antibodies. (C) SKBR3 cells cultured in serum-free medium 
supplemented without or with EGF, plus either LY294002, PD98059, or BAY 11-
7082 for 2 days were lysed and the extracts immunoblotted with tTG and actin 
antibodies. The level of tTG expression detected in each sample was quantified 
using ImageJ software and the results listed below the tTG blot (Fold tTG 
expression). (D) Extracts of serum-deprived SKBR3 cells ectopically expressing 
the vector, the oncogenic Dbl protein (onco-Dbl), or the indicated combinations of 
activated forms of RhoA (RhoA F30L) and Cdc42 (Cdc42 F28L), were 
immunoblotted with the indicated antibodies. (E) SKBR3 cells expressing Ras 
G12V and/or Cdc42 F28L were incubated without or with either LY294002 or 
BAY 11-7082 for 2 days and then were lysed. The extracts were immunoblotted 
with the indicated antibodies. 
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  as shown in Figure 2.1I, knock-downs of tTG or treatment with MDC also inhibited 
the ability of EGF to stimulate the growth of SKBR3 cells in monolayer.  
 
Co-activation of the Ras- and Cdc42-signaling cascades promotes tTG expression 
To determine how EGF promotes the up-regulation of tTG expression, I 
examined several signaling proteins known to act down-stream of the EGFR including 
the small GTPases Ras, Rac1, Cdc42, and RhoA, as well as PI3K and focal adhesion 
kinase (FAK) (17). Figure 2.3A shows the results obtained when I introduced activated 
forms of these different GTPases, PI3K [myristoylated (M)-PI3K], or wild-type FAK, 
into SKBR3 cells and assayed for changes in the expression levels of tTG. Despite 
expressing considerable amounts of each protein (Figure 2.3A, middle panel), none 
was capable of enhancing tTG expression (Figure 2.3A, top panel). This suggested that 
the ability of EGF to induce tTG expression is likely not mediated by a single 
signaling cascade, but rather results from the combined activation of two or more 
pathways. In fact, I found that when different combinations of activated Ras and Rho 
GTPases (e.g. Cdc42) were expressed in SKBR3 cells, there was a marked up-
regulation of tTG expression that fully mimicked the actions of EGF (Figure 2.3B). 
While combinations of activated Ras and Cdc42, or Ras and Rac1, appeared to be 
most effective at restoring tTG expression, different combinations of Rho GTPases in 
the absence of activated Ras (e.g. Cdc42 and RhoA), or the expression of oncogenic 
Dbl, a guanine nucleotide-exchange factor for Cdc42 and RhoA (18), will at least 
partially mirror the actions of EGF in up-regulating tTG (Figure 2.3D). 
54 
 The ability of the activated Ras and Rho proteins to work together to up-
regulate tTG expression led to the question of what might be functioning downstream 
from these GTPases. One of the best known signaling effectors for activated Ras is 
ERK, and so I examined how blocking ERK activity using the inhibitor PD98059 
affected EGF-stimulated tTG expression. The results in Figure 2.3C show that the 
EGF-stimulated expression of tTG in SKBR3 cells was unaffected under conditions 
where ERK activity was inhibited. However, another well known signaling target for 
activated Ras, PI3K (19), appears to be essential, as treatment of SKBR3 cells with the 
PI3K inhibitor LY294002 blocked the ability of EGF to induce the up-regulation of 
tTG in SKBR3 cells, consistent with our earlier findings that PI3K activation is 
necessary for tTG expression (10). Likewise, inhibiting PI3K activity prevented the 
combination of Ras and Cdc42 from up-regulating tTG expression (Figure 2.3E). 
Because my findings suggested that a signaling target capable of responding to 
one or more different Rho GTPases contributes to the EGF-induced expression of tTG, 
I also examined NF B. I felt that NF B represented a　 　 n attractive candidate because 
it is activated by Cdc42, Rac1, and RhoA, and participates in the malignant 
transformation of breast cancer cells (20, 21). Indeed, the results shown in Figure 2.3C 
and 2.3E demonstrate that blocking NF B activation using the small molecule BAY 　
11-7082, which prevents the phosphorylation and ensuing degradation of the NF B　 -
negative regulator, IB , significantly compro　 mised the ability of EGF, as well as 
the combination of activated Ras and Cdc42, to up-regulate tTG expression. 
 
Overexpression of tTG in SKBR3 cells mimics the growth-promoting effects of EGF 
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Figure 2.4 Overexpression of tTG in SKBR3 cells promotes cell cycle 
progression, chemoresistance, anchorage-independent growth, and xenograft 
tumor formation. (A) Extracts of SKBR3 cells stably expressing the vector-only 
or Myc-tagged forms of tTG WT and tTG C277V were immunoblotted with tTG 
and actin antibodies (top two panels) and assayed for transamidation activity as 
read-out by the incorporation of BPA into lysate proteins. Shown is an 
autoradiogram of these results (bottom panel). (B) Immunofluorescence was 
performed on the stable cell lines using a Myc antibody and DAPI. (C) Equal 
numbers of each stable cell line were seeded and maintained in medium containing 
5% FBS. The cells were counted at the indicated times and their growth rates 
recorded. Experiemts were repeated twice. SKBR3 cells stably expressing the 
vector or Myc-tagged forms of tTG WT or tTG C277V were (D) incubated with 
BrdU for 30 minutes and then were washed and fixed with ethanol. The fixed cells 
were stained with a BrdU antibody and then analyzed by fluorescence microscopy. 
Those cells that incorporated BrdU into their DNA were considered actively 
proliferating and counted. The experiments were performed 3 times and the results 
were averaged together and graphed; (E) treated without or with 0.5 µM or 1.5 µM 
doxorubicin (Dox) for 24 hours. The stable cell lines were then fixed and stained 
with 4, 6-diamidino-2-phenylindole (DAPI) for viewing by fluorescence 
microscopy. Apoptotic cells were identified by nuclear condensation and blebbing. 
The experiment was performed in triplicate and the average percentage of cell 
death was plotted; (F) subjected to anchorage-independent growth assays. The 
results from 3 separate assays were averaged together and graphed. Insets are 
representative images of the assays; (G) injected subcutaneously into nude mice (6 
mice for each cell line). The tumors were allowed to grow for 1 month before their 
final volumes were determined. The relative tumor volume for each of the stable 
cell lines was then graphed. Experiemts were repeated twice. All the errors bars 
shown from (C) to (G) represent standard deviation.  
 
*The experiments described in (E) and (G) were performed by Marc A. Antonyak 
and Bo Li. 
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Since the induction of tTG expression by EGF is required for its growth-promoting 
effects in SKBR3 cells, I was interested in determining whether overexpressing tTG in 
these cells was sufficient to mirror the actions of this growth factor. Therefore, 
SKBR3 cells that stably expressed either vector alone, Myc-tagged wild-type tTG 
(tTG WT), or a Myc-tagged transamidation-defective form of tTG (tTG C277V), were 
generated. The expression of the different tTG constructs was similar in these cells 
(Figure 2.4A, top panel), and as expected, the overexpression of wild-type tTG was 
accompanied by clearly detectable transamidation activity when assaying the 
incorporation of BPA into cell lysate proteins, whereas the activity in cells expressing 
the tTG C277V mutant was similar to that of the vector-control cells (Figure 2.4A, 
bottom panel). Immunofluorescent analysis of the stable cell lines revealed that both 
wild-type tTG and tTG C277V exhibited a similar cytoplasmic, non-nuclear 
distribution, indicating that eliminating the ability of tTG to transamidate substrates 
does not affect its cellular localization (Figure 2.4B). 
These stable cell lines were used to examine whether tTG overexpression is 
sufficient to mimic the actions of EGF and enhance the transformed phenotype of 
SKBR3 cells. Figure 2.4C shows that SKBR3 cells overexpressing wild-type tTG had 
a marked growth advantage over the vector-control cells, whereas the growth rates of 
cells expressing the tTG C277V mutant were similar to control cells. Moreover, 
overexpression of wild-type tTG in SKBR3 cells resulted in a 2-fold increase in 5-
bromo-deoxyuridine (BrdU) incorporation over control cells (Figure 2.4D), as well as 
provided a protective effect from doxorubicin-induced apoptosis (Figure 2.4E). I then 
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 examined the ability of the different stable cell lines to form colonies in soft agar. 
Consistent with my findings with parental SKBR3 cells (see Figure 2.1C), SKBR3 
cells expressing the vector alone were capable of forming colonies in soft agar (Figure 
2.4F, inset and graph). The overexpression of wild-type tTG resulted in a ~4-fold 
increase in colony formation, with the average size of the colonies being larger than 
the background colonies formed by the control cells. In contrast, SKBR3 cells 
expressing tTG C277V failed to grow under anchorage-independent conditions 
(Figure 2.4F, inset and graph). In fact, the transamidation-defective tTG C277V 
mutant behaved like a dominant-negative inhibitor by effectively eliminating 
anchorage-independent growth such that it was well below the basal levels observed in 
the vector-control cells. Tumor formation assays performed in mice using these same 
stable cell lines yielded results that further demonstrated that tTG enhanced the 
transformed phenotype of SKBR3 cells (Figure 2.4G). 
 
The ability of tTG to enhance the growth and transforming phenotypes of breast 
cancer cells is due to its activation of Src  
How does increasing the levels of tTG expression in breast cancer cells 
enhance their oncogenic potential? To address this question, I asked whether 
overexpressing tTG in SKBR3 cells led to the activation of signaling proteins that 
have been implicated in cell growth and transformation. Extracts were prepared from 
serum-deprived SKBR3 cells stably expressing vector alone, wild-type tTG (tTG WT), 
or the transamidation-defective tTG C277V and then immunoblotted with antibodies 
that recognize the activated forms of different mitogenic signaling proteins. I found 
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Figure 2.5 tTG-stimulated Src tyrosine kinase activity promotes aberrant cell 
growth. (A) Extracts of serum-starved SKBR3 cells stably expressing the vector, 
Myc-tagged tTG WT, or Myc-tagged tTG C277V were immunoblotted with 
antibodies that detect the activated forms of the indicated signaling proteins. (B) 
The same cell extracts were also immunoblotted with an anti-phospho-tyrosine 
antibody. A distinct protein doublet (Mr ~60-65 kDa) detected in each cell lysate 
(arrow) was (C) quantified using ImageJ software. The experiemts were preformed 
in triplicate, and the results were averaged and graphed. (D) Immunoprecipitations 
with a total-Src antibody (IP: Total Src) were performed on extracts of the 
indicated SKBR3 stable cell lines and the resulting immunocomplexes were 
immunoblotted with phospho-Src and total-Src antibodies. The extent of Src 
activity detected in each sample was quantified using ImageJ software and listed 
below its corresponding band in the Anti-Phospho-Src blot (Fold Phospho-Src). 
To confirm equal amounts of each cell extract were used for the 
immunoprecipitations, the whole cell extracts were immunoblotted with Myc and 
actin antibodies (Input). (E) tTG stable cell lines deprived of serum were 
stimulated with EGF for increasing lengths of time and then lysed. The cell 
extracts were immunoblotted with the indicated antibodies. (F and G) SKBR3 
cells overexpressing vector-only or tTG WT (F), or parental SKBR3 cells treated 
without or with EGF (G), were incubated without or with 5 µM PP2, and then 
subjected to anchorage-independent growth assays. The results from 3 separate 
assays were averaged together and graphed. All the errors bars shown in (C), (F) 
and (G) represent standard deviations.  
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Figure 2.5 (Continued)
  that the overexpression of tTG in SKBR3 cells did not increase the activities of AKT 
or S6K, nor did it activate the MAP-kinases JNK, ERK, or p38, relative to their 
activities in vector-control cells (Figure 2.5A). However, when the same cell extracts 
were subjected to immunoblot analysis using an anti-phospho-tyrosine antibody, a 
protein doublet with an apparent molecular mass in the 60-65 kDa area was enhanced 
in SKBR3 cells overexpressing wild-type tTG (Figure 2.5B and 2.5C). Because c-Src 
is a phospho-tyrosine-containing protein with Mr ~ 60 kDa, I examined whether tTG 
might be capable of enhancing the auto-phosphorylation of Src in cells. Indeed, I 
found that there was a better than 2-fold increase in Src auto-phosphorylation (i.e. a 
measure of Src activation) in cells expressing wild-type tTG compared to the vector-
control cells (Figure 2.5D), whereas in cells expressing the tTG C277V mutant, the 
extent of Src activation was about half of that for control cells. Figure 2.5E shows that 
the magnitude and duration of EGF-dependent Src activation in SKBR3 cells was also 
potentiated by tTG overexpression. I then demonstrated that blocking Src activity 
using the small molecule PP2 inhibited the anchorage-independent growth of SKBR3 
cells caused by tTG overexpression (Figure 2.5F), as well as by EGF stimulation 
(Figure 2.5G). Thus, the ability of tTG to stimulate Src kinase activity is directly 
responsible for the role that it plays in the EGF-stimulated growth and transformation 
of breast cancer cells. 
 
tTG activates Src through its interaction with keratin-19 
I then set out to determine how tTG influences Src kinase activity. While I was 
able to co-immunoprecipitate tTG with HA-tagged c-Src from SKBR3 cells (Figure 
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Figure 2.6 A tTG-K19 interaction enhances the ability of tTG to bind to and 
stimulate Src kinase activity. Immunoprecipitations with a HA antibody (IP: HA) 
were performed on the extracts of SKBR3 cells co-expressing HA-tagged Src and 
either the vector-only or Myc-tagged tTG WT (A), as well as BT20 or MDAMB468 
cells co-expressing HA-tagged Src and Myc-tagged tTG WT (B). The resulting 
immunocomplexes were immunoblotted with Myc and HA antibodies. These cell 
extracts were also immunoblotted with Myc and HA antibodies (Input). (C) Protein 
pull-down assays were carried-out by incubating recombinant His-tagged tTG alone 
or together with GST-tagged forms of either Src or fibronectin. Glutathione-agarose 
beads were then added to each sample and the resulting protein complexes that 
formed were precipitated and subjected to immunoblot analysis with tTG and GST 
antibodies (GST Pull-down). An equivalent volume of each sample was removed 
just prior to the addition of the glutathione-agarose beads and immunoblotted with 
tTG and GST antibodies to show the relative amounts of the recombinant proteins 
present in each sample (Input). (D) Immunoprecipitations with a Myc antibody (IP: 
Myc) were performed on extracts of SKBR3 cells stably expressing the vector-only, 
Myc-tagged tTG WT, or Myc-tagged tTG C277V. The resulting immunocomplexes 
were resolved by SDS-PAGE and then Silver-stained to detect proteins that co-
immunoprecipitated with Myc-tTG WT. (E) The protein (Mr ~40 kDa) that was 
detected by Silver staining was identified as K19 by Mass Spectroscopy. Shown is 
the protein sequence of human K19. The peptide fragments identified by Mass 
Spectroscopy are shaded. Immunoprecipitations with a Myc antibody (IP: Myc) 
were performed on the extracts of SKBR3 cells stably overexpressing Myc-tTG WT 
or Myc-tTG C277V mutant (F), or on the lysates from BT20 or MDAMB468 cells 
overexpressing Myc-tagged tTG WT (G). The resulting immunocomplexes were 
immunoblotted with K19 and Myc antibodies. (H) An in vitro transamidation 
activity assay was performed on recombinant K19 by incubating it with BPA 
without or with either recombinant His-tagged tTG WT or recombinant His-tagged 
tTG C277A. Shown is an autoradiogram of the results (top panel). The reactions 
were also immunoblotted with tTG and K19 antibodies to show the relative 
amounts of each of the recombinant proteins (Input). (I) HA immunoprecipitations 
were performed on the extracts of SKBR3 cells co-expressing Myc-tTG and HA-
Src and transfected with either control siRNA or K19 siRNAs (denoted K19 
siRNA-1 or K19 siRNA-2). The immunocomplexes (IP: HA) were immunoblotted 
with Myc and HA antibodies. (J) Total-Src immunoprecipitations were performed 
on lysates of SKBR3 cells expressing Myc-tTG WT and transfected with either 
control or K19 siRNAs. The immunocomplexes (IP: Total Src) were 
immunoblotted with phospho-Src and total-Src antibodies. All cell extracts were 
also immunoblotted with the indicated antibodies (Input). The extent of Src activity 
detected in each sample was quantified using ImageJ software and listed below its 
corresponding band in the Anti-Phospho-Src blot (Fold Phospho-Src). (K) SKBR3 
cells stably expressing the vector-only or Myc-tTG WT were transfected with 
control siRNA or K19 siRNAs (inset) and then subjected to anchorage-independent 
growth assays. The results from 3 separate assays were averaged together and 
graphed (graph). Errors bars represent standard deviations.  
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  2.6A), as well as from BT20 and MDAMB468 cells (Figure 2.6B), I was unable to 
demonstrate a direct interaction between purified recombinant tTG and c-Src under 
conditions where I could detect an interaction between tTG and one of its best-known 
binding partners, fibronectin (22) (Figure 2.6C). This suggested that an intermediate 
protein was involved in mediating the effects of tTG on Src activity. Given that only 
transamidation-competent tTG, and not a transamidation-defective mutant, was 
capable of increasing Src activity and enhancing the transforming phenotypes of breast 
cancer cells, I wanted to search for candidate transamidation substrates of tTG that 
might serve to mediate the tTG-dependent regulation of Src. Thus, I used Myc-tagged 
wild-type tTG and the transamidation-defective tTG C277V mutant to screen lysates 
of SKBR3 cells for tTG-interacting proteins. The idea was that candidate substrates 
should be able to form a stable acyl-intermediate with the active site cysteine residue 
of wild-type tTG but not with the C277V mutant. The ectopically expressed forms of 
tTG were immunoprecipitated from these extracts using an anti-Myc antibody, and 
then the resulting immunocomplexes were resolved by SDS-PAGE and Silver-stained 
to detect proteins that co-immunoprecipitated with the Myc-tagged tTG constructs. 
Two proteins of Mr ~40 kDa and ~45 kDa specifically associated with Myc-tagged 
wild-type tTG (Figure 2.6D, arrows). The ~45 kDa protein was determined to be actin 
by co-immunoprecipitation and subsequent immunoblot analysis with an anti-actin 
antibody, a known transamidation substrate of tTG (23). The identity of the smaller 
protein was initially determined by sequencing (Figure 2.6E), and subsequently 
confirmed by co-immunoprecipitation and immunoblot analysis (Figure 2.6F), to be 
the intermediate filament protein keratin-19 (K19). I also determined that K19 
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 associates with tTG in two additional breast cancer cell lines, namely in BT20 and 
MDAMB468 cells (Figure 2.6G). Moreover, I showed that tTG is capable of labeling 
K19 with BPA in an in vitro transamidation assay (Figure 2.6H), indicating that tTG 
can both bind and transamidate K19. 
Interestingly, K19 is a human breast tumor marker (24-26). This, coupled with 
the recent finding that the related family member, K17, can promote epithelial cell 
growth by acting as a scaffold protein to bring together the necessary signaling 
proteins to trigger the PI3K/AKT- and mTOR-dependent activation of p70 ribosomal 
S6 kinase (27), led me to consider the possibility that K19 may serve to mediate the 
tTG-dependent activation of c-Src. This in fact turned out to be the case, as shown by 
the data in Figure 2.6I where the ability of tTG to be co-immunoprecipitated with HA-
tagged Src from SKBR3 cells was dependent on K19, i.e. knock-downs of K19 
blocked the ability of tTG to interact with Src. Moreover, the ability of tTG to activate 
Src is dependent on K19 as indicated by the loss of this activation when K19 
expression is knocked-down by RNAi (Figure 2.6J), and K19 is necessary for the 
ability of tTG to enhance the anchorage-independent growth of SKBR3 cells (Figure 
2.6K).  
 
Discussion 
Excessive activation of the EGFR contributes to oncogenesis by stimulating 
the growth and survival of cancer cells, while small molecule inhibitors or antibody-
based approaches that target the EGFR or its immediate downstream effectors, have 
shown some promise as treatments for certain human cancers (1, 2, 4, 5). Therefore,  
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Figure 2.7 Diagram depicting how tTG participates in an EGFR/Src signaling 
pathway that leads to enhanced cancer cell growth. 
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 continuing efforts to better understand the mechanisms by which the EGFR stimulates 
cancer progression will play a critical part in the development of alternative strategies 
to treat cancers. While it is generally appreciated that the EGFR modifies global gene 
expression patterns in cells, the identities of those gene products whose induction is 
most important for cell growth and/or survival are largely unknown. Here, I have 
identified tTG, a dual function GTPase/acyl-transferase, as one such protein. The 
initial indication for this came from the finding that stimulating SKBR3 or BT20 
breast cancer cells with EGF not only increased their proliferative capacity and ability 
to form colonies in soft agar, but also resulted in the induction of tTG expression and 
activation. Suppressing tTG expression or activity potently inhibited the EGF-induced 
growth advantages in each of these cell lines. I further showed that overexpression of 
wild-type tTG in SKBR3 cells could fully recapitulate the growth-stimulatory actions 
of EGF, therefore implicating tTG as a key participate in EGFR-promoted cellular 
transformation.   
Thus far, very little has been known about the signaling pathways that mediate 
EGF-induced tTG expression. However, I have begun to delineate some of the events 
that must occur to stimulate tTG expression and cellular transformation, as 
summarized in Figure 2.7. Although the individual ectopic expression of activated 
forms of various signaling proteins in SKBR3 cells did not induce tTG expression, I 
found that the Ras- and Cdc42-signaling pathways cooperated to up-regulate tTG. I 
then showed that the induction of tTG expression by either EGF stimulation or co-
expression of activated Ras and Cdc42 was sensitive to the PI3K inhibitor LY294002, 
as well as the NFB inhibitor BAY 11-7082.  
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 Increasing the levels of tTG expression in SKBR3 breast cancer cells enhances 
their oncogenic potential, and thus mirrors the actions of EGF-treatment. Surprisingly, 
I discovered that this is due to the ability of tTG to activate c-Src. Consistent with 
these results, as well as with several lines of evidence linking Src kinase activity to 
tumor progression, the anchorage-independent growth advantage afforded to SKBR3 
cells by either EGF-stimulation or tTG overexpression was severely compromised 
when these cells were cultured in the presence of the Src inhibitor PP2. Overall, these 
findings highlight an interesting connection between the overexpression of tTG 
observed in increasing numbers of breast cancer as well as other human cancers and 
the presence of elevated Src activity. 
An intriguing question concerns how tTG expression leads to increased Src 
activity in cells. I obtained a clue when I found that Src co-immunoprecipitated with 
tTG from SKBR3 cell lysates, but that the recombinant forms of these two proteins 
failed to show a similar association in vitro, implying that the tTG-Src interaction in 
cells was indirect and most likely mediated by another protein. Indeed, I identified the 
intermediate filament K19 as a tTG-binding partner that is essential for the ability of 
tTG to associate with Src in cells, as well as for the enhanced Src activity observed in 
the SKBR3 cells stably overexpressing tTG. Moreover, I demonstrated that K19 is 
capable of being transamidated by tTG in vitro. Thus, the tTG-catalyzed crosslinking 
of K19 might enable it to act as a signaling scaffold that binds and favors the activated 
state of c-Src, an idea that I am currently investigating. Interestingly, K19 belongs to a 
family of cytokeratins, many of which, including K19, are overexpressed in a large 
number of human cancer types (28, 29) and are routinely used as diagnostic indicators 
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 of metastasis and tumor aggressiveness (24-26). Given the connections between K19 
and human cancers, an important question has been whether the cytokeratins directly 
contribute to oncogenesis. My findings that K19 serves to bridge the interaction 
between tTG and Src, resulting in enhanced Src kinase activity and aberrant cell 
growth, point to a novel and rather unexpected role for K19 in EGFR-promoted 
cellular transformation. 
In summary, the findings presented in this study demonstrate for the first time 
to my knowledge that the induction of tTG expression and activation by EGF is both 
necessary and sufficient for mediating the growth-promoting actions of EGF in human 
breast cancer cells. Interestingly, a recent proteomic screen of the U87 brain tumor cell 
line overexpressing a highly oncogenic form of the EGFR known as EGFR variant 
type III (EGFRvIII) showed that tTG was one of three proteins whose expression was 
enhanced by this mutant EGFR (30). Whether tTG is important for promoting the 
oncogenic potential of EGFRvIII remains to be determined. However, my findings 
now point to an important relationship between EGFR-mediated transformation and 
tTG expression and suggest that tTG may represent a potentially valuable therapeutic 
target. 
 
Materials and Methods 
Materials. Cell culture reagents, EGF, Lipofectamine, Lipofectamine 2000, protein G-
beads, glutathione-agarose beads, tTG and K19 RNAis, and the HA, GST, and Myc 
antibodies were from Invitrogen. LY 294002, PP2, PD 98059, BAY11-7082, DAPI 
and MDC were from Calbiochem. The 5-(biotinamido) pentylamine was from Pierce. 
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 The tTG, actin, and K19 antibodies were from Neomarkers, while antibodies 
recognizing total or activated Src, AKT, JNK, P38, p70 S6-kinase, and ERK, as well 
as the anti-phospho-tyrosine antibody, were from Cell Signaling.  
 
Cell Culture. SKBR3 and BT20 cell lines were grown in RPMI 1640 medium 
containing 10% FBS. Expression constructs were transfected into cells using 
Lipofectamine, while RNAis were introduced into cells using Lipofectamine 2000. 
Cells stably expressing Myc-tagged pcDNA3 vector, Myc-tTG WT or Myc-tTG 
C277V were generated by selection with growth medium supplemented with 800 
µg/ml G418. Where indicated, cells were treated with various combinations of 0.1 
µg/ml EGF, 20 µM MDC, 10 µM LY294002, 20 µM PD98059, 2 µM BAY 11-7082, 
or 5 M PP2.  
 
Immunoblot Analysis. Cells were lysed with lysis buffer (25 mM Tris, 100 mM NaCl, 
1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM -glycerol 
phosphate, and 1 g/mL aprotinin), and then the lysates were resolved by SDS-PAGE 
and the proteins transferred to PDVF membranes. The filters were incubated with the 
various primary antibodies diluted in TBST (20 mM Tris, 135 mM NaCl, and 0.02% 
Tween 20). The primary antibodies were detected with horseradish peroxidase-
conjugated secondary antibodies followed by exposure to ECL reagent.  
 
Immunofluorescence. SKBR3 cells expressing the Myc-pCDNA3 vector, Myc-tTG 
WT, or Myc-tTG C277V, were fixed using 5% formaldehyde, permeabilized with 
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 0.2% Triton X-100, and then incubated with a Myc antibody. The Myc antibody was 
detected using an Oregon green 488-conjugated secondary antibody and DAPI was 
used to stain nuclei. 
          
Transamidation Assay. These assays were performed as previously described (10). 
 
Cell growth assays. Parental SKBR3 cells or the SKBR3 stable cell lines were plated 
in dishes at a density of 5×104 cells/dish and cultured in medium containing 2% FBS, 
without or with EGF, MDC, or PP2. Every other day for one week, one set of cells 
was collected and counted, while the medium on the remaining sets of cells was 
replenished.  
 
Soft agar assays. Parental SKBR3 and BT20 cells or the SKBR3 stable cell lines were 
plated at a density of 6×103 cells/ml in medium containing 0.3% agarose, without or 
with EGF, MDC, or PP2 onto underlays composed of growth medium containing 
0.6% agarose in six-well dishes. The cultures were fed one week later, and after 14 
days of growth the colonies were counted. 
 
Immunoprecipitation. Cell extracts (typically 600 g) were pre-cleared with protein G 
beads before incubating with a particular antibody for 2 hours, followed by addition of 
protein G beads for 1 hour. The beads were washed with cell lysis buffer before being 
boiled with Laemmli’s sample buffer and subjected to SDS-PAGE and Western-
blotting. 
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Silver-staining and MS-peptide sequence identification. Silver-staining of proteins 
resolved by SDS-PAGE was performed based on the manufacturer’s instructions (Bio-
Rad). Protein bands of interest were excised from the gel and washed 3 times with 
50% acetonitrile. The samples were analyzed at the Harvard Microchemistry and 
Proteomics Analysis Facility by micro-capillary reverse-phase HPLC nano-
electrospray tandem mass spectrometry on a Thermo LTQ-Orbitrap mass spectrometer. 
 
Immunihistochemistry. Human breast cancer tissue arrays (catalog # BR1921, U.S. 
Biomax) containing 80 cases of invasive ductal breast cancer tissue and 16 normal 
ductal mammary tissues were subjected to immunohistochemical analysis with tTG, 
EGFR, and ErbB2 antibodies. Briefly, the tissue array slides were deparaffinized by 
baking at 60 °C for 30 minutes and then rehydrated in distilled water containing 3% 
H2O2 for 30 min. After washing with PBS, the slides were boiled for 10 min in 10 mM 
sodium citrate buffer (pH 6.0) and allowed to cool to room temperature. The slides 
were then blocked with 2.5% horse serum and with Avidin and Biotin blocking 
solutions (Avidin/Biotin Blocking Kit, Vector Labs). The tissue arrays were then 
incubated with the various primary antibodies, followed by biotinylated secondary 
antibodies, and then a 30 minute treatment with the Elite ABC reagent (Universal 
R.T.U. Vectastain Elite ABC Kit, Vector Labs). After washing with PBS, the slides 
were processed with chromogen solution (ImmPACT DAB Substrate, Vector Labs). 
The slides were then dehydrated and mounted. 
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 CHAPTER 3 
 
*Cancer cell-derived microvesicles induce transformation by transferring tissue 
transglutaminase and fibronectin to recipient cells 
 
Introduction 
The release of MVs or oncosomes from different types of high-grade or 
aggressive forms of human cancer cells into their surroundings is becoming 
increasingly recognized as a feature of tumor biology (1-3), yet how these structures 
are generated and their importance in cancer progression are only just beginning to be 
appreciated. Of particular interest are the recent findings showing that at least some of 
the MVs generated by aggressive brain, breast, and prostate cancer cells involve the 
direct budding or shedding of vesicles from their plasma membranes. These 
membrane-bound structures range in size up to ~2.0 microns in diameter and contain a 
variety of cell surface receptors, intracellular signaling proteins, cytoskeletal 
components, as well as RNA transcripts encoding mitogenic factors, depending upon 
their cellular origin (4-8). Interestingly, they have been shown to be taken-up by 
recipient cancer cells where the transferred cargo can promote the activation of 
survival and mitogenic signaling proteins, including AKT and ERK (5, 7, 9). 
By determining that MVs provide a means for cancer cells to share 
intracellular proteins and genetic information with each other, the above findings have 
begun to shed some light on a poorly understood but potentially important mechanism 
underlying the onset and development of human cancers. However, numerous 
81 
*Published previously as Antonyak MA & Li B, et al. (2011) PNAS 108:4852-4857. 
 82 
Figure 3.1 Distinct types of human cancer cells generate MVs. (A) 
MDAMB231 cells were analyzed by SEM (left image) and immunofluorescent 
microscopy using rhodamine-conjugated phalloidin to detect F-actin (right image). 
Some of the largest MVs are indicated with arrows. (B) Quantification of MV 
production by various cell lines cultured under serum-starved or EGF-stimulated 
conditions. Cells generating MVs were detected by labeling the samples with 
rhodamine-conjugated phalloidin. The data shown represents the mean ± s.d. from 
three independent experiments. (C) Images of cells from the experiment performed 
in (B). Some of the MVs are denoted with arrows. (D) MDAMB231 cells 
transiently expressing a GFP-tagged form of the plasma membrane-targeting 
sequence from the Lyn tyrosine kinase (GFP-PM) were subjected to live-imaging 
fluorescent microscopy. Shown are a series of time-lapsed images taken in 2 
minute intervals of a transfectant. The arrow denotes a MV that forms and is shed 
from a cell. (E) Serum-deprived MDAMB231 cells that were either mock 
transfected or transfected with pEGFP (a plasmid encoding GFP) were lysed, and 
the MVs shed into the medium by the transfectants were isolated and lysed as well. 
The whole cell lysates (WCLs) and the MV lysates were then immunoblotted with 
antibodies against GFP, the MV-marker flotillin-2, and the cytosolic-specific-
marker IκB. MDAMB231 cells that were either mock transfected or transfected 
with a plasmid encoding GFP (pEGFP) were placed in serum-free medium for a 
day. The conditioned medium from the transfectants were collected and the intact 
MVs present in the medium were isolated and subjected to FACS analysis by 
gating for GFP-positive MVs that are between ~1-3 µm in diameter. (F) The 
results obtained when the MVs isolated from the mock transfected MDAMB231 
cells were analyzed. (G) The results obtained when the MVs isolated from 
MDAMB231 cells transiently expressing GFP were analyzed. 
 
*The experiments described in (B) and (C) were performed by Marc A. Antonyak 
and Bo Li. The experiments described in (F) and (G) were performed by Kristen L. 
Bryant.  
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  questions regarding MV biogenesis and function need to be addressed in order to 
more thoroughly understand the significance of this unconventional form of cell 
communication in oncogenesis. Here I will describe findings that suggest a novel role 
for MVs in cancer progression, as well as identify the proteins that are essential to this 
function.  
 
Results  
Analysis of serum-starved cultures of the highly aggressive human breast 
cancer cell line MDAMB231 by scanning electron microscopy (SEM) (Figure 3.1A, 
left image) or by fluorescent microscopy performed on cells stained for F-actin (Figure 
3.1A, right image) showed that MVs ranging in size from ~0.2-2.0 microns in 
diameter were present on the surface of ~35% of these cells (Figure 3.1B). MVs were 
also detected on ~25% of serum-deprived U87 human glioblastoma cells, while their 
formation was induced in HeLa cervical carcinoma cells by epidermal growth factor 
(EGF) stimulation (Figure 3.1B and 3.1C). In contrast, MVs were not detected on the 
surface of normal NIH3T3 fibroblasts cultured under serum-starved or EGF-
stimulated conditions, indicating that some cell types may not generate MVs. 
Moreover, I determined that MVs were actively shed from these cancer cells as 
demonstrated by time-lapsed images of the release of a GFP-labeled MV from the 
plasma membrane of a MDAMB231 cell transfected with a pEGFP plasmid encoding 
the plasma membrane targeting sequence of the Lyn tyrosine kinase (GFP-PM) 
(Figure 3.1D), as well as through the detection of MVs containing GFP in the 
culturing medium collected from pEGFP-only expressing transfectants by immunoblot  
85 
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Figure 3.2 MDAMB231 and U87 cancer cell-derived MVs are capable of 
transforming normal fibroblasts and normal mammary epithelial cells. (A) 
Whole cell lysates (WCLs) of serum-starved MDAMB231 and U87 cells, as well 
as lysates of the MVs shed by these cells, were immunoblotted with antibodies 
against the MV-markers actin and flotillin-2, the cytosolic-specific-marker IκB, 
and the activated (phospho)-EGF-receptor. Multiple sets of serum-deprived 
NIH3T3 fibroblasts were incubated with serum-free medium, medium containing 
2% calf serum (CS), or medium supplemented with intact MVs derived from either 
MDAMB231 or U87 cells as indicated. (B) One set of cells was lysed after being 
exposed to the various culturing conditions for the indicated lengths of time and 
then immunoblotted with antibodies that recognize the activated and total forms of 
AKT and ERK. Two additional sets of fibroblasts were evaluated for their abilities 
to (C) undergo serum-deprivation-induced cell death and (D) grow in low serum 
(2% CS). For the growth assays, the culturing medium (including the MVs) was 
replenished daily. (E) NIH3T3 fibroblasts incubated without or with MVs derived 
from either MDAMB231 or U87 cells were subjected to anchorage-independent 
growth assays. The soft agar cultures were re-fed (including adding freshly 
prepared MVs) every third day. NIH3T3 cells expressing Cdc42 F28L was used as 
a positive control for these experiments. (F) Images of the resulting colonies that 
formed in (E). The data shown in (C), (D), and (E) represent the mean ± s.d. from 
at least three independent experiments. (G) Cell death assays were performed on 
MCF10A cells that were cultured for 3 days in serum-free medium, medium 
containing 2% fetal bovine serum (FBS), or serum-free medium supplemented 
with intact MVs derived from 5.0 x 106 MDAMB231 cells. (H) Anchorage-
independent growth assays were performed on MCF10A cells incubated with MVs 
derived from 5.0 x 106 MDAMB231 cells treated without or with the tTG inhibitor 
T101. (I) Anchorage-independent growth assays were performed on NIH3T3 
fibroblasts incubated with U87 cell-derived MVs treated without or with the EGF 
receptor inhibitor AG1478. The culturing medium (including the MVs, T101, and 
AG1478) for the soft agar assays performed in (H) and (I) was replenished every 
third day for 12 days, at which time the colonies that formed were counted. The 
data shown in (G), (H), and (I) represent the mean  s.d. from three independent 
experiments. 
 
*The experiments described in (C) and (G) were performed by Marc A. Antonyak 
and Bo Li. 
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Figure 3.2 (Continued)
 analysis (Figure 3.1E) and fluorescence-activated cell sorting (FACS) analysis (Figure 
3.1F and 3.1G). 
While MVs had been previously reported to share their cargo between cancer 
cells, I was interested in seeing whether MVs might be capable of conferring onto 
normal (non-transformed) recipient cells some of the transformed characteristics of the 
donor cancer cells. Thus, I isolated MVs constitutively shed by MDAMB231 breast 
cancer cells and U87 brain tumor cells from their serum-free culturing medium 
(Figure 3.2A) and added them to cultures of non-transformed NIH3T3 fibroblasts. The 
MVs generated by either of these cancer cell lines were capable of stimulating the 
activities of the signaling protein kinases AKT and ERK in the recipient fibroblasts 
(Figure 3.2B), similar to what has been observed when cancer cell-derived MVs were 
incubated with other cancer cells or endothelial cells (5, 7, 9). Moreover, when 
NIH3T3 fibroblasts were incubated with MVs derived from MDAMB231 cells or U87 
cells, they exhibited two phenotypes characteristic of cancer cells, namely an 
enhanced survival capability (Figure 3.2C) and an ability to grow under low serum 
conditions (Figure 3.2D). I then asked whether the cancer cell-derived MVs, when 
added to normal cells, could induce cellular transformation as read-out by anchorage-
independent growth (i.e. colony formation in soft agar). Figure 3.2E and 3.2F show 
that while the control NIH3T3 fibroblasts failed to form colonies in soft agar, 
sustained treatment of fibroblasts with MVs collected from either MDAMB231 cells 
or U87 cells conferred upon them the ability to grow under anchorage-independent 
conditions. MDAMB231 cell-derived MVs similarly promoted the survival (Figure 
3.2G) and aberrant growth (Figure 3.2H) of the normal human mammary epithelial  
89 
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Table 3.1 Proteins common to both MDAMB231 cell- and U87 cell-derived 
MVs. Proteomic analysis was performed on MVs shed by either MDAMB231 
breast cancer cells or U87 brain tumor cells. A list was compiled (based on general 
cellular function) of those proteins that were identified in the MVs from both 
MDAMB231 and U87 cells. The complete list of proteins identified in each MV 
samples is attached in the Appendix.  
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Nucleic Acid-binding Proteins
eukaryotic translation elongation factor 1
eukaryotic translation elongation factor 2
histone cluster 1
histone cluster 2
RuvB-like protein 1 
RuvB-like protein 2 
Extracellular Matrix and Plasma Membrane-associated Proteins
annexin A2
CD9 antigen 
collagen
Ecto-5'-nucleotidase
EGF-like repeats and discoidin I-like domains-containing protein 3 
fibronectin
galectin 3 binding protein 
integrin beta 1
laminin
lysyl hydroxylase precursor 
major histocompatibility complex
Na+/K+ -ATPase
transglutaminase 2 isoform a 
Metabolic Proteins
aldolase A 
enolase
ferritin
glyceraldehyde-3-phosphate dehydrogenase 
L-lactate dehydrogenase A
nicotinamide phosphoribosyltransferase precursor 
phosphoglycerate kinase 1 
pyruvate kinase
UDP-glucose pyrophosphorylase
Cytoskeletal Proteins
actin
actinin
chaperonin 
moesin 
T-complex protein 1
tubulin 
vimentin 
Signaling,Trafficking, and other functional proteins
adenylyl cyclase-associated protein 
alpha-2-macroglobulin precursor 
heat shock protein 70kDa 
heat shock protein 90kDa
HtrA serine peptidase 1 precursor 
valosin-containing protein 
Proteomic analyses of microvesicles shed by MDAMB231 cells and U87 cells
 cell line MCF10A. Thus, the continuous MV-mediated transfer of cargo from cancer 
cells to normal cells is indeed capable of endowing these cells with the characteristics 
induced by oncogenic transformation. 
I then asked what MV-associated protein(s) is responsible for mediating the 
transfer of transforming capability. I initially considered the EGF-receptor (EGFR) as 
a possible candidate protein, since it was shown that activated forms of this receptor 
can be shared between brain cancer cells via MVs (5, 6, 9). However, it is unlikely 
that the EGFR accounts for the similar transforming abilities associated with the MVs 
derived from MDAMB231 breast cancer cells and U87 glioblastoma cells (Figure 
3.2C-E), given that activated EGFRs cannot be detected in the MVs shed from U87 
cells (Figure 3.2A). This was further supported by the finding that the anchorage-
independent growth advantage imparted to NIH3T3 cells by U87 cell-derived MVs is 
insensitive to treatment with the EGFR tyrosine kinase inhibitor AG1478 (Figure 3.2I).  
To identify proteins potentially involved in the transforming actions of these 
MVs, proteomic screens were carried-out. Proteins common to MVs derived from 
MDAMB231 cells and U87 cells are listed in Table 3.1. Notably among the MV-
associated proteins was tTG, a protein cross-linking enzyme that has been linked to 
the chemoresistance and aberrant cell growth exhibited by some cancer cells (10-15), 
and is secreted from cells by an unknown mechanism (15-17). I confirmed that tTG is 
a component of MVs derived from MDAMB231 and U87 cells by immunoblot 
analysis (Figure 3.3A) and demonstrated that the MVs on the surfaces of MDAMB231 
cells were detectable when immunostained with a tTG antibody (Figure 3.3B, top 
images), but not when stained with only the secondary antibody (Figure 3.3B, bottom- 
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Figure 3.3 MVs shed by cancer cells contain tTG on the outer leaflet of MV 
membrane. (A) Whole cell lysates (WCLs) of serum-starved MDAMB231 and 
U87 cells, as well as lysates of the MVs shed by these cells, were immunoblotted 
with several antibodies, including one against tTG. (B) Top images- MDAMB231 
cells immuno-stained with a tTG antibody. The boxed area was enlarged and 
arrows are used to denote certain MVs. Bottom images- a MDAMB231 cell co-
stained with just the secondary antibody (left image) and Rhodamine-conjugated 
phalloidin to label the MVs (right image). (C) Images of serum-starved U87 
glioblastoma cells and HeLa cervical carcinoma cells that were left untreated or 
stimulated with EGF for 15 minutes as indicated, and then immuno-stained with a 
tTG antibody. Pronounced MVs are denoted with arrows. (D) Whole cell lysates 
(WCLs) of MDAMB231 cells ectopically expressing either GFP-only or GFP-
tTG, as well as lysates of the MVs shed by these transfectants into their culturing 
medium, were immunoblotted with antibodies against GFP, the MV-marker 
flotillin-2, and the cytosolic-specific-marker IκB. (E) Fluorescent images of 
permeabilized and non-permeabilized samples of MDAMB231 cells stained with 
antibodies against tTG and the intracellular protein Rheb, and DAPI to label 
nuclei. (F) Intact MDAMB231 cell-derived MVs were isolated, fixed, immuno-
stained with a tTG antibody, and then processed for detection by SEM. Shown is a 
representative SEM image of a MV. Note the detection of tTG on the surface of 
the MV. (G) The transamidation activity of a fixed concentration of purified 
recombinant tTG (1 µM) incubated with increasing concentrations of the tTG 
inhibitor T101 was assayed. The IC50 of T101 (dashed lines) was determined to 
be ~1.5 µM. This experiment was repeated two additional times, with comparable 
results. (H) Transamidation activity assays, as readout by the incorporation of 
BPA into lysate proteins, were performed on the cell extracts of MDAMB231 cells 
that had been cultured in medium supplemented without or with 200 µM T101 (a 
133-fold greater concentration than the IC50 calculated for this inhibitor in B) for 
~10 hours prior to being washed extensively and then lysed (cell cultures). Equal 
amounts of a MDAMB231 cell extract were left untreated or were incubated with 
10 µM T101 15 minutes before being subjected to a transamidation activity assay 
(cell extracts). Data are mean ± s.d. from three independent experiments. (I) 
Whole cell lysates (WCLs) of serum-starved MDAMB231 cells, as well as intact 
MVs generated by these cells treated without or with the tTG inhibitors T101 (cell-
impermeable) or MDC (cell-permeable), were assayed for transamidation activity 
as readout by the incorporation of BPA into casein. The samples were then 
immunoblotted with antibodies against tTG, flotillin-2, and IκB. 
 
*The experiments described in (B), (C) and (E) were performed by Marc A. 
Antonyak and Bo Li. 
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Figure 3.3 (Continued)
 left image). Likewise, the MVs generated by U87 cells and HeLa cervical carcinoma 
cells stimulated with EGF also contained tTG (Figure 3.3C). These findings, when 
coupled with the fact that a GFP-tagged form of tTG is more efficiently incorporated 
into MVs shed by MDAMB231 compared to GFP alone (Figure 3.3D), demonstrate 
that tTG is targeted to MVs generated by distinct types of cancer cells and in response 
to specific cell culturing conditions.  
As shown in Figure 3.3B, tTG was frequently enriched in the membranes of 
MVs, as indicated by the ring-shaped staining patterns detected with a tTG antibody in 
cells actively forming MVs. The same tTG antibody also labeled MVs that protruded 
from the plasma membranes of non-permeabilized MDAMB231 cells (Figure 3.3E), 
as well as detected tTG on the surfaces of individually isolated MVs from 
MDAMB231 cells by immuno-SEM (Figure 3.3F). The top panel in Figure 3.3I 
shows that tTG expressed in whole cell lysates (WCL) from MDAMB231 cells, or in 
intact MVs shed by these cells, was enzymatically active as readout by its ability to 
catalyze the incorporation of biotinylated pentylamine (BPA) into casein. Pre-
treatment of the intact MDAMB231 cell-derived MVs with the cell permeable tTG 
inhibitor monodansylcadaverine (MDC) greatly diminished the levels of BPA-labeled 
casein detected in the assay. Interestingly, the cell impermeable tTG inhibitor T101 
(Figure 3.3G and 3.3H) also effectively blocked the cross-linking activity associated 
with MVs derived from MDAMB231 cells (Figure 3.3I), suggesting that tTG is 
predominantly localized and activated on the outer leaflet of MV membranes. 
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Figure 3.4 tTG is not important for the ability of human cancer cells to 
generate MVs. (A) Serum-starved MDAMB231 cells treated without or with 
T101, MDC, BFA, or Exo1, were immuno-stained with a tTG antibody. Shown 
are representative images of the cells exposed to the various inhibitors. Cells 
forming MVs are denoted with arrows. (B) Serum-starved MDAMB231 cells 
treated without or with the tTG inhibitors T101 and MDC (left panel), transfected 
with either control siRNA (siCont) or two distinct tTG siRNAs (siTG-1 and siTG-
2) (middle panel), or treated without or with the inhibitors of classical secretion, 
BFA and Exo1 (right panel), were lysed (WCLs) and the MVs released into the 
medium by the cells were also collected and lysed. The extracts were 
immunoblotted with antibodies against tTG, the MV-marker flotillin-2, and the 
cytosolic-specific-marker IκB. (C) Whole cell lysates (WCLs) of MDAMB231 
cells ectopically expressing vector-only or Myc-tagged forms of wild-type tTG 
(TG WT), a transamidation-defective form of tTG (TG C277V), or a GTP-
binding-defective form of tTG (TG R580L), as well as lysates of the MVs shed by 
the transfectants, were immunoblotted with antibodies against the Myc-tag, 
flotillin-2, and IκB.  
 
*The experiments described in (A) were performed by Marc A. Antonyak and Bo 
Li. 
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The MVs derived from MDAMB231 breast cancer cells were not sensitive to 
the traditional secretory inhibitors, BFA or ExoI, which block Arf GTPase activation 
(18), as indicated by monitoring MV formation by immunofluorescence staining of 
vesicle-associated tTG (Figure 3.4A). I then considered the possibility that the ability 
of tTG to cross-link proteins was important for the formation and/or shedding of MVs 
by cancer cells. Immunofluorescent analysis with a tTG antibody revealed that 
exposing MDAMB231 cells to the tTG inhibitors MDC and T101 had no effect on 
MV formation (Figure 3.4A). The shedding of MVs by MDAMB231 cells also did not 
require tTG enzymatic activity, nor was it affected by ExoI or BFA, as shown by the 
detection of nearly equivalents amounts of the MV-marker flotillin-2 (5) and tTG in 
MVs isolated from the culturing medium of control cells or cells treated with different 
inhibitors (Figure 3.4B, left and right panels). Correspondingly, knocking-down tTG 
in MDAMB231 cells, which depleted the expression of tTG in the MVs, caused little 
change in the amount of MVs shed by these cells as read-out by the flotillin-2 marker 
(Figure 3.4B, middle panel). Moreover, tTG mutants, defective in their ability to cross-
link substrates (tTG C277V) or to bind GTP (tTG R580L), when ectopically expressed 
in MDAMB231 cells were targeted to MVs as efficiently as ectopically expressed, 
wild-type tTG (Figure 3.4C). Thus, these results indicate that tTG is not essential for 
the ability of cancer cells to form or shed MVs, nor is the enzymatic activity of tTG 
needed for its targeting to MVs. 
I then examined whether tTG might function as MV cargo and be transferred 
to recipient cells. NIH3T3 fibroblasts were incubated for 30 minutes with MVs  
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Figure 3.5 tTG can be transferred from MDAMB231 cells or U87 cells to 
recipient fibroblasts via MVs. Extracts of serum-starved NIH3T3 fibroblasts that 
were incubated with serum-free medium or serum-free medium supplemented with 
MDAMB231 cell (A) or U87 cell (B) -derived MVs that had been pre-treated 
without or with the tTG inhibitor T101 for 30 minutes were immunoblotted with 
tTG and actin antibodies. (C) NIH3T3 cells incubated for 30 minutes with serum-
free medium supplemented without or with intact MVs generated by either 
MDAMB231 or U87 cells were immuno-stained with a tTG antibody and 
rhodamine-conjugated phalloidin to detect actin. Shown are representative 
fluorescent images of the fibroblasts. Note that tTG is only detected in the 
fibroblasts that were incubated with cancer cell-derived MVs. Lysates of 
fibroblasts incubated for 30 minutes with MDAMB231 cell (D) or U87 cell (E) -
derived MVs that had been pre-treated without or with T101 were assayed for 
transamidation activity as read-out by the incorporation of BPA into lysate 
proteins. Data shown in (D) and (E) are mean ± s.d. from three independent 
experiments. 
 
*The experiments described in (C) were performed by Marc A. Antonyak and Bo 
Li. 
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 derived from serum-starved cultures of either MDAMB231 cells or U87 cells and then 
analyzed for tTG expression by immunoblot analysis (Figure 3.5A and 3.5B) and 
immunofluorescent microscopy (Figure 3.5C). The results from these experiments 
show that the levels of tTG were significantly increased in fibroblasts that had been 
incubated with the cancer cell-derived MVs relative to the barely discernible levels of 
tTG in control fibroblasts.  
These findings then raised the question of whether the MV-mediated transfer 
of activated tTG into recipient fibroblasts might be important for conferring these cells 
with enhanced survival capability and the characteristics of transformation. To address 
this I took advantage of my earlier findings that tTG is localized on the surfaces of 
MVs such that its cross-linking activity is susceptible to inhibition by the cell 
impermeable, irreversible inhibitor T101 (Figure 3.3B, 3.3E and 3.3I). By pre-treating 
cancer cell-derived MVs with T101 before adding them to fibroblast cultures, I was 
able to selectively and irreversibly inhibit the cross-linking activity of the MV-
associated tTG (Figure 3.5D and 3.5E). Using this approach, I compared how the 
survival advantage afforded to NIH3T3 fibroblasts by MVs collected from cancer cells 
would be affected under conditions where tTG activity was inhibited. Figure 3.6A and 
3.6B show that pre-treatment of the MVs derived from either MDAMB231 or U87 
cells with T101 severely compromised their ability to protect the recipient fibroblasts 
from serum-deprivation-induced cell death. Importantly, the extent of cell survival 
achieved by culturing NIH3T3 cells in medium supplemented with a nominal amount 
of calf serum (2% CS) was unchanged by the addition of T101, indicating that the 
ability of this small molecule inhibitor to abolish the protection afforded by the cancer  
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Figure 3.6 The ability of MDAMB231 cell or U87 cell-derived MVs to induce 
cellular transformation requires the transfer of active tTG from MVs to 
recipient cells. Cell death assays were performed on fibroblasts maintained in 
serum-free medium, 2% CS-medium, or serum-free medium containing 
MDAMB231 cell (A) or U87 cell (B) -derived MVs. Each culturing medium was 
further supplemented without or with the tTG inhibitors T101 (cell-impermeable) 
or MDC (cell-permeable) as indicated. (C) The MVs shed from serum-starved 
MDAMB231 cells transfected with either control siRNA (siCont) or two different 
tTG siRNAs (siTG-1 and siTG-2) were collected and resuspended in serum-free 
DMEM. NIH3T3 cells plated in each well of a 6-well dish were then placed in 
serum-free medium or serum-free medium containing the different MV 
preparations for ~35 hours, at which time the cell death rates of the different cell 
cultures were determined. (D) Anchorage-independent growth assays were 
performed on fibroblasts incubated with MDAMB231 cell-derived MVs treated 
without or with T101, the RGD-peptide, or the control RGE-peptide. (E) 
Anchorage-independent growth assays were performed on NIH3T3 fibroblasts 
incubated with the different MV preparations as indicated. The soft agar cultures 
were re-fed (including the addition of freshly prepared MVs) every third day for 
12 days, at which time the colonies that formed were counted. (F) Anchorage-
independent growth assays were performed on control NIH3T3 fibroblasts or on 
fibroblasts incubated with MVs derived from U87 cells treated with either T101, 
the RGD-peptide, the RGE-control-peptide, or untreated. (G) Anchorage-
independent growth assays were also performed on NIH3T3 cells stably 
expressing vector alone or an activated form of Cdc42 (Cdc42 F28L) treated with 
200 µM T101 or untreated. Note that the ability of Cdc42 F28L to induce colony 
formation is insensitive to T101. Data shown in (A) though (G) are all mean ± s.d. 
from three independent experiments. (H) Tumor formation assays were performed 
in which 5 x 105 mitotically-arrested (using mitomycin-C) MDAMB231 cells 
(denoted as Mito-C-MDAMB231) expressing either control siRNA (siCont) or 
tTG siRNAs (denoted as siTG-1 or siTG-2) were subcutaneously injected singly, 
or combined with 5 x 105 NIH3T3 fibroblasts, into nude mice. As controls, 
untreated MDAMB231 and NIH3T3 cells were injected into nude mice. The 
resulting tumors that formed for each condition were counted and the results 
shown in the table.. 
 
*The experiments described in (A), (B), (C) and (H) were performed by Marc A. 
Antonyak and Bo Li. 
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Figure 3.6 (Continued)
 cell-derived MVs was not due to off-target effects that sensitized the fibroblasts to 
apoptosis. Analogous experiments were then performed where either MDAMB231 
cell-derived MVs were incubated with serum-starved NIH3T3 cells in the presence of 
the cell permeable tTG inhibitor MDC (Figure 3.6A), or MVs collected from 
MDAMB231 cells in which tTG had been knocked-down (Figure 3.4B) were added to 
serum-starved NIH3T3 cells (Figure 3.6C). Collectively, the results from these 
experiments point to a critical role for tTG in mediating the survival advantage 
imparted to fibroblasts by cancer cell-derived MVs.     
I then asked whether the transforming abilities of the cancer cell-derived MVs 
were dependent upon tTG. As shown previously in Figure 3.2E and 3.2H, and again in 
Figure 3.6D, 3.6E and 3.6F, incubating normal NIH3T3 fibroblasts and MCF10A 
epithelial cells with MVs derived from MDAMB231 cells or U87 cells induced their 
ability to grow (i.e. to form colonies) under anchorage-independent conditions. 
However, when recipient fibroblasts or epithelial cells were incubated with MV 
preparations that had been pre-treated with T101 (Figure 3.6D, 3.2H and 3.6F), or in 
which tTG had been knocked-down (Figure 3.6E), the number of colonies that formed 
in each case was reduced. I then verified that T101 did not generally inhibit cellular 
transformation by showing that this inhibitor had no influence on the ability of 
NIH3T3 cells expressing an activated form of the small GTPase Cdc42 (Cdc42 F28L) 
to grow under anchorage-independent conditions, even when a 5-fold excess of T101 
was used (Figure 3.6G).  
These findings prompted me to then consider whether cancer cell-derived MVs 
might function similarly in vivo and promote tumor growth by causing normal cells in 
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Figure 3.7 tTG functionally cooperates with FN to mediate the transforming 
actions of MVs on recipient fibroblasts. (A) Lysates of NIH3T3 cells stably 
overexpressing vector alone or Myc-tTG were immunoblotted with Myc and actin 
antibodies, and assayed for transamidation activity as readout by the incorporation 
of BPA into lysate proteins. (B) Cell death assays were performed on the NIH3T3 
stable cell lines maintained in serum-free medium that was treated with T101, 
MDC, or 2% CS-medium, or was untreated. (C) Anchorage-independent growth 
assays were performed on the NIH3T3 stable cell lines. Vector-control fibroblasts 
were incubated with MDAMB231 cell-derived MVs, as a positive control. Data 
shown in (B) and (C) are mean ± s.d. from two independent experiments. (D) 
Whole cell lysates (WCLs) of MDAMB231 and lysates of the MVs shed by these 
cells were either immunoblotted (Input), or subjected to immunoprecipitation 
using a tTG antibody (IP: tTG) and then immunoblotted, with FN, tTG, and actin 
antibodies. Note the detection of crosslinked FN in the MV lanes (FN dimer). (E) 
Intact MVs collected from MDAMB231 or U87 cells were treated without or with 
T101 prior to being lysed. The MV extracts were then subjected to 
immunoprecipitation using a tTG antibody (IP: tTG). The resulting 
immunocomplexes were immunoblotted with FN and tTG antibodies. (F) Intact 
MVs collected from MDAMB231 or U87 cells were treated without or with T101 
prior to being lysed. The MV extracts were then immunoblotted with FN and tTG 
antibodies. Note that the crosslinked forms of FN detected in the MV samples (FN 
dimer) were significantly reduced by T101 treatment. (G) Lysates of fibroblasts 
that were incubated without or with MVs derived from MDAMB231 and U87 
cells that had been pre-treated without or with T101, or the RGD-peptide, were 
immunoblotted with antibodies against FAK and ERK, or with antibodies that 
specifically recognize the activated forms of these protein kinases. (H) Diagram 
depicting how MVs transform recipient cells. MVs containing tTG and fibronectin 
are generated and released from the surfaces of human cancer cells. The MVs can 
then be taken-up by, or directly alter the microenvironment of, neighboring normal 
cells, where the co-transfer of tTG and FN function cooperatively on the recipient 
cells to induce signaling events that promote cell survival and aberrant cell growth.
 
*The experiments described in (B) were performed by Marc A. Antonyak and Bo 
Li. 
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Figure 3.7 (Continued)
 the tumor microenvironment to acquire the ability to form a tumor. To investigate this, 
I took advantage of the fact that exposing MDAMB231 cells to the mitotic arresting 
agent mitomycin-C, before injecting them into nude mice, inhibited their ability to 
form tumors under conditions where their control counterparts (untreated 
MDAMB231 cells) were quite effective at inducing tumor formation (Figure 3.6H). 
However, when the mitomycin-C-treated MDAMB231 cells were co-injected with an 
equal number of normal (non-transformed) NIH3T3 fibroblasts into mice, 4 of 6 mice 
formed tumors, suggesting that the MVs shed by the mitotically arrested cancer cells 
were capable of causing the neighboring NIH3T3 fibroblasts to become transformed, 
inducing tumor growth. Interestingly, I then went on to show that knocking-down tTG 
expression in the mitotically-arrested MDAMB231 cells blocked the ability of the co-
injected NIH3T3 fibroblasts to form tumors in mice. Thus, these results are consistent 
with the idea that cancer cells can generate MVs in vivo, and that their ability to cause 
normal cells in the tumor microenvironment to promote tumor formation is dependent 
on tTG. 
These findings demonstrate that the MV-mediated transfer of tTG into 
recipient cells is necessary for the ability of MDAMB231 cell- and U87 cell-derived 
MVs to transform fibroblasts.  However, is tTG alone sufficient to confer survival and 
transforming capabilities to the recipient cells?  In fact, I found that while NIH3T3 
fibroblasts stably overexpressing Myc-tagged tTG (Figure 3.7A) were indeed resistant 
to serum-deprivation-induced apoptosis, an effect that was ablated by treating the cells 
with MDC (Figure 3.7B), they were unable to form colonies in soft agar unlike the 
case when the vector-control expressing fibroblasts were incubated with MVs derived 
110 
 from MDAMB231 cells (Figure 3.7C). This means that while overexpression/over-
activation of tTG in normal cells is not sufficient to fully induce their transformation 
(i.e. NIH3T3 cells ectopically expressing tTG do not acquire the ability to form 
colonies when grown under anchorage-independent conditions), it does confer upon 
normal cells some characteristics of the transformed state, allowing them to grow in 
monolayer under low serum conditions, as well as to become less sensitive to serum-
deprivation-induced cell death. However, these findings also indicate that in order for 
cancer cell-derived MVs to enable recipient cells to exhibit one of the major hallmarks 
of cellular transformation, namely anchorage-independent growth, another protein 
must be transferred along with tTG. The cytoskeletal component fibronectin (FN) was 
a particularly attractive candidate, as it is a known binding partner of tTG (16, 17, 19) 
and was identified in my proteomics screen of MDAMB231 cell- and U87 cell-
derived MVs (Table 3.1). I confirmed that FN was expressed in the MVs collected 
from each of the cancer cell lines by immunoblot analysis (Figure 3.3A). I then 
assessed the potential role of the MV-associated FN in conferring upon fibroblasts the 
ability to exhibit anchorage-independent growth, by using the RGD-peptide as a 
means to interfere with the ability of FN to bind to and activate integrins on the 
surface of the recipient fibroblasts (20, 21). Anchorage-independent growth assays 
performed on fibroblasts co-treated with MVs derived from MDAMB231 or U87 cells, 
and either the RGD-peptide or the control RGE-peptide, showed that the RGD-peptide, 
like T101, blocked the MV-triggered induction of cellular transformation, whereas the 
control RGE-peptide did not (Figure 3.6D and 3.6F).  
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 Since both tTG and FN are important for the ability of cancer cell-derived 
MVs to transform recipient cells, might they work together to elicit this cellular 
outcome?  To address this I first examined whether tTG interacted with FN in MVs. 
Figure 3.7D shows that FN co-immunoprecipitates with tTG from MDAMB231 whole 
cell lysates as previously reported (16, 17, 19), as well as from lysates of MVs shed by 
these cells. In addition to binding the monomeric form of FN, tTG also associated with 
a larger form of FN with an apparent Mr of ~440 kDa that likely represented cross-
linked FN dimers and was detectable only in the MV lysate. Pre-treating intact MVs 
collected from MDAMB231 cells or U87 cells with the tTG inhibitor T101, prior to 
lysing the MVs and subjecting the extracts to immunoblot analysis, did not affect the 
ability of tTG to be co-immunoprecipitated with monomeric FN from the MV lysates 
(Figure 3.7E). However, pre-treating the MVs with the tTG inhibitor resulted in a 
marked reduction in the amount of the ~440 kDa FN species detected in the MV lysate 
samples (Figure 3.7F), suggesting that the higher molecular mass form of FN in the 
cancer cell-derived MVs is generated through the ability of tTG to interact with and 
cross-link FN.  
The dimerization of FN strongly enhances its ability to bind and activate 
integrins on the surfaces of cells (22, 23). The ability of tTG to cross-link FN in MVs 
shed by cancer cells suggested that this covalently modified form of FN is capable of 
potentiating integrin activation. Indeed, I found that preparations of intact MVs 
isolated from the medium of serum-deprived MDAMB231 cells or U87 cells were 
capable of stimulating signaling activities that are well-known to be downstream from 
activated integrins including FAK and ERK (Figure 3.7G). Moreover, the activation of 
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 these kinases by MVs was blocked either by using the tTG inhibitor T101 or the RGD 
peptide that interferes with integrin-signaling (Figure 3.7G), thus further 
demonstrating the importance of tTG and FN for the signaling functions of MVs.  
 
Discussion 
The findings described here shed important new light on an unconventional 
and poorly understood mechanism of cell-to-cell communication and how it may have 
significant consequences in human cancer progression. In particular, I have shown that 
exposing normal recipient cells to bio-active MVs that are constitutively shed by 
certain human cancer cells can cause them to acquire a transformed phenotype (Figure 
3.7H). I have identified the protein cross-linking enzyme tTG and the extracellular 
matrix protein FN as components of cancer cell-derived MVs that functionally 
cooperate to mediate the transforming activities of the MVs. The fact that tTG and FN 
are aberrantly regulated in several types of human cancers (24-30), raises exciting 
possibilities regarding the broad roles played by MVs in cancer progression. 
One aspect of my work to consider further involves the potential implications 
of MVs on tumor growth. There is a growing body of evidence demonstrating that 
cancer cells are capable of generating MVs in vivo, suggesting that the shedding of 
MVs by cancer cells is not merely an artifact of tissue culture, but rather represents a 
tumor-relevant process. A particularly good example comes from a recent study which 
showed that brain tumor cell-derived MVs could be routinely detected in blood 
samples taken from human patients afflicted with glioblastoma multiforme (4). 
Moreover, it was also shown that when MVs shed by cultures of several different 
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 human primary tumor cells or established cancer cell lines were subsequently added 
back to the same cancer cells, the growth and the survival of these cells were 
significantly enhanced (4-7). When considering these findings in the context of a 
tumor setting, the increased proliferative capacity afforded by sharing MVs among 
cancer cells could be envisioned as a mechanism to augment tumor growth. However, 
my results now suggest that MVs may impact cancer progression in a new and 
unexpected way, specifically, by conferring upon normal cell lineages that are major 
constituents of the tumor microenvironment (i.e. fibroblasts and epithelial cells), the 
transformed characteristics of cancer cells. This would be consistent with the idea that 
the expansion of a tumor mass would not necessarily depend solely on the 
proliferation of the cancer cells, but rather could also include the aberrant growth 
exhibited by stromal cells (including fibroblasts) and normal epithelium in the tumor 
microenvironment that have been exposed to MVs shed by cancer cells. If this turns 
out to be true, then how we think about cancer progression in vivo needs to be adjusted 
to include the potential contribution of MVs.        
However, it is important to note that the ability of the cancer cell-derived MVs 
to induce a transformed phenotype in normal (non-transformed) recipient cell types is 
not sustained. In order for MVs derived from either MDAMB231 breast cancer cells 
or U87 brain tumor cells to promote the growth of normal cells (i.e. NIH3T3 
fibroblasts and MCF10A mammary epithelial cells) in low serum and to induce their 
ability to form colonies in soft agar, the recipient cells needed to be repeatedly treated 
with freshly prepared MVs throughout the duration of these growth assays. This 
implies that the proteins and RNA transcripts contained within MVs that are involved 
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 in promoting their transforming activity, after being added to normal recipient cells, 
have a finite lifespan and need to be continuously replenished. When considering this 
in the context of a tumor setting, the chronic shedding of MVs by the cancer cells into 
their microenvironment might provide the continuous supply of MVs required by the 
nearby recipient stroma and normal epithelium to induce and maintain a transformed 
phenotype.  
The MV field is still in its infancy and many of the advances made in our 
understanding of MV formation, as well as the identity of their contents and their 
mechanisms of action (i.e. transforming capability), have thus far been largely limited 
to tissue culture experiments. However, as our methods for isolating and 
characterizing cancer cell-derived MVs continue to advance, it will ultimately be 
important to extend these studies into animal models. Toward this end, I am currently 
focusing my efforts on understanding the signaling events that are coupled to the 
formation and shedding of MVs from the surface of human cancer cells, and on 
determining whether additional proteins (i.e. aside from tTG and FN) contribute to the 
abilities of cancer cell-derived MVs to transform recipient cells. 
 
Materials and Methods  
 
Materials. 4,6-diamidino-2-phenylindole (DAPI), brefelden A, mitomycin-C, and 
Exo1 were obtained from Calbiochem, while T101 was from Zedira. The rhodamine-
conjugated phalloidin, EGF, Lipofectamine, Lipofectamine 2000, protein G beads, 
control and tTG siRNAs, and all cell culture reagents were from Invitrogen. The FN 
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 antibody, MDC, and BPA were from Sigma. The tTG and actin antibodies were 
obtained from Lab Vision/Thermo. Flotillin-2 antibody was obtained from Santa Cruz, 
and HA and Myc antibodies were from Covance. The Steriflip PVDF-filters (0.45µm 
pore size) were from Millipore. The antibodies against IκB, GFP, as well as 
antibodies that recognize ERK, AKT, FAK and the EGF receptor were from Cell 
Signaling.  
 
Cell Culture. The MDAMB231, U87, MCF10A, and HeLa cell lines were grown in 
RPMI 1640 medium containing 10% fetal bovine serum, while the NIH3T3 cell line 
was grown in DMEM medium containing 10% calf serum. Expression constructs were 
transfected into cells using Lipofectamine, whereas the control and tTG siRNAs were 
introduced into cells with Lipofectamine 2000. As indicated, cells were incubated with 
serum-free medium containing combinations of 0.1 µg/ml EGF, 100 µM MDC, 10 
µM T101, 10 µM BFA, and 10 µM Exo1. To mitotically arrest MDAMB231 cells, 
plates of cells were treated with 10 µg/ml mitomycin-C for 2 hours, before rinsing the 
solution away and allowing the cells to recover in growth medium (RPMI-1640 
medium containing 10% FBS) for a day.   
 
Isolation of Microvesicles from Cancer Cells. For each of the experiments that used 
MV preparations, the conditioned medium from 5.0 x 106 serum-starved MDAMB231 
cells or U87 cells (which is the equivalent of two nearly confluent 150 mm dishes of 
either of these cell lines) were collected and the MVs isolated from the medium as 
previously described (4, 5). Briefly, the conditioned medium was subjected to two 
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 consecutive centrifugations; the first at 300 g for 10 minutes pelleted intact cells, 
while the second at 12,000 g for 20 minutes pelleted cell debris. To generate MV 
lysates, the conditioned medium was centrifuged a third time at 100,000 g for 2 hours 
and the resulting pellet was washed with PBS and then lysed in 250 µl cell lysis buffer 
(25 mM Tris, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM 
NaVO4, 1 mM -glycerol phosphate, and 1 g/mL aprotinin). To generate intact MVs 
for the cell-based assays and other experiments as indicated, the partially purified 
conditioned medium (medium cleared of cells and cell debris) was then filtered using 
a Millipore Steriflip PVDF-filter with a 0.45 µm pore size. The microvesicles retained 
by the PVDF membrane were then resuspended in serum-free medium, with each 
preparation yielding enough MVs to treat 2-3 wells of a 6-well dish of recipient cells 
for a given experiment.     
 
Immunoblot Analysis and Immunoprecipitation. The protein concentrations of the 
whole cell lysates (WCLs) were determined using the Bio-Rad DC protein assay, 
while the MV lysates were normalized for comparison by isolating them from the 
conditioned medium of 5.0 x 106 serum-starved MDAMB231 cells or U87 cells for 
each of the experimental conditions assayed, and then lysing in 250 µl of cell lysis 
buffer. For immunoprecipitations, equal volumes of MV lysates, or 300 µg of WCLs, 
were incubated with a tTG antibody and protein G beads. The bead-antibody-protein 
complexes collected by centrifugation, as well as the WCLs (40 µg) and MV extracts 
(75 µl), were resolved by SDS-PAGE and the proteins transferred to polyvinylidene 
difluoride membranes. The filters were incubated with the indicated primary 
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 antibodies diluted in TBST (20 mM Tris, 135 mM NaCl, and 0.02% Tween 20). The 
primary antibodies were detected with horseradish peroxidase-conjugated secondary 
antibodies (Amersham Biosciences) followed by exposure to ECL reagent.  
 
Immunofluorescence. Cells were fixed with 3.7% paraformaldehyde and then some 
samples were permeabilized with phosphate-buffered saline (PBS) containing 0.1% 
Triton X-100. Permeabilized and non-permeabilized samples were incubated with a 
tTG antibody, and then incubated with Oregon green 488-conjugated secondary 
antibody. Rhodamine-conjugated phalloidin was used to stain actin and DAPI was 
used to stain nuclei. The cells were visualized by fluorescent microscopy and the 
images were captured and processed using IPLABS.  
 
Live Image Fluorescence Microscopy. MDAMB231 cells transiently expressing GFP-
PM, a GFP-tagged form of the plasma membrane targeting sequence in Lyn, were 
visualized by fluorescent microscopy. Images of the transfectants were captured in 30 
second intervals over a span of 15 minutes.  
   
Transamidation Assay. The transamidation activity in whole cell extracts was readout 
by the incorporation of BPA into lysate proteins as previously described (30), whereas 
the transamidation activity of recombinant tTG (0.1 M) exposed to increasing 
concentrations of T101 was determined using a spectrophotometric assay (31). The 
transamidation activity associated with MVs was readout by incubating equal amounts 
(75 l) of each MV sample in a buffer containing 40 mM N’N-dimethyl casein, 2 mM 
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 BPA, 40 mM CaCl2, and 40 mM dithiothreitol for 15 minutes. The reaction was 
stopped by the addition of Laemmli sample buffer followed by boiling. The reactions 
were then resolved by SDS-PAGE and the proteins transferred to polyvinylidene 
difluoride membranes. The filters were blocked with BBST (100 mM boric acid, 20 
mM sodium borate, 0.01% SDS, 0.01% Tween 20, and 80 mM NaCl) containing 10% 
bovine serum albumin, and then incubated with horseradish peroxidase-conjugated 
streptavidin diluted in BBST containing 5% bovine serum albumin for 1 hour at room 
temperature, followed by extensive washing with BBST. The incorporation of BPA 
into N’N-dimethyl casein was visualized after exposing the membranes to ECL 
reagent.  
 
Scanning Electron Microscopy (SEM) and Immuno-SEM. MDAMB231 cells grown 
on Lab-Tek chamber slides (Nunc) were fixed for 1 hour with 2% EM-grade 
glutaraldehyde diluted in a 0.05 M Cacodylic acid buffer solution (PH=7.4). For 
immuno-SEM, filter-isolated MDAMB231 cell-derived MVs were added to Lab-Tek 
chamber slides, allowed to attach, and then were fixed for 1 hour with 2% EM-grade 
glutaraldehyde in PBS. Following blocking for 15 minutes in 0.1M glycine, and for an 
additional 30 minutes in PBS containing 5% BSA, 0.1% gelatin and 5% goat serum, 
the MVs were incubated for 1 hour with the tTG antibody diluted in PBS (2 µg/mL). 
After washing with PBS, the MV samples were incubated for 1 hour with 6 nm gold 
particle-conjugated Goat-anti-Mouse IgG (Electron Microscopy Sciences) diluted in 
PBS. Both the cell and the immuno-labeled MV samples were post-fixed for 1 hour 
with 1% osmium tetroxide in PBS and dehydrated in graded ethanol solutions of 25%, 
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 50%, 70%, 95%, and 100% ethanol, before being placed in a CPD-30 critical point 
drying machine (BAL-TEC SCD050). The cells were then sputter-coated with 
platinum, whereas the immuno-labeled MVs were sputter-coated with amorphous 
carbon, before being observed with a Leo 1550 Field-Emission Scanning Electron 
Microscope.  
 
Cell Growth Assays. NIH3T3 cells were plated in each well of a 6-well dish at a 
density of 10×104 cells/well and were maintained in DMEM medium containing 2% 
CS supplemented without or with MVs derived from 5.0 X 106 MDAMB231 cells or 
U87 cells. Once a day for three days, one set of cultures was collected and counted, 
while the remaining sets of cells had their culturing medium replenished (including the 
addition of freshly isolated MVs). The assays were performed three times and the 
results were averaged together and graphed.     
   
Anchorage-independent Growth Assays. Parental NIH3T3 cells or MCF10A cells 
incubated without or with MVs derived from 5.0 X 106 MDAMB231 cells or U87 
cells, or NIH3T3 cells stably overexpressing the vector-control, wild-type tTG, or 
Cdc42 F28L, were plated at a density of 7×103 cells/ml in medium containing 0.3% 
agarose, without or with various inhibitors as indicated, onto underlays composed of 
growth medium containing 0.6% agarose in six-well dishes. The soft agar cultures 
were re-fed (including the addition of freshly prepared MVs and treatments with 
various inhibitors as indicated) every third day for 12 days, at which time the colonies 
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 that formed were counted. Each of the assays was performed at least three times and 
the results were averaged together and graphed.  
 
Cell Death Assays. NIH3T3 cells or MCF10A cells were plated in each well of a 6-
well dish and then cultured in medium containing 2% CS or serum-free medium 
supplemented without or with MVs derived from 5.0 x 106 MDAMB231 cells or U87 
cells, and without or with MDC or T101, as indicated. Two days later the cultures 
were fixed and stained with DAPI for viewing by fluorescence microscopy. Cells 
undergoing apoptosis were identified by nuclear condensation or blebbing and the 
percentage of cell death was determined by calculating the ratio of apoptotic to total 
cells for each condition. These experiments were conducted at least three times and 
the results from each experiment were averaged together and graphed.  
 
Flow Cytometry. Intact MVs were isolated from the conditioned medium of 5.0 x 106 
mock transfected MDAMB231 cells or MDAMB231 cells transiently expressing GFP 
using the filter method (described above) and re-suspended in PBS containing 0.1% 
BSA. The MV samples were evaluated using a BD LSR II flow cytometer by gating 
events that were between ~1-3 µm in size and determining whether they expressed 
GFP. At least 500 events were collected for each sample and then the data was 
analyzed using BD FACSDiva software. The experiments were performed at least 
three times, with similar results being obtained from each experiment.   
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 Proteomic Analyses. Lysates of MDAMB231 cell- and U87 cell-derived MVs (~30 µg 
of each sample) were resolved by SDS-PAGE and then stained using the Colloidal 
Blue Staining Kit (Invitrogen) according to the manufacturer’s protocol. The proteins 
were excised from the gel and then digested with trypsin. The resulting protein 
samples were analyzed at Cornell Proteomic Facility using a 4000 Q Trap (Triple 
quadrupole linear ion trap) On-line LC/MS/MS system (Applied Biosystems/MDS 
Sciex) or Synapt HDMS system (Waters). Protein identification was achieved by 
performing peptide alignment searches against the NCBI refseq protein database. 
 
Mouse Studies. 5 x 105 mitotically arrested (using mitomycin-C) MDAMB231 cells 
stably expressing control or tTG siRNAs were combined with 5 x 105 NIH3T3 
fibroblasts and growth factor-reduced Matrigel (BD Biosciences) to achieve 30% 
Matrigel in the final solution. The cell preparations were subcutaneously injected into 
the flanks of 6-8 weeks-old female NIH-III nude mice. As controls, parental 
MDAMB231 cells and NIH3T3 cells (5 x 105 cells of each cell line) were singly 
combined with growth factor-reduced Matrigel (to a final concentration of 30% 
Matrigel) and then were injected into mice as well. After a month, the animals were 
sacrificed and the resulting tumors that formed for each experimental condition were 
excised and counted. The experiments involving mice were performed in accordance 
with the protocols approved by The Cornell Center for Animal Resources and 
Education (CARE). 
122 
 APPENDIX 
 
 
 
 
 
 
The following table listed all the proteins identified from MDAMB231 cell- or U87 
cell-derived microvesicles by proteomic analysis as described in the "materials and 
methods" section. As referred to each column, "Access No." presents the accession 
number of each identified protein in the NCBI Genebank. "Protein Name" and 
"MW/Da" are the name and molecular weight (as a unit of Dalton) of identified 
proteins. "Score" is the evaluation score of each protein hit given by Mass 
spectrometry, and "Matches" are the numbers of identified peptides for each protein. 
The order of protein list is arranged based on their evaluation score, and the item of 
"transglutaminase 2 isoform a" is highlighted in bold.   
 
Access No. Protein Name MW/Da Score Matches
                   [MDAMB231 cell-derived Microvesicles]   
gi|16933542 fibronectin 1 isoform 3 preproprotein  259063 3278 130 
gi|4501887 actin, gamma 1 propeptide  41766 3152 121 
gi|37138 unnamed protein product  129330 2990 126 
gi|5031863 galectin 3 binding protein  65289 1891 74 
gi|4501881 actin, alpha 1, skeletal muscle  42024 1765 83 
gi|41872631 fatty acid synthase  273254 1527 83 
gi|5174735 tubulin, beta, 2  49799 1508 76 
gi|340021 alpha-tubulin 50120 1372 53 
gi|11602963 heparan sulfate proteoglycan perlecan  466304 1364 67 
gi|14389309 tubulin alpha 6  49863 1301 50 
gi|33350932 dynein, cytoplasmic, heavy polypeptide 1  532072 1285 99 
gi|35505 pyruvate kinase  57841 1140 48 
gi|32097 unnamed protein product  11260 1041 35 
gi|88191913 Chain A, Crystal Structure Of The Thrombospondin-1 N-Terminal Domain 23554 1037 50 
gi|223582 histone H4 11230 957 28 
gi|4758012 clathrin heavy chain 1  191493 941 48 
gi|18645167 Annexin A2  38552 906 32 
gi|31092 unnamed protein product  50095 851 46 
gi|306891 90kDa heat shock protein 83242 833 38 
gi|31979 histone H2A.2  13898 722 20 
gi|1568551 histone H2B  13928 691 20 
gi|6005942 valosin-containing protein  89266 594 41 
gi|5729877 heat shock 70kDa protein 8 isoform 1  70854 555 28 
gi|21361181 Na+/K+ -ATPase alpha 1 subunit isoform a proprotein  112824 553 19 
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 gi|671527 gamma subunit of CCT chaperonin  60292 538 24 
gi|31645 glyceraldehyde-3-phosphate dehydrogenase 36031 536 17 
gi|4502101 annexin I  38690 534 14 
gi|340062 pro-ubiquitin 17434 527 16 
gi|4503483 eukaryotic translation elongation factor 2  95277 517 33 
gi|4503571 enolase 1  47139 516 17 
gi|2804273 alpha actinin 4  102204 511 22 
gi|32111 unnamed protein product  14164 509 16 
gi|4503481 eukaryotic translation elongation factor 1 gamma  50087 498 21 
gi|61656603 Heat shock protein HSP 90-alpha 2  98052 488 25 
gi|10800144 histone cluster 1, H2aj  13928 480 17 
gi|35830 ubiquitin activating enzyme E1  117715 479 16 
gi|115206 C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) 101495 452 18 
gi|5174447 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1  35055 448 14 
gi|4092054 GTP binding protein  24440 440 15 
gi|1136741 KIAA0002  58465 440 17 
gi|2988422 agrin precursor  212745 438 23 
gi|4505763 phosphoglycerate kinase 1  44586 433 13 
gi|687239 tumor necrosis factor type 1 receptor associated protein 93863 412 18 
gi|55770868 tubulin, beta polypeptide 4, member Q  48456 397 19 
gi|1431788 
Chain A, Determination Of The Nmr Solution 
Structure Of The Cyclophilin A-Cyclosporin A 
Complex 
17981 395 11 
gi|603074 ATP:citrate lyase 120748 386 19 
gi|220141 VLA-3 alpha subunit  113433 385 25 
gi|38455427 chaperonin containing TCP1, subunit 4 (delta) 57888 374 13 
gi|6273399 melanoma-associated antigen MG50  167105 371 15 
gi|1346343 
Keratin, type II cytoskeletal 1 (Cytokeratin-1) 
(CK-1) (Keratin-1) (K1) (67 kDa cytokeratin) 
(Hair alpha protein) 
65978 368 17 
gi|112911 
Alpha-2-macroglobulin precursor (Alpha-2-M) 
(C3 and PZP-like alpha-2-macroglobulin 
domain-containing protein 5) 
163175 364 20 
gi|61744475 
solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
isoform a  
71079 361 21 
gi|28243 unnamed protein product  280586 358 17 
gi|12667788 myosin, heavy polypeptide 9, non-muscle  226392 352 22 
gi|21410823 EGF-like repeats and discoidin I-like domains 3  53760 350 18 
gi|356168 histone H1b 21721 347 14 
gi|119625804 moesin, isoform CRA_b  66564 336 16 
gi|31545 valyl-tRNA synthetase  140367 335 17 
gi|19743813 integrin beta 1 isoform 1A precursor  88357 335 14 
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 gi|2506545 
78 kDa glucose-regulated protein precursor 
(GRP 78) (Heat shock 70 kDa protein 5) 
(Immunoglobulin heavy chain-binding protein) 
(BiP) 
72377 329 17 
gi|62089222 heat shock 70kDa protein 1A variant  77448 329 15 
gi|4505467 5~ nucleotidase, ecto  63327 327 12 
gi|32358 hnRNP U protein  88890 316 8 
gi|547754 Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK 2e) (K2e) (keratin-2) 65825 313 13 
gi|122920512 Chain A, Human Serum Albumin Complexed With Myristate And Aspirin 66412 310 15 
gi|45439306 aspartyl-tRNA synthetase  57100 299 16 
gi|122138 
HLA class I histocompatibility antigen, A-2 
alpha chain precursor (MHC class I antigen 
A*2) 
40896 298 13 
gi|4588526 nuclear chloride channel  26907 296 11 
gi|20147503 laminin alpha5 chain precursor  399390 287 25 
gi|2656092 proteasome subunit p58  60968 286 15 
gi|119606902 phosphofructokinase, platelet, isoform CRA_b 84001 284 15 
gi|575249 lymphocyte antigen  40924 272 12 
gi|34234 laminin-binding protein  31774 269 7 
gi|13606056 DNA dependent protein kinase catalytic subunit  465266 266 22 
gi|3282771 actin-binding protein homolog ABP-278  278018 262 19 
gi|93141047 collagen, type XII, alpha 1 long isoform precursor  332941 261 18 
gi|809185 
Chain A, The Effect Of Metal Binding On The 
Structure Of Annexin V And Implications For 
Membrane Binding 
35783 256 14 
gi|47775861 MHC class I antigen  34120 241 10 
gi|179100 asparagine synthetase 64389 238 13 
gi|4506607 ribosomal protein L18  21621 237 7 
gi|4503841 ATP-dependent DNA helicase II, 70 kDa subunit  69799 235 12 
gi|11276938 hypothetical protein DKFZp762H157.1 - human (fragment) 73890 233 10 
gi|5730023 RuvB-like 2  51125 232 10 
gi|4506667 ribosomal protein P0  34252 227 6 
gi|4506671 ribosomal protein P2  11658 224 5 
gi|126369 Laminin subunit gamma-1 precursor (Laminin B2 chain) 177492 222 10 
gi|4503529 eukaryotic translation initiation factor 4A isoform 1  46125 217 10 
gi|1228049 multifunctional protein CAD  242762 214 14 
gi|532313 NF45 protein 44669 214 6 
gi|62088648 tumor rejection antigen (gp96) 1 variant  65912 213 8 
gi|38638698 KIAA1199  152900 207 15 
gi|178277 S-adenosylhomocysteine hydrolase 47684 205 8 
gi|2150046 26S proteasome subunit 9  47418 204 9 
gi|39777597 transglutaminase 2 isoform a  77280 198 15 
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 gi|1050527 seryl-tRNA synthetase  58713 197 11 
gi|4506753 RuvB-like 1  50196 193 8 
gi|493066 glycyl-tRNA synthetase 77463 188 5 
gi|306553 ribosmal protein small subunit 29980 187 7 
gi|4504255 H2A histone family, member Z  13545 186 9 
gi|30851181 FER1L3 protein  179438 185 9 
gi|339880 tripeptidyl peptidase II 138362 185 9 
gi|4826898 profilin 1  15045 183 7 
gi|183182 guanine nucleotide-binding regulatory protein alpha-inhibitory subunit 40437 183 5 
gi|339834 plasminogen activator  62863 180 7 
gi|2506380 
Lactadherin precursor (Milk fat globule-EGF 
factor 8) (MFG-E8) (HMFG) (Breast epithelial 
antigen BA46) (MFGM)  
43095 178 8 
gi|5031857 lactate dehydrogenase A  36665 178 9 
gi|7765076 S3 ribosomal protein  26699 177 9 
gi|5032051 ribosomal protein S14  16263 176 3 
gi|7661914 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6  45502 172 8 
gi|4504299 histone cluster 3, H3  15499 170 14 
gi|25777600 proteasome 26S non-ATPase subunit 1  105769 170 13 
gi|4506179 proteasome alpha 1 subunit isoform 2  29537 168 5 
gi|971270 proteasome subunit p40 / Mov34 protein  37037 166 4 
gi|4506209 proteasome 26S ATPase subunit 2  48603 165 10 
gi|10863945 ATP-dependent DNA helicase II  82652 163 15 
gi|4506743 ribosomal protein S8  24190 161 4 
gi|21361144 proteasome 26S ATPase subunit 3  49172 161 9 
gi|4505893 proteolipid protein 2 (colonic epithelium-enriched)  16680 161 3 
gi|4502643 chaperonin containing TCP1, subunit 6A isoform a  57988 159 10 
gi|1806048 nuclear DNA helicase II  140788 159 10 
gi|4507467 transforming growth factor, beta-induced, 68kDa precursor  74634 158 4 
gi|1526426 proteasome subunit p42  44133 158 8 
gi|1702932 yeast methionyl-tRNA synthetase homolog  101065 156 8 
gi|4092058 proteasome subunit HSPC  27886 154 5 
gi|6005882 protease, serine, 23 precursor  42974 154 10 
gi|1705996 Coatomer subunit alpha (Alpha-coat protein) (Alpha-COP) (HEP-COP) (HEPCOP)  138244 153 13 
gi|7705433 eukaryotic translation initiation factor 3 subunit 6 interacting protein  66684 153 5 
gi|4504981 beta-galactoside-binding lectin precursor  14706 151 7 
gi|31952 unnamed protein product  45623 150 5 
gi|28317 unnamed protein product  59492 149 9 
gi|4505011 lysyl oxidase-like 2 precursor  86668 147 9 
gi|14591909 ribosomal protein L5  34341 146 6 
gi|976227 26S proteasome subunit p45  45624 145 5 
gi|11559929 coatomer protein complex, subunit gamma 1  97655 145 5 
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 gi|3493529 histone macroH2A1.2  39576 144 5 
gi|403456 26S protease (S4) regulatory subunit 49155 139 5 
gi|19070472 p600  573536 138 9 
gi|5106785 HSPC027  42644 137 5 
gi|190281 protein phosphatase I alpha subunit (PPPIA) 35103 136 6 
gi|5453603 chaperonin containing TCP1, subunit 2  57452 134 11 
gi|15431301 ribosomal protein L7  29207 133 9 
gi|11545918 tubulointerstitial nephritis antigen-like 1  52353 131 3 
gi|4503519 eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa  37540 131 4 
gi|292059 MTHSP75 73734 131 4 
gi|37433 unnamed protein product  84848 130 6 
gi|74709215 Histone H2B type 2-C (H2.t) (H2B/t) 21458 130 4 
gi|6739602 talin  269486 129 11 
gi|234746 RAS-related protein MEL  23582 129 4 
gi|38014351 EEF1D protein  60845 128 4 
gi|28614 aldolase A  39307 126 6 
gi|33942 integrin alpha6 subunit  118824 125 4 
gi|2736256 aflatoxin aldehyde reductase AFAR  36625 125 3 
gi|999892 Chain A, Crystal Structure Of Recombinant Human Triosephosphate Isomerase 26522 124 4 
gi|5031635 cofilin 1 (non-muscle)  18491 123 3 
gi|4758648 kinesin family member 5B  109617 121 7 
gi|460789 transformation upregulated nuclear protein  51040 120 4 
gi|6424942 ALG-2 interacting protein 1  96019 119 6 
gi|124942 
Integrin alpha-2 precursor (Platelet 
membrane glycoprotein Ia) (GPIa) (Collagen 
receptor) (VLA-2 alpha chain) (CD49 antigen-
like family member B) (CD49b antigen) 
129214 117 7 
gi|440799 isoleucyl-tRNA synthetase 144388 116 13 
gi|2529707 Hpast  60665 114 7 
gi|1082300 collagen alpha 1(XVIII) chain - human (fragment) 70325 114 5 
gi|13325075 quiescin Q6 sulfhydryl oxidase 1 isoform a  82526 114 7 
gi|119616219 adaptor-related protein complex 3, beta 1 subunit, isoform CRA_c  68368 113 3 
gi|126366 Laminin subunit beta-1 precursor (Laminin B1 chain) 197937 111 10 
gi|7513316 ribosomal protein L14 23788 108 4 
gi|5031755 heterogeneous nuclear ribonucleoprotein R isoform 2  70899 108 3 
gi|36796 t-complex polypeptide 1  60356 108 10 
gi|4335941 leucine aminopeptidase  56014 108 6 
gi|125333 
Ephrin type-A receptor 2 precursor (Tyrosine-
protein kinase receptor ECK) (Epithelial cell 
kinase) 
108185 108 4 
gi|8394076 proteasome (prosome, macropain) subunit, alpha type 6 [Rattus norvegicus] 27382 107 2 
gi|182516 ferritin light subunit 16384 107 4 
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 gi|4506597 ribosomal protein L12  17808 106 3 
gi|951338 CAS 110244 106 11 
gi|1174149 small GTP binding protein Rab7  23447 106 4 
gi|31958 glutaminyl-tRNA synthetase  162923 105 5 
gi|662841 heat shock protein 27  22313 105 4 
gi|4507953 tyrosine 3/tryptophan 5 -monooxygenase activation protein, zeta polypeptide  27728 104 5 
gi|33055 unnamed protein product  274133 104 5 
gi|15341931 Lysyl oxidase-like 4  84327 104 2 
gi|1478281 neutral amino acid transporter B 56585 103 6 
gi|4506017 protein phosphatase 2, catalytic subunit, alpha isoform  35571 103 3 
gi|183303 glucose transporter glycoprotein 54083 102 8 
gi|339992 tumor necrosis factor 41975 101 6 
gi|2696613 ATP-dependent RNA helicase #46  92770 101 4 
gi|5031573 ARP3 actin-related protein 3 homolog  47341 101 5 
gi|5453595 adenylyl cyclase-associated protein  51641 100 6 
gi|42716297 clusterin isoform 1  57796 100 7 
gi|1778051 Prt1 homolog  98820 100 5 
gi|4557032 lactate dehydrogenase B  36615 99 4 
gi|38202255 threonyl-tRNA synthetase  83382 99 9 
gi|4506631 ribosomal protein L30  12776 99 2 
gi|190074 lysyl hydroxylase 83527 98 5 
gi|9802306 DNA-binding protein TAXREB107  32871 97 5 
gi|32449796 EIF3A protein  96804 97 11 
gi|3088342 ribosomal protein S23  6465 97 2 
gi|4506141 HtrA serine peptidase 1 precursor  51255 97 5 
gi|1040689 Human Diff6,H5,CDC10 homologue  46556 96 2 
gi|28395033 ras homolog gene family, member C precursor  21992 95 2 
gi|306875 C protein 31947 95 4 
gi|183353 glycogen phosphorylase 97161 94 3 
gi|4506691 ribosomal protein S16  16435 94 5 
gi|550021 ribosomal protein S5 22763 93 2 
gi|4758756 nucleosome assembly protein 1-like 1  45346 93 2 
gi|7243085 KIAA1352 protein  138273 92 10 
gi|119611239 ATPase, Na+/K+ transporting, beta 1 polypeptide, isoform CRA_b  22414 91 3 
gi|14495609 CTP synthase  66674 91 4 
gi|119625894 
phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase, isoform 
CRA_a  
49648 90 3 
gi|6006515 spliceosomal protein SAP 130  135507 89 4 
gi|703093 serine hydroxymethyltransferase 52429 89 5 
gi|23398 1-8U  14581 88 1 
gi|5257007 beta-cop homolog  107071 88 6 
gi|3420181 WDR1 protein  57966 87 5 
gi|5453607 chaperonin containing TCP1, subunit 7 59329 87 10 
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 isoform a  
gi|4506183 proteasome alpha 3 subunit isoform 1  28415 87 4 
gi|87196339 collagen, type VI, alpha 1 precursor  108462 87 5 
gi|181914 DNA-binding protein 35801 86 5 
gi|4506661 ribosomal protein L7a  29977 84 3 
gi|4759160 small nuclear ribonucleoprotein polypeptide D3  13907 84 4 
gi|6042196 cathepsin F  53332 84 4 
gi|37227 tenascin  240565 83 4 
gi|6678271 TAR DNA binding protein  44711 83 2 
gi|12804225 Unknown (protein for IMAGE:3543711)  59431 80 6 
gi|5803225 tyrosine 3/tryptophan 5 -monooxygenase activation protein, epsilon polypeptide  29155 80 2 
gi|181387 cystatin C 15819 77 2 
gi|56203471 histone cluster 2, H3, pseudogene 2  15421 77 10 
gi|1477646 plectin  518173 77 14 
gi|7023053 unnamed protein product  40297 77 4 
gi|119618541 hCG2016250, isoform CRA_j  28191 76 6 
gi|4759158 small nuclear ribonucleoprotein polypeptide D2  13518 76 2 
gi|37267 transketolase  67751 76 3 
gi|32189394 ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit precursor  56525 75 6 
gi|8886884 platelet-derived growth factor C  39019 75 1 
gi|183008 glucocerebrosidase precursor 57399 75 1 
gi|6808243 hypothetical protein  78295 75 3 
gi|381964 actin-related protein 42545 75 6 
gi|208115 p21 protein 21327 74 3 
gi|4506221 proteasome 26S non-ATPase subunit 12  52871 74 4 
gi|307200 brain glycogen phosphorylase 98891 73 3 
gi|219588 DnaJ protein homolog  44848 73 2 
gi|11610605 testis-specific poly(A)-binding protein  70072 73 3 
gi|4503523 eukaryotic translation initiation factor 3 subunit D  63932 73 4 
gi|18379349 vesicle amine transport protein 1  41893 72 8 
gi|4680691 CGI-26 protein  36955 72 1 
gi|1657268 aminopeptidase  98467 72 2 
gi|5031977 nicotinamide phosphoribosyltransferase precursor  55487 71 2 
gi|5453998 importin 7  119440 71 3 
gi|4503143 cathepsin D preproprotein  44524 70 9 
gi|449441 UDP-glucose pyrophosphorylase 56914 70 1 
gi|4506185 proteasome alpha 4 subunit isoform 1  29465 70 2 
gi|494066 
Chain A, Three-Dimensional Structure Of 
Class Pi Glutathione S- Transferase From 
Human Placenta In Complex With S- 
Hexylglutathione At 2.8 Angstroms Resolution
23210 70 1 
gi|10835165 CD59 antigen preproprotein  14168 70 3 
gi|1419567 dynactin  139873 69 4 
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 gi|2624694 Chain A, Human Mitochondrial Single-Stranded Dna Binding Protein 15186 69 3 
gi|4506613 ribosomal protein L22 proprotein  14778 69 1 
gi|78070384 CDC2 protein  25923 69 5 
gi|119599627 hCG1646871  29121 69 4 
gi|20146101 EMMPRIN  29134 69 3 
gi|7212811 EH domain containing 4  54530 68 1 
gi|5107666 Chain A, Structure Of Importin Beta Bound To The Ibb Domain Of Importin Alpha 97172 68 5 
gi|183709 small G protein 20214 68 3 
gi|2209347 p21-Arc  20502 68 2 
gi|21706696 Calsyntenin 1  108601 68 2 
gi|226021 growth regulated nuclear 68 protein 66881 68 3 
gi|4504975 low density lipoprotein receptor precursor  95314 67 3 
gi|4503981 glucosamine-fructose-6-phosphate aminotransferase  76698 67 3 
gi|1346766 
26S proteasome non-ATPase regulatory 
subunit 8 (26S proteasome regulatory subunit 
S14) (p31) 
29986 67 3 
gi|462190 Glypican-1 precursor [Contains: Secreted glypican-1] 61611 67 2 
gi|62511242 
4-trimethylaminobutyraldehyde 
dehydrogenase (TMABADH) (Aldehyde 
dehydrogenase family 9 member A1) 
(Aldehyde dehydrogenase E3 isozyme) 
53767 67 3 
gi|35218 unnamed protein product  75812 66 8 
gi|4757944 CD81 antigen  25792 66 2 
gi|2852617 unknown  12012 66 2 
gi|4506787 IQ motif containing GTPase activating protein 1  189134 66 4 
gi|1931584 eIF-3 p110 subunit  105276 66 7 
gi|5031931 nascent polypeptide-associated complex alpha subunit isoform b  23370 66 1 
gi|6648067 Malate dehydrogenase, mitochondrial precursor 35509 66 2 
gi|5031595 actin related protein 2/3 complex subunit 4 isoform a  19654 66 4 
gi|9624998 heterogeneous nuclear ribonucleoprotein H2  49232 65 2 
gi|440177 flightless-I homolog  144528 65 2 
gi|1217668 arginyl-tRNA synthetase; ArgRS  74930 65 4 
gi|2791898 CYR61 protein  41997 65 7 
gi|1699163 ETX1  49901 64 2 
gi|56203429 copine I  33831 64 3 
gi|495126 ribosomal protein L11  20103 64 1 
gi|181486 DNA-binding protein B 39954 64 1 
gi|550023 ribosomal protein S9 22558 64 3 
gi|45751608 Myosin IC  117876 64 6 
gi|4505753 phosphoglycerate mutase 1 (brain)  28786 64 2 
gi|306506 antigen CD9 3227 64 1 
gi|4506439 retinoblastoma binding protein 7  47790 63 3 
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 gi|4261795 eukaryotic initiation factor 5A  16790 61 1 
gi|12585547 
Tripartite motif-containing protein 25 (Zinc 
finger protein 147) (Estrogen-responsive 
finger protein) (Efp) (RING finger protein 147)
70944 61 1 
gi|4506605 ribosomal protein L23  14856 60 1 
gi|496902 translation initiation factor  46803 60 3 
gi|3088338 ribosomal protein S10  9429 60 2 
gi|40789067 KIAA0010  124156 60 3 
gi|17986258 myosin, light chain 6, alkali, smooth muscle and non-muscle isoform 1  16919 59 4 
gi|23503239 aldehyde dehydrogenase 16 family, member A1  85060 59 3 
gi|1710248 protein disulfide isomerase-related protein 5  46170 59 1 
gi|119575878 hCG37513, isoform CRA_a  15044 58 2 
gi|34412 unnamed protein product  78029 58 2 
gi|119592221 ribosomal protein S4, X-linked, isoform CRA_a  43436 58 4 
gi|31147 PAI precursor polypeptide  44973 58 6 
gi|4506681 ribosomal protein S11  18419 58 2 
gi|4506181 proteasome alpha 2 subunit  25882 58 3 
gi|40675522 ARCN1 protein  21840 58 4 
gi|148225456 hypothetical protein LOC644928  12969 57 2 
gi|340368 transfer RNA-Trp synthetase 53054 57 1 
gi|4758256 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa  36089 56 1 
gi|30173225 
Structural maintenance of chromosomes 
protein 2 (Chromosome-associated protein E) 
(hCAP-E) (XCAP-E homolog) 
135696 56 5 
gi|577295 KIAA0088  106702 56 3 
gi|340219 vimentin 53681 56 4 
gi|20521848 KIAA0219  292956 56 6 
gi|36142 ribosomal protein homologous to yeast S24  14707 56 11 
gi|2224677 KIAA0368  159376 56 4 
gi|307066 inosine-5~-monophosphate dehydrogenase 55885 56 3 
gi|307110 lysosomal membrane glycoprotein-2 44804 56 1 
gi|19923903 myeloid-associated differentiation marker  35250 56 2 
gi|14042058 unnamed protein product  100221 56 3 
gi|62087228 3-mercaptopyruvate sulfurtransferase variant 34730 56 2 
gi|337514 ribosomal protein S6 28614 55 4 
gi|763130 YPT3  24559 55 2 
gi|4759300 vesicle-associated membrane protein 3  11302 55 1 
gi|4506697 ribosomal protein S20  13364 55 2 
gi|296734 macropain subunit delta  19362 55 2 
gi|4506707 ribosomal protein S25  13734 54 1 
gi|4826878 oxidative-stress responsive 1  57986 54 1 
gi|263099 Tat binding protein 7, TBP-7-transcriptional activator  51519 53 3 
gi|4503507 eukaryotic translation initiation factor 2, subunit 3 gamma 51077 53 3 
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 gi|119581148 keratin 9 (epidermolytic palmoplantar keratoderma)  57526 53 5 
gi|1666075 ubiquitin hydrolase  289438 53 4 
gi|4504897 karyopherin alpha 2  57826 52 3 
gi|531202 spermidine synthase 33790 52 1 
gi|13172664 hemidesmosomal tetraspanin CD151  28294 52 3 
gi|7023260 unnamed protein product  48659 52 1 
gi|438069 thiol-specific antioxidant protein  21843 52 2 
gi|110171861 decay-accelerating factor splicing variant 1  48482 51 2 
gi|119609715 integrin, beta 4, isoform CRA_d  107154 51 3 
gi|62897071 oxygen regulated protein precursor variant  111210 51 2 
gi|4506625 ribosomal protein L27a  16551 51 2 
gi|799177 100 kDa coactivator 99628 50 3 
gi|62897675 ribosomal protein L4 variant  47688 50 1 
gi|119628884 heat shock 105kDa/110kDa protein 1, isoform CRA_b  97398 49 3 
gi|542850 heterogeneous nuclear ribonucleoprotein G - human 47419 48 1 
gi|31189 unnamed protein product  23182 48 1 
gi|35068 Nm23 protein  20398 48 1 
gi|118090 
Peptidyl-prolyl cis-trans isomerase B 
precursor (PPIase) (Rotamase) (Cyclophilin 
B) (S-cyclophilin) (SCYLP) (CYP-S1) 
22728 48 2 
gi|4502171 adenine phosphoribosyltransferase isoform a 19595 48 2 
gi|4758762 asparaginyl-tRNA synthetase  62903 47 2 
gi|33985 trypsin inhibitor  106647 47 2 
gi|458727 RCK  53183 47 1 
gi|2323410 Skb1Hs  72740 47 3 
gi|219510 collagen alpha 1(V) chain precursor  183505 47 2 
gi|56417899 ARF-binding protein 1  481605 47 2 
gi|4506619 ribosomal protein L24  17768 46 1 
gi|32528284 acyl-CoA thioesterase 7 isoform hBACHc  38966 46 5 
gi|22477159 Sec23 homolog A (S. cerevisiae)  86109 46 2 
gi|1230564 Gu protein 89196 46 3 
gi|508285 
Rab5c-like protein, similar to Canis familiaris 
Rab5c protein, PIR Accession Number 
S38625 
23553 46 1 
gi|29446 unnamed protein product  15956 46 1 
gi|1403050 phosphoenolpyruvate carboxykinase (GTP)  70539 45 2 
gi|473583 DNA topoisomerase I 90222 45 2 
gi|83753119 Chain A, Crystal Structure Of Human Full-Length Vinculin (Residues 1- 1066) 115928 45 6 
gi|6841182 HSPC266  43276 43 2 
gi|5454028 related RAS viral (r-ras) oncogene homolog  23466 43 1 
gi|5803185 synaptophysin-like 1 isoform a  28547 43 1 
gi|36038 rho GDP dissociation inhibitor (GDI)  23179 43 1 
gi|114940 Beta-galactosidase precursor (Acid beta-galactosidase) (Lactase) (Elastin receptor 1) 76043 43 1 
gi|2102696 karyopherin beta 3  123512 42 3 
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 gi|4502281 Na+/K+ -ATPase beta 3 subunit  31492 41 1 
gi|255317 nuclear autoantigen RA33-A2 hnRNP homolog 2371 41 1 
gi|5031571 actin-related protein 2 isoform b  44732 41 7 
gi|4689134 60S ribosomal protein L36  12227 40 2 
gi|3288815 citrate synthase  51673 40 1 
gi|4502875 claudin 3  23303 40 1 
gi|1942609 
Chain A, Human Rap1a, Residues 1-167, 
Double Mutant (E30d,K31e) Complexed With 
Gppnhp And The Ras-Binding-Domain Of 
Human C-Raf1, Residues 51-131 
19011 40 2 
gi|2224663 KIAA0361  147958 39 1 
     
 [U87 cell-derived Microvesicles]    
gi|16933542 fibronectin 1 isoform 3 preproprotein  259063 3136 103 
gi|55743098 alpha 3 type VI collagen isoform 1 precursor  343457 2823 118 
gi|68533131 TNC variant protein  244248 2372 81 
gi|1346343 Keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) (Keratin-1) (K1) (Hair alpha protein) 65978 2020 89 
gi|28317 unnamed protein product  59492 1413 76 
gi|55956899 keratin 9  62027 1015 38 
gi|112911 
Alpha-2-macroglobulin precursor (Alpha-2-M) 
(C3 and PZP-like alpha-2-macroglobulin 
domain-containing protein 5) 
163175 999 36 
gi|4501885 beta actin  41710 983 29 
gi|5031863 galectin 3 binding protein  65289 771 34 
gi|122920512 Chain A, Human Serum Albumin Complexed With Myristate And Aspirin 66412 692 27 
gi|4507467 transforming growth factor, beta-induced, 68kDa precursor  74634 660 22 
gi|29799 CD44R1  53366 631 20 
gi|31645 glyceraldehyde-3-phosphate dehydrogenase 36031 586 13 
gi|87196339 collagen, type VI, alpha 1 precursor  108462 578 20 
gi|115298678 complement component 3 precursor  187030 559 25 
gi|4501881 actin, alpha 1, skeletal muscle  42024 540 21 
gi|22760207 unnamed protein product  96376 535 21 
gi|7243270 KIAA1436 protein  102932 502 21 
gi|547754 Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK 2e) (K2e) (keratin-2) 65825 487 30 
gi|5729877 heat shock 70kDa protein 8 isoform 1  70854 456 15 
gi|21361181 Na+/K+ -ATPase alpha 1 subunit isoform a proprotein  112824 454 17 
gi|4503571 enolase 1  47139 437 13 
gi|4699714 
Chain A, Human Plasminogen Activator 
Inhibitor Type-1 In Complex With A 
Pentapeptide 
42800 435 21 
gi|4505467 5~ nucleotidase, ecto  63327 424 11 
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 gi|19743813 integrin beta 1 isoform 1A precursor  88357 407 18 
gi|220141 VLA-3 alpha subunit  113433 399 19 
gi|35825 pregnancy zone protein  163733 387 19 
gi|1195531 type I keratin 16; K16  51206 382 22 
gi|12803709 Keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner)  51619 373 24 
gi|78101267 Chain A, Human Complement Component C3 71146 369 15 
gi|50080140 MHC class I antigen  31497 364 11 
gi|122138 
HLA class I histocompatibility antigen, A-2 
alpha chain precursor (MHC class I antigen 
A*2) 
40896 357 11 
gi|4757756 annexin A2 isoform 2  38580 335 12 
gi|28614 aldolase A  39307 327 10 
gi|180671 collagenase type IV precursor 72196 321 10 
gi|339992 tumor necrosis factor 41975 316 8 
gi|152148396 MHC class I antigen  34026 310 7 
gi|33985 trypsin inhibitor  106647 300 7 
gi|71680364 Leucine rich repeat containing 15  64325 296 12 
gi|4507265 stanniocalcin 1 precursor  27604 277 4 
gi|5031857 lactate dehydrogenase A  36665 268 11 
gi|126369 Laminin subunit gamma-1 precursor (Laminin B2 chain) 177492 262 8 
gi|306891 90kDa heat shock protein 83242 255 10 
gi|258295 C33 antigen  29610 238 8 
gi|50284497 MHC class I antigen  31623 233 6 
gi|124942 
Integrin alpha-2 precursor (Platelet 
membrane glycoprotein Ia) (GPIa) (Collagen 
receptor) (VLA-2 alpha chain) (CD49 antigen-
like family member B) (CD49b antigen) 
129214 232 9 
gi|229532 ubiquitin 8446 231 9 
gi|32488 unnamed protein product  84621 225 6 
gi|4505763 phosphoglycerate kinase 1  44586 220 5 
gi|230867 
Chain R, Twinning In Crystals Of Human 
Skeletal Muscle D- Glyceraldehyde-3-
Phosphate Dehydrogenase 
35853 215 6 
gi|61744475 
solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
isoform a  
71079 214 7 
gi|6005942 valosin-containing protein  89266 205 12 
gi|20146101 EMMPRIN  29134 204 8 
gi|119617032 keratin 6B, isoform CRA_a  59874 201 15 
gi|183182 guanine nucleotide-binding regulatory protein alpha-inhibitory subunit 40437 193 6 
gi|50428530 MHC class I antigen  31698 192 6 
gi|2506545 
78 kDa glucose-regulated protein precursor 
(GRP 78) (Heat shock 70 kDa protein 5) 
(Immunoglobulin heavy chain-binding protein) 
(BiP) 
72377 189 9 
gi|4557032 lactate dehydrogenase B  36615 189 5 
gi|4505257 moesin  67778 185 13 
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 gi|4502101 annexin I  38690 170 4 
gi|190074 lysyl hydroxylase 83527 170 5 
gi|136066 Triosephosphate isomerase (TIM) (Triose-phosphate isomerase) 26609 165 3 
gi|31438 unnamed protein product  114437 165 7 
gi|16445029 immunoglobulin superfamily, member 8  64994 155 4 
gi|5031977 nicotinamide phosphoribosyltransferase precursor  55487 139 6 
gi|12274842 laminin, alpha 5  398951 139 12 
gi|46016221 MHC class I antigen  21098 137 4 
gi|998626 85 kda glioma membrane protein/CD44 homolog  1336 135 3 
gi|4506141 HtrA serine peptidase 1 precursor  51255 132 7 
gi|183531 platelet glycoprotein IIIa 84277 130 3 
gi|13603394 type VI collagen alpha 2 chain precursor  108506 127 8 
gi|112910 
Alpha-2-HS-glycoprotein precursor (Ba-alpha-
2-glycoprotein) (Alpha-2-Z-globulin) (Fetuin-
A)  
39300 125 4 
gi|312137 fructose bisphosphate aldolase  39417 122 3 
gi|553734 putative  2212 121 18 
gi|34412 unnamed protein product  78029 120 4 
gi|4758012 clathrin heavy chain 1  191493 108 3 
gi|286005 KIAA0006  51586 108 4 
gi|187387 myristoylated alanine-rich C-kinase substrate 31857 106 3 
gi|5729850 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 40506 104 2 
gi|4502719 cadherin 13 preproprotein  78238 102 2 
gi|2804273 alpha actinin 4  102204 101 5 
gi|31189 unnamed protein product  23182 97 2 
gi|39777597 transglutaminase 2 isoform a  77280 96 4 
gi|93141049 collagen, type XII, alpha 1 short isoform precursor  205363 94 5 
gi|908801 keratin type II 60163 93 10 
gi|4504763 integrin alpha-V precursor  115978 92 3 
gi|35505 pyruvate kinase  57841 91 3 
gi|4502049 aldo-keto reductase family 1, member B1  35830 89 2 
gi|31092 unnamed protein product  50095 84 3 
gi|4502281 Na+/K+ -ATPase beta 3 subunit  31492 83 3 
gi|28334 unnamed protein product  102910 83 4 
gi|4506803 stem cell growth factor precursor  35672 82 4 
gi|31952 unnamed protein product  45623 82 2 
gi|1136741 KIAA0002  58465 82 2 
gi|30795231 brain abundant, membrane attached signal protein 1  22680 81 5 
gi|4502107 annexin 5  35914 79 3 
gi|296736 macropain subunit iota  24564 74 1 
gi|1708865 
Prolow-density lipoprotein receptor-related 
protein 1 precursor (LRP) (Alpha-2-
macroglobulin receptor) (A2MR) 
504245 71 3 
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 (Apolipoprotein E receptor) (APOER) (CD91 
antigen)  
gi|4507953 tyrosine 3/tryptophan 5 -monooxygenase activation protein, zeta polypeptide  27728 71 2 
gi|126366 Laminin subunit beta-1 precursor (Laminin B1 chain) 197937 70 4 
gi|558526 proteasome subunit X  22882 70 2 
gi|404722 guanine nucleotide regulatory protein  44036 70 2 
gi|21754275 unnamed protein product  76396 70 2 
gi|178855 apolipoprotein J precursor 48772 69 2 
gi|4506183 proteasome alpha 3 subunit isoform 1  28415 68 1 
gi|4218955 gamma-filamin  288721 68 5 
gi|558528 proteasome subunit Y  25299 67 2 
gi|119593150 filamin A, alpha (actin binding protein 280), isoform CRA_a  248350 67 4 
gi|21739753 hypothetical protein  90929 66 3 
gi|6980496 Chain C, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor 71681 65 3 
gi|7671639 dJ34F7.1.1 (tenascin XB (isoform 1))  463945 65 4 
gi|5821140 ASY  40308 64 2 
gi|189868 phosphoglycerate mutase 28832 63 2 
gi|18999435 
Keratin 5 (epidermolysis bullosa simplex, 
Dowling-Meara/Kobner/Weber-Cockayne 
types)  
62340 62 7 
gi|2344812 Drg1  42796 61 1 
gi|2407641 neuropilin  103056 61 1 
gi|4503481 eukaryotic translation elongation factor 1 gamma  50087 59 2 
gi|5453914 phospholipid transfer protein isoform a precursor  54705 59 1 
gi|4503483 eukaryotic translation elongation factor 2  95277 58 1 
gi|30102 type I collagen  41496 58 1 
gi|178277 S-adenosylhomocysteine hydrolase 47684 57 2 
gi|577295 KIAA0088  106702 57 1 
gi|463907 syntaxin 34173 56 1 
gi|5851638 major vault protein  19256 54 4 
gi|4505011 lysyl oxidase-like 2 precursor  86668 53 1 
gi|4505891 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 precursor  84731 53 1 
gi|5803225 tyrosine 3/tryptophan 5 -monooxygenase activation protein, epsilon polypeptide  29155 52 2 
gi|135691 
Latent-transforming growth factor beta-
binding protein, isoform 1S precursor (LTBP-
1) (Transforming growth factor beta-1-binding 
protein 1) (TGF-beta1-BP-1) 
152689 51 1 
gi|11545873 secreted modular calcium-binding protein 1 isoform 2  48132 48 1 
gi|21739834 hypothetical protein  55126 47 6 
gi|21265101 transmembrane 4 superfamily member 1  21617 46 1 
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 gi|1916850 scaffold protein Pbp1  32397 45 1 
gi|190447 prosomal protein P30-33K 30208 45 1 
gi|31979 histone H2A.2  13898 45 2 
gi|4691726 ARF GTPase-activating protein GIT1  84279 44 1 
gi|6424942 ALG-2 interacting protein 1  96019 43 2 
gi|340219 vimentin 53681 43 3 
gi|119599578 hCG2040552  8864 43 1 
gi|1000702 p54/58N  49699 42 1 
gi|34234 laminin-binding protein  31774 40 1 
gi|4235275 talin  269661 40 2 
gi|2988400 Unknown gene product  61410 40 1 
gi|87901 Ig lambda chain V-IV region 15451 39 1 
gi|188619 matrix metalloproteinase-3 53944 39 1 
gi|48425723 Chain E, Structure Of Human Transferrin Receptor-Transferrin Complex 38222 39 1 
gi|13537204 MAST205  189320 39 1 
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 CHAPTER 4 
 
RhoA-ROCK-Lim kinase signaling triggers the biogenesis of cancer cell-derived 
microvesicles 
 
Introduction 
Classical cell-cell communication involves the secretion of hormones or 
cytokines that stimulate signaling activities within cells in either an autocrine or 
paracrine fashion upon binding to their cell-surface receptors (1, 2). Although these 
secretory events have been commonly assumed to serve as the predominant mode of 
cell-cell communication, a novel type of vesicle secretion, referred to as microvesicles 
(MVs) or oncosomes (when shed from cancer cells), has begun to receive a great deal 
of attention (3-7). MVs are an unconventional form of cellular secretory structures that 
are directly shed from the plasma membranes of cells. They contain a variety of types 
of cargo including cell surface receptors and other signaling proteins, as well as 
mRNA transcripts, with their specific composition being primarily determined by their 
cellular origins (8-15). MVs have sometimes been mis-identified as exosomes, which 
are conventional secretory vesicles generated through the classical endosome - 
multivesicular body (MVB) trafficking pathway (16). However, MVs are distinct from 
exosomes with regard to how they are generated, as well as their size, lipid 
composition, and cargo (17).  
Once shed from donor cells, MVs are able to either alter the microenvironment 
through their cargo, or fuse to recipient cells where certain signaling activities can be 
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 triggered upon the transfer of their cargo. For example, MVs secreted from endothelial 
cells, platelets, or monocytes were shown to contain phosphatidylserine and tissue 
factor, which can bind and facilitate the actions of coagulation factor at the vascular 
site of injury (18), whereas MVs generated from microglial cells were able to transfer 
interleukin-1 into recipient cells that do not express this cytokine, thereby regulating 
their inflammatory response (19). Moreover, it was recently shown that murine 
embryonic stem cell-derived MVs are capable of prolonging the expansion of 
hematopoietic progenitor cells (HPCs) by transferring mRNAs encoding several 
pluripotent transcription factors into recipient HPCs (20).  
In addition to the biological functions described above, there has been a rapidly 
growing appreciation that MVs play important roles in different aspects of cancer 
progression. It was recently discovered that several malignant cancer cell lines exhibit 
significantly enhanced MV production, including glioblastoma, melanoma, prostate, 
colorectal and breast cancer cells (3, 4, 6, 21-25). Cancer cell-derived MVs were 
shown to play critical roles by influencing the tumor microenvironment as well as 
stimulating angiogenesis and metastasis, and promoting tumor growth (13-15, 26, 27). 
Moreover, MVs shed from cancer cells have been shown to help to generate a more 
“tumor-friendly” niche through the actions of some of their cargo such as metallo-
proteases, or by directly stimulating signaling activities within recipient cells 
following the transfer of their cargo (28, 29). For example, it was recently shown that 
the overexpression of the constitutively-active truncated form of the EGF receptor, 
EGFR vIII, in glioblastomas stimulates MV formation in these cancer cells. EGFR 
vIII was also found to be part of the cargo of the released MVs, which upon engaging 
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 neighboring glioblastoma cells, induced enhanced EGFR-signaling and oncogenic 
transformation (3). 
Remarkably, recent studies have shown that MV-mediated intercellular 
communication not only occurs between cancer cells, but also between cancer cells 
and adjacent normal cells, including stromal fibroblasts and endothelial cells (29, 30). 
Indeed, we recently demonstrated that MVs derived from breast cancer or 
glioblastoma cells are capable of conferring onto normal fibroblasts, as well as normal 
epithelial cells, the characteristics of transformed cells. This required the MV-
mediated transfer of an essential protein cargo, tissue transglutaminase (tTG), together 
with its transamidation substrate, fibronectin (6). When taken together, these results 
highlight a previously unappreciated role of MVs in cancer progression, suggesting 
that tumor formation not only depends on cancer cell proliferation, but also involves 
the MV-mediated exchange of cargo among cancer cells, normal cells, and their 
microenvironment. 
Given the important roles played by MVs in cancer progression, it is of great 
interest to understand how these vesicles are generated in cancer cells. Studies 
performed in colorectal cancer cells suggested that MV production may be an outcome 
of mutated K-Ras or the result of the deletion of p53 (23), while studies in 
glioblastoma and prostate cancer cells have suggested that MV formation is stimulated 
by EGFR activation (3, 22). However, thus far the mechanisms underlying the 
biogenesis of these vesicles have remained largely undetermined. In the present study, 
I set out to delineate the signals responsible for MV biogenesis in two different types 
of cancer cells, MDAMB231 breast cancer cells and HeLa cervical carcinoma cells. I  
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Figure 4.1 Various human cancer cells generate tTG- and actin-containing 
MVs that are capable of transforming NIH3T3 fibroblasts. (A) A 
MDAMB231 cell shedding MVs from its surface was visualized by scanning 
electron microscope (SEM). (B) Shown are immunofluorescence pictures of 
MDAMB231 cells, U87 cells or HeLa cells treated without or with EGF. The cells 
were stained using tTG antibody, rhodamine-conjugated phalloidin and DAPI to 
visualize tTG, actin filaments and cell nuclei respectively. Some of the pronounced 
MVs associated with cell membranes were denoted by arrows. (C) Quantification 
of the experiments performed in (B). Cells showing membrane-bound MVs were 
counted over the total cells in the field. The histogram represents the mean ± 
standard deviation from three independent experiments. (D) MDAMB231cells or 
U87 cells were lysed, and the MVs shed into the medium were isolated and lysed 
as well. The whole cell lysates (WCLs) and the MV lysates were then 
immunoblotted with antibodies against tTG, actin, the MV marker flotillin-2, and 
the cytosolic-specific marker IκBα. (E) Serum-starved HeLa cells treated without 
or with EGF, as well as the secreted MVs were lysed and subjected to Western 
blot analysis using tTG, flotillin-2 and IκBα antibodies. (F) MDAMB231cells 
overexpressing empty vector or the dominant-negative truncation of V5-tagged 
CHMP3 protein were lysed, and the secreted MVs were also isolated and lysed. 
The whole cell lysates (WCLs) and the MV lysates were then immunoblotted with 
antibodies against tTG, V5, the MV marker flotillin-2, and the cytosolic marker 
IκBα. (G) NIH3T3 fibroblasts incubated without or with MVs derived from 
MDAMB231 cells, U87 cells or HeLa cells treated without or with EGF were 
subjected to anchorage-independent growth assay. The soft agar cultures were re-
fed every fourth day for 12 days, when the colony numbers were scored. The 
histogram represents the mean ± standard deviation from three independent 
experiments. (H) Representative images of the resulting colonies that formed in 
(G). (I) Mitotically-arrested MDAMB231 cells were mixed without or with 
NIH3T3 cells, or the same number of parental MDAMB231 or NIH3T3 cells were 
injected into nude mice as described in the materials and methods. A month later 
the formed tumors were counted and presented. 
 
*The experiments described in (B), (C) and (I) were performed by Marc A. 
Antonyak and Bo Li. 
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Figure 4.1 (Continued)
 show that the formation of MVs is an outcome of a specific Rho GTPase-dependent 
signaling pathway that is activated in HeLa cells by EGF and is constitutively 
activated in MDAMB231 cells. This pathway triggers the activation of Rho kinase 
(ROCK), and subsequently Lim kinase (LIMK), culminating in the phosphorylation of 
cofilin. I further demonstrate that the hyper-activation of this signaling pathway and 
the resultant generation of MVs have a significant impact on tumor formation in mice. 
In light of the roles suggested for Rho GTPases and ROCK in cancer cell migration, 
invasion, and the development of the metastatic state (31), these findings carry 
exciting implications regarding how these signaling proteins might contribute to 
malignant transformation.  
 
Results 
Several malignant cancer cell lines exhibit membrane-bound MVs  
The generation of MVs has been observed in different malignant human cancer 
cell lines. An example is shown in Figure 4.1A, in which MVs are visualized on the 
surface of a MDAMB231 breast cancer cell by scanning electron microscopy. MVs 
can also be visualized by immunofluorescence, as demonstrated for MDAMB231 cells, 
U87 glioblastoma cells, and HeLa cervical carcinoma cells stimulated by EGF (Figure 
4.1B). In each case, the cells were co-stained using rhodamine-conjugated phalloidin 
to label actin filaments which form the base of the MVs, and with an antibody against 
tTG, a protein cross-linking enzyme that is overexpressed in a number of cancer types 
including brain, pancreatic, ovarian and breast cancers (32-35), and is a component of 
MV cargo (6). Increased tTG expression in cancer cells has been suggested to 
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 contribute to multiple aspects of cancer progression, with recent studies showing that 
this may be the result of tTG’s ability to cross-link fibronectin in MVs, thereby 
generating a potent activator of integrin-signaling in acceptor cells (36). As shown in 
Figure 4.1B, the anti-tTG antibody labeled the membrane-bound MVs with higher 
contrast compared to phalloidin, and therefore I have used tTG staining to visualize 
MVs, and to quantify the percentage of cells bearing these vesicles (Figure 4.1C). 
Approximately 35% of MDAMB231 cells, 25% of U87 cells, and 40% of EGF-
stimulated HeLa cells exhibited membrane-associated MVs (Figure 4.1C), whereas 
HeLa cells that were not treated with EGF showed little or no MV production.  
 
MVs shed from cancer cells are capable of inducing malignant transformation  
As an initial step toward demonstrating that MVs formed on the surfaces of 
cancer cells can be shed and influence their surrounding environment, I collected MVs 
from the conditioned medium of MDAMB231 and U87 cells. Figure 4.1D shows that 
the isolated MVs contained the cargo proteins tTG and actin, as well as flotillin-2, 
which has been used as a general MV-marker (3). The cytosolic protein IB served 
as a negative control and was absent from these MV preparations, verifying the lack of 
cytosolic contamination. Moreover, in the case of HeLa cells, I was only able to 
collect MVs when these cancer cells were stimulated by EGF, and not in the absence 
of growth factor treatment (Figure 4.1E), which are consistent with my 
immunofluorescence studies (Figures 4.1B and 4.1C). To confirm that the MV 
preparations from these different cancer cell lines did not contain exosomes, I 
ectopically expressed the dominant-negative form of the CHMP3 protein (CHMP3 
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 DN), which is the mammalian homolog of the yeast VPS24 protein that is essential for 
the secretion of exosomes (37), in MDAMB231 cells. The levels of MVs were 
unaffected by the presence of CHMP3 DN (Figure 4.1F), indicating that MVs and 
exosomes are distinct species.  
Recently, we reported that MVs isolated from cancer cells were biologically 
active and capable of inducing the transformation of normal cells (6). Indeed, an 
example of their transforming capability can be demonstrated through the following 
type of experiment. MVs generated in a constitutive manner from MDAMB231 or 
U87 cells, as well as MVs produced in an EGF-dependent manner in HeLa cells, were 
collected and added to NIH3T3 cells. The ability of the MV-treated cells to exhibit 
anchorage-independent growth, which is often considered a hallmark for malignant 
transformation, was then examined. As shown in Figures 4.1G and 4.1H, while normal 
NIH3T3 cells were unable to form colonies in soft agar, those fibroblasts that were 
incubated with the cancer cell-derived MVs were capable of forming colonies. The 
numbers and sizes of these colonies correlated well with the amount of MVs secreted 
from the different cancer cells. Perhaps even more significant is our finding that the 
ability of cancer cell-derived MVs to induce transformation in cell culture, carries-
over to tumor formation in vivo. This was demonstrated by treating MDAMB231 cells 
with the mitosis-arresting reagent mitomycin-C and then injecting the treated cells into 
nude mice, alone or together with an equivalent number of NIH3T3 fibroblasts. 
Incubation with mitomycin-C completely abolished the ability of MDAMB231 cells to 
form tumors, whereas their control counterparts (i.e. MDAMB231 cells that were 
untreated) were quite effective at inducing tumor formation under the same  
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Figure 4.2 RhoA signaling pathway is specific for controlling the generation 
of MVs in cancer cells. (A) HeLa cells overexpressing the HA-tagged activated 
forms of Rac (Rac F28L), Cdc42 (Cdc42 F28L), Ras (Ras G12V) or RhoA (RhoA 
F30L) were immunostained with tTG and HA antibodies. Noted were MVs 
specifically generated from RhoA F30L-overexpressing HeLa cells, some of 
which were denoted by arrows. (B) Quantification of the immunofluorescence 
experiments performed in (A). Shown percentage is the ratio of MVs-bearing cells 
over the pool of HeLa cells overexpressing various constructs. The histogram 
represents the mean ± standard deviation from three independent experiments. (C) 
HeLa cells overexpressing Vector or RhoA F30L were lysed and the secreted MVs 
were also collected from the conditioned medium. Both WCLs and MV lysates 
were then immunoblotted using tTG, flotillin-2, HA and IκBα antibodies. HeLa 
cells treated without or with EGF (D) or MDAMB231 cells (E) transfected with 
control siRNA or RhoA specific siRNAs were lysed, and the secreted MVs were 
also lysed. Immunoblotting on collected lysates were performed by using tTG, 
flotillin-2, IκBα and RhoA antibodies. (F) The RBD binding assay was performed 
on lysates collected from MDAMB231 cells, or HeLa cells treated without or with 
EGF as described in the materials and methods. The amount of active or total 
RhoA protein was detected by using anti-RhoA antibody, and actin antibody was 
also applied on the same membrane to conform equal input. (G) Quantification of 
the MVs-bearing HeLa Cells respectively overexpressing vector, RhoA F30L, 
RhoC F30L, Src Y527F or the oncogenic form of Dbl protein (Onco-Dbl). The 
histogram represents the mean ± standard deviation from three independent 
experiments. 
 
*The experiments described in (A), (B) and (G) were performed by Marc A. 
Antonyak and Bo Li. 
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 experimental conditions (Figure 4.1I). However, when the mitotically-arrested 
MDAMB231 cells were co-injected with NIH3T3 fibroblasts into nude mice, 4 tumors 
were formed following 6 injections (Figure 4.1I). Thus, MVs shed by the mitotically-
arrested cancer cells were capable of causing the co-injected fibroblasts to become 
transformed in vivo, as indicted by the observed tumor formation. 
 
Activated RhoA is both necessary and sufficient for inducing the biogenesis of MVs in 
cancer cells 
Given the indications that cancer cell-derived MVs play critically important 
roles in malignant transformation, a key question then becomes the underlying 
mechanistic basis for their biogenesis. In various cancer cell lines, including HeLa 
cervical carcinoma cells, U373 glioblastoma cells, and DU145 prostate cancer cells, 
MV production appears to be stimulated by EGF treatment (3, 6, 22). Thus, I used 
HeLa cells as the model system to determine the signaling proteins downstream of 
EGFR that are responsible for controlling the formation of MVs. The fact that MVs 
are characterized by “actin-ring” structures (Figure 4.1B) suggested the possible 
involvement of the cytoskeletal machinery, which prompted me to consider the 
potential roles of small GTPases in MV biogenesis. Among the different classes of 
GTPases, the Ras, Rac, Rho and Cdc42 proteins are best known for their ability to 
reorganize actin cytoskeletal structures in cells upon EGF stimulation (38-40). To 
determine whether any of these GTPases are linked to MV formation, I first 
individually overexpressed the HA-tagged dominant-active forms of Rac (Rac F28L), 
Cdc42 (Cdc42 F28L), Ras (Ras G12V), or RhoA (RhoA F30L) in HeLa cells, and 
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 then visualized MVs along the cell surface by immunostaining transfected cells with 
tTG and HA antibodies. As shown in Figure 4.2A, neither activated Rac, Cdc42, nor 
Ras, was able to induce the generation of MVs in HeLa cells. However, cells 
expressing the constitutively-active form of RhoA exhibited significant MV formation 
(Figure 4.2A, bottom row). Quantification of the immunofluorescence results showed 
that approximately 40% of HeLa cells-expressing RhoA F30L produced MVs, 
compared to ~5% of the HeLa cells ectopically expressing the other constitutively 
active small GTPases (Figure 4.2B). Likewise, cells expressing activated RhoA 
showed increased amounts of MVs in the conditioned medium (Figure 4.2C).  
Since RhoA-dependent signaling is sufficient to induce MV formation, I then 
asked whether RhoA is essential for the ability of EGF to trigger MV production in 
HeLa cells. By using two siRNAs specifically targeting RhoA, I found that knocking-
down RhoA expression from HeLa cells completely abolished EGF-stimulated MV 
formation (Figure 4.2D). Similar results were obtained in MDAMB231 cells, where 
the levels of endogenous MVs were greatly reduced upon the introduction of siRNAs 
targeting RhoA (Figure 4.2E).  
The ability of MDAMB231 cells to constitutively generate MVs, whereas 
HeLa cells required EGF treatment to produce these vesicles, exactly matched the 
activation status of RhoA in these cancer cells. Specifically, RhoA was constitutively 
activated in MDAMB231 cells, while its activation required EGF treatment in HeLa 
cells (Figure 4.2F). Interestingly, RhoC was ineffective in generating MVs despite 
sharing a high degree of sequence similarity with RhoA. The over-expression of 
oncogenic Src or onco-Dbl was also unable to mimic the actions of RhoA in HeLa  
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Figure 4.3 Activation of ROCK signaling is both necessary and sufficient to 
induce the MV formation in HeLa cells. (A) Serum-starved HeLa cells, 
MDAMB231 cells and U87 were left untreated or were incubated with ROCK 
specific inhibitor Y-27632. The HeLa cells were further treated with EGF as 
indicated and then all of the cells were stained for tTG to identify MVs. (B) 
Quantification of the experiments performed in (A). Shown is the percentage of 
MVs-bearing cells over the total cells in the field. The error bars represent the 
standard deviation from three independent experiments. (C) The WCLs and MV 
lysates were collected from MDAMB231 cells and U87 cells treated without or 
with Y-27632 and then subjected to immunoblotting analysis using tTG, flotillin-2 
and IκBα antibodies. (D) HeLa cells overexpressing Myc-tagged wild-type 
ROCK-2 (ROCK WT) were fixed and then immunostained with tTG and Myc 
antibodies. DAPI stain was also applied to show the nuclei. (E) Quantification of 
the MV generation in HeLa cells transfected with vector, RhoA F30L and ROCK 
WT. The data shown was the average of three experiments and errors bars 
represent standard deviation. (F) HeLa cells transfected with vector, ROCK WT or 
RhoA F30L were lysed and the MVs secreted into the medium were also collected 
and lysed. Both WCLs and MV lysates were then subjected to Western blot 
analysis using indicated antibodies. (G) Picture illustrating the downstream 
signaling pathway of ROCK. Briefly, active ROCK can phosphorylate LIMK, 
which turns on its kinase activity and then phosphorylates cofilin, therefore 
prevents cofilin’s actin-severing activity. On the other hand, active ROCK can also 
phosphorylate MYLP, which inhibits its phosphatase activity, therefore increases 
the phosphorylation and activity of myosin. Please note that the cellular outcome 
of suppressing MYLP activity by ROCK can also be achieved by enhancing 
MYLK activity. (H) Serum-starved HeLa cells stimulated by EGF for indicated 
period of time treated without or with ROCK inhibitor Y-27632 were lysed and 
blotted with various antibodies. 
 
*The experiments described in (A), (B), (D) and (E) were performed by Marc A. 
Antonyak and Bo Li.
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 cells (Figure 4.2G). The ineffectiveness of onco-Dbl was particularly interesting as it 
serves as a guanine exchange factor (GEF) that activates RhoA and Cdc42 (41). Thus, 
the inability of onco-Dbl to induce MV formation suggests that active Cdc42 may 
counteract RhoA in this process. 
 
ROCK is a specific signaling target downstream from RhoA in the pathway leading to 
MV generation 
The essential role of RhoA in regulating MV formation prompted me to search 
for its downstream signaling partners that are involved in this process. There are 
several known protein targets for activated RhoA, with the serine/threonine protein 
kinases ROCK-1 and ROCK-2 (for Rho kinases 1 and 2), collectively referred to as 
ROCK, being especially attractive candidates because of their roles in actin 
cytoskeletal remodeling and actomyosin contraction (31, 42). As a first step in 
examining the roles of these Rho effector proteins in MV formation, I took advantage 
of the small molecule Y-27632, which is a specific ATP-competitive inhibitor of both 
ROCK-1 and ROCK-2 (43). Figures 4.3A and 4.3B show that treatment of 
MDAMB231 cells, U87 cells, or EGF-stimulated HeLa cells, with Y-27632 
completely eliminated the appearance of MVs along the cell surface. Similarly, the 
amount of MVs collected from MDAMB231 cells or U87 cells was significantly 
reduced upon Y-27632 treatment (Figure 4.3C).  
Thus far, attempts to determine whether ROCK-1, ROCK-2 or both protein 
kinases can mediate the signaling actions of RhoA in MV formation, based on RNAi 
knock-down experiments have failed. Therefore, I set out to complement these efforts 
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 by seeing whether the overexpression of ROCK was sufficient to drive the MV 
formation in cancer cells. While I have not obtained significant ectopic expression of 
ROCK-1 in HeLa cells, I have achieved measurable overexpression of Myc-tagged 
ROCK-2. Figure 4.3D shows that I observed a clear increase in the amount of 
membrane-bound MVs in HeLa cells overexpressing ROCK-2, with the extent of MV 
formation in cells overexpressing ROCK-2 being comparable to that obtained when 
ectopically expressing the constitutively active RhoA (Figure 4.3E). Consistent with 
this finding, the overexpression of ROCK-2 also promoted the secretion of MVs from 
HeLa cells that could be isolated using the standard MV preparation (Figure 4.3F). 
Collectively, these results indicated that the RhoA-ROCK-signaling pathway is 
essential for generating MVs in cancer cells.  
 
The generation of MVs in cancer cells is dependent on a Lim kinase-cofilin signaling 
pathway activated by ROCK  
There are two well-studied signaling targets thought to be immediately 
downstream from ROCK, namely Lim kinase (LIMK) and myosin light chain 
phosphatase (MYLP), both of which can regulate actin cytoskeletal dynamics (44-46) 
(Figure 4.3G). Activated ROCK phosphorylates the kinase domain of LIMK, thereby 
stimulating its kinase activity. Upon activation by ROCK, LIMK phosphorylates Ser3 
on cofilin, which prevents cofilin from severing actin filaments and thereby prolongs 
the extension of actin fibers in situ (45). ROCK is also able to inhibit MLCP activity 
through the direct phosphorylation of the myosin phosphatase-targeting subunit 
(MYPT), a critical regulatory component of MLCP, which results in a significant  
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Figure 4.4 LIMK and cofilin, but not MYLK or Myosin, are the critical 
effectors downstream of ROCK to regulate MV formation in HeLa cells. (A) 
HeLa cells overexpressing either HA-tagged wild-type LIMK (LIMK WT) or 
Myc-tagged wild-type MYLK (MYLK WT) were fixed and then immunostained 
with tTG and HA or Myc antibodies. DAPI staining was also performed. The 
experiments in (A) were quantified by counting MVs-associated cells over cells 
transfected with LIMK WT (B) or MYLK WT (D) as compared to vector- and 
RhoA F30L-overexpressing cells. The error bars represent the standard deviation 
from three experiments. (C&E) The same sets of transfected HeLa cells as in (B) 
or (D) were collected together with their secreted MVs in the medium, and then 
probed by tTG, HA, Myc, flotillin-2 and IκBα antibodies in the subsequent 
Western blot experiments. (F) HeLa cells transfected without or with RhoA F30L 
were co-transfected with mock, dominant-negative LIMK (LIMK D460N) or 
dominant-negative MYLK (MYLK ATPDEL) as indicated and immunostained for 
MVs. The percentage of MVs-bearing cells was calculated from three parallel 
experiments and errors bars represent standard deviation. (G) HeLa cells treated 
with EGF, or MDAMB231 cells were transfected with V5-tagged cofilin S3A. The 
cells were then fixed and stained with tTG and V5 antibodies. Noted that cells 
overexpressing V5-tagged cofilin S3A were deprived of membrane-bound MVs. 
The MVs on HeLa cells stimulated without or with EGF (H), or MDAMB231 
cells (I) overexpressing various constructs were visualized and quantified. 
Experiments were repeated three times and errors bars represent standard 
deviation. 
 
*The experiments described in (A), (B), (D), (F), (G), (H) and (I) were performed 
by Marc A. Antonyak and Bo Li. 
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 enhancement of myosin phosphorylation and actomyosin contraction (46). Figure 
4.3H shows that the treatment of HeLa cells with EGF significantly increased the 
phosphorylation of LIMK and myosin, with each of these phosphorylation events 
being antagonized by the specific ROCK inhibitor Y-27632. I then examined whether 
the overexpression of LIMK in HeLa cells, or the increased phosphorylation of 
myosin that occurs when overexpressing myosin light chain kinase (MYLK), 
mimicked the ability of ROCK to stimulate MV formation. Interestingly, I found that 
while the overexpression of MYLK gave rise to only a modest increase in MV 
formation (Figure 4.4A, bottom row and Figure 4.4D), the ectopic expression of wild-
type LIMK (LIMK WT) in HeLa cells was sufficient to generate MVs to an extent 
comparable to RhoA F30L (Figure 4.4A, top row, and Figure 4.4B) or ROCK (Figure 
4.3E). The overexpression of LIMK, but not the overexpression of MYLK, also gave 
rise to MVs that were shed and subsequently isolated from EGF-treated HeLa cells in 
much the same way as occurred when ectopically expressing the constitutively active 
RhoA (Figure 4.4C and 4.4E). 
I then examined whether disabling LIMK had adverse effects on the ability of 
RhoA to induce MV formation in cancer cells. In particular, I first wanted to see 
whether the LIMK D460N mutant, that is defective for protein kinase activity (45), 
might act as a dominant-negative inhibitor of MV formation. Figure 4.4F shows that 
while the overexpression of LIMK D460N alone in HeLa cells had no effect on the 
generation of MVs, the co-expression of LIMK D460N together with the 
constitutively active RhoA F30L mutant in HeLa cells significantly suppressed the 
ability of RhoA to induce MV formation (compare the last column with the second 
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 column). For the sake of comparison, I also examined the MYLK ATPDEL mutant, 
which is kinase-defective because of an internal deletion that prevents the binding of 
ATP to MYLK (47), as a potential dominant-negative inhibitor of RhoA-dependent 
MV formation. However, overexpressing MYLK ATPDEL together with RhoA F30L 
exhibited little, if any inhibitory effect (Figure 4.4F, compare the second column to 
the fifth column). 
I then investigated the role of cofilin, the major downstream effector of LIMK, 
in MV formation. I generated a dominant-active form of cofilin (cofilin S3A), which 
prevented it from being phosphorylated by LIMK, and then transfected this mutant 
into HeLa cells treated with or without EGF. Immunofluorescence experiments 
suggested that over-expression of cofilin S3A severely impaired the generation of 
MVs in HeLa cells stimulated by EGF (Figure 4.4G, top row), and this was further 
supported by quantifying the percentage of MVs-bearing cells in these samples 
(Figure 4.4H). The same was true when ectopically expressing the cofilin S3A mutant 
in MDAMB231 cells, as it strongly blocked the constitutive shedding of MVs from 
these breast cancer cells in a manner similar to the kinase-defective LIMK D460N 
mutant (Figure 4.4G, bottom row, and Figure 4.4I). 
 
RhoA signaling to LIMK and cofilin is essential for MV-mediated transformation 
To further confirm the significance of LIMK, I collected MVs from 
MDAMB231 cells that stably expressed a control siRNA, or two siRNAs that 
specifically targeted LIMK. As expected, the effectiveness of the LIMK knock-down 
(Figure 4.5A) was inversely correlated with the amount of MVs secreted from 
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Figure 4.5 Suppressing LIMK expression inhibits the biogenesis of MVs in 
cancer cells and blocks MV-mediated transformation of recipient fibroblasts. 
(A) Control siRNA and two specific LIMK siRNAs were transfected into HeLa 
cells. The cells were lysed and immunoblotted by LIMK and actin antibodies. 
Three sets of MDAMB231 cells were stably transfected with the referred control 
siRNA and LIMK siRNAs. One set of MDAMB231 cells were lysed together with 
the MVs secreted from these cells and subjected to Western blot analysis (B), 
using tTG, flotillin-2 and IκBα antibodies. MVs collected from the second set of 
MDAMB231 cells were mixed with the parental NIH3T3 fibroblasts, which were 
used to perform the anchorage-independent growth assay (C). The histogram 
presents the average number of formed colonies obtained from three independent 
experiments. Errors bars represent standard deviation. (D) The third set of 
mitotically-arrested MDAMB231 cells stably expressing control siRNA or two 
specific LIMK siRNAs were mixed with the same number of NIH3T3 cells and 
then respectively injected into nude mice. The shown box plot described the mass 
distribution of formed tumors derived from 6 independent injections of each cell 
samples. The box range indicates the standard deviation, and the black dots on the 
left side of each box represent the original data of measured tumor mass. (E) 
Schematic representation of the signaling pathways that control the generation of 
MVs in human cancer cells. 
 
*The experiments described in (D) were performed by Marc A. Antonyak and Bo 
Li. 
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  MDAMB231 cells (Figure 4.5B) and, in a corresponding manner, with the extent of 
anchorage-independent growth that these MVs were able to induce in the recipient 
NIH3T3 cells (Figure 4.5C). I then set out to establish the importance of LIMK 
activity for MV-mediated tumor formation in vivo by using a similar experimental 
strategy that was initially utilized to establish the role of MVs in this process. Figure 
4.5D shows that the stable knock-down of LIMK expression in mitotically-arrested 
MDAMB231 cells markedly suppressed the ability of co-injected NIH3T3 fibroblasts 
to form tumors in mice. Thus, when taken together, these findings are consistent with 
the depiction in Figure 4.5E, which shows that the biogenesis of MVs as a result of a 
hyper-activated RhoA-ROCK-LIMK pathway in cancer cells can have a profound 
effect on the ability of recipient normal cells to show transformed properties in 
cultures, and also to give rise to tumors in mice. 
 
Discussion 
Tumor development involves the interaction and communication of cancer 
cells with the tumor microenvironment, including the surrounding tumor cells, normal 
stromal cells, blood vessels, macrophages, as well as the extracellular matrix (48). To 
facilitate tumor growth, invasion and metastasis, cancer cells exchange information 
with the tumor microenvironment, as predominantly occurs through secretory events. 
One such secretory mechanism that has been receiving a great deal of attention 
involves the generation and shedding of large, 2 micron-diameter vesicles (MVs) from 
cancer cells. These vesicles appear to play multiple roles in promoting cancer 
progression, including extracellular matrix remodeling, stimulation of blood vessel 
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 formation, recruitment of tumor-associated microphages, activation of surrounding 
tumor cells, and the induction of transformed phenotypes within neighboring normal 
cells (13-15). This in turn has led to the thinking that the development and growth of a 
tumor not only involves the proliferation of compartmentalized tumor cells, but also 
requires the tight cooperation of adjacent tumor cells, stromal cells, and other 
components in the tumor “niche”, through their communication via MVs. Given the 
increasingly important roles that MVs play in cancer progression, a great deal of 
attention has been directed toward understanding how these vesicles are generated 
from cancer cells. Although there have been suggestions that EGFR-signaling plays an 
important part in regulating MV formation, the details of this signaling pathway have 
remained elusive. Here my findings shed new light on this question by demonstrating 
that a RhoA-ROCK signaling pathway, which can be activated downstream from 
EGFR, works through LIMK and cofilin to generate MVs in cancer cells. 
Interestingly, RhoA-ROCK signaling has also been implicated in the formation 
and regulation of another type of membrane structure, commonly referred to as plasma 
membrane blebs (PM blebs). PM blebs are initiated by the local disruption of the 
membrane-actomyosin connection, which results in a rapid protrusion of the plasma 
membrane due to intracellular hydrostatic pressure (49). The subsequent steps in 
forming PM blebs involves the recruitment of the actomyosin machinery beneath the 
detached membrane, the in situ build-up of new actin cortex, as well as the final 
retraction of the mature blebs (50). Although PM blebs were initially thought to only 
form in apoptotic cells, later studies indicated that PM blebs were also frequently 
generated in non-apoptotic cells, where they participated in several important cellular 
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 activities including cytokinesis and cell migration (51). Surprisingly, studies focused 
on non-apoptotic PM blebs highlight some common features shared between these 
structures and membrane-associated MVs, i.e. an identical “actin-ring” phenotype as 
visualized by phalloidin staining, and a similar biogenesis as initiated by activated 
RhoA-ROCK signaling (50). This raises the question of how similar these two 
membrane vesicular structures are to each other. In fact, I am unaware of a study that 
specifically addresses this issue, and no specific markers have been proposed to 
distinguish blebs from MVs, which leads me to hypothesize that PM blebs and MVs 
may arise through a common mechanism from initiation to maturation. Their 
divergence might occur at a later point, such that those membrane structures 
undergoing inward contraction represent PM blebs, whereas those that are shed 
outward from the cell surface become secreted MVs. This raises the interesting 
possibility that there might be some signaling/regulatory proteins that influence the 
ratio of MV shedding to bleb retraction, in which case, understanding how cells 
maintain the balance between these two structures is important and deserves further 
research attention.  
The actions of ROCK in reorganizing the actin cytoskeleton are generally 
mediated by two sets of downstream signaling activities, one resulting in the 
phosphorylation of cofilin by LIMK and the other being the phosphorylation of 
myosin through the regulation of MYLP. I have shown that LIMK activity induced by 
ROCK is not only necessary but also sufficient for the biogenesis of MVs from cancer 
cells. This is achieved through the ability of LIMK to phosphorylate its substrate 
cofilin, thereby inhibiting its actin-severing activity. The resultant elongation of actin 
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 filaments along the plasma membranes is thought to precede the formation of an 
“actin-ring” structure, which is an established hallmark and also an essential step for 
the maturation of MVs. In contrast to LIMK, the ROCK target MYLP is 
phosphorylated and consequently inhibited by activated ROCK. As a result, the 
phosphorylation of myosin is significantly enhanced. Interestingly, I found that 
overexpression of MYLK, which mimics the cellular effects of inhibiting MYLP by 
ROCK, can also cause a modest stimulation of MV formation. This is consistent with 
an earlier finding in melanoma cells, where the activation of Arf6, a small GTPase 
involved in membrane trafficking, leads to a MYLK-dependent stimulation of MV 
production (21). Although my work suggests that myosin phosphorylation is not 
necessary for the formation of RhoA-induced MVs in HeLa cells, or for the 
constitutive formation of MVs in MDAMB231 cells, it is still possible that in some 
cellular contexts, MVs can be induced by signals that feed into the regulation of 
myosin, as apparently can occur downstream from activated Arf6 in the case of 
melanoma cells.  
It has been shown that tumor-derived MVs are able to not only alter the 
surrounding environment to facilitate tumor progression, but also contain protein 
cargo and RNA transcripts that reflect the oncogenic features of the tumor cells from 
which they originate. A good deal of effort including work from our own laboratory 
has been focused on characterizing the components of MVs derived from cancer cells 
or tumors, which has provided insight into the molecular mechanisms of how these 
vesicles contribute to different aspects of oncogenesis, as well as raised the intriguing 
possibility of using MVs as novel tumor biomarkers. My discovery that RhoA-ROCK-
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 signaling controls the biogenesis of MVs provides further support to the idea that 
targeting RhoA-signaling may offer important strategies for interfering with tumor 
progression. What I find to be truly remarkable is that RhoA, and not the highly 
similar family member RhoC, is specifically responsible for signaling through ROCK 
to drive MV formation in cancer cells. This raises some interesting questions 
regarding where RhoC, which has also been often implicated in cancer progression 
and particularly with the development of metastasis (52), fits in relative to the actions 
of RhoA. Presumably, RhoC might be involved in the sorting of the MV cargo that is 
responsible for mediating the transforming capability of MVs, especially given the 
expectation that there is a tight coordination between MV biogenesis and vesicle cargo 
trafficking. 
 
Materials and Methods 
Materials. Cell culture reagents, EGF, oregon green or texas red–conjugated 
secondary IgG, rhodamine-conjugated phalloidin, Lipofectamine, Lipofectamine 2000, 
RhoA, LIMK and ROCK siRNAs were purchased from Invitrogen. Y-27632 and 4,6-
diamidino-2-phenylindole (DAPI) were from Calbiochem. The tTG and actin 
antibodies were from Lab Vision/Thermo, Flotillin-2 and ROCK antibody were 
obtained from Santa Cruz, and HA and Myc antibodies were from Covance. The 
antibodies against IκB, RhoA, LIMK, phospho-LIMK, MLC and phospho-MLC 
were from Cell Signaling. 
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 Cell Culture. HeLa, MDAMB231 and U87 cell lines were grown in RPMI 1640 
medium containing 10% fetal bovine serum, and NIH3T3 cells were maintained in 
DMEM medium containing 10% calf serum. RhoA (NM_001664), Rac (NM_006908), 
Ras (NM_005343), Cdc42 (NM_001791), Src (XM_001232484) and onco-Dbl 
(J03639) were cloned into PKH3 vector, while ROCK-1 (NM_005406.2), ROCK-2 
(NM_004850), LIMK (NM_002314), MYLK (NM_053025), Cofilin (NM_005507), 
CHMP3 (NM_016079) and RhoC (NM_175744) were cloned into PCDNA3 plasmid. 
Different point mutations or truncations were generated as indicated in the paper. All 
of the expression constructs were transfected into cells using Lipofectamine, while the 
control, ROCK, LIMK and RhoA siRNAs were introduced into cells using 
Lipofectamine 2000. Where indicated, cells were treated with 0.1 µg/ml EGF or 10 
µM Y-27632. To mitotically arrest MDAMB231 cells, plates of cells were treated 
with 10 µg/ml mitomycin-C for 2 hours, before rinsing the solution away and allowing 
the cells to recover in the complete growth medium for a day. 
 
Isolation of MVs from Cancer Cells. For preparing MVs subjected to Western blot 
analysis, the conditioned medium from 5.0 x 106 serum-starved MDAMB231 cells, 
U87 or HeLa cells stimulated without or with EGF were collected and the MVs were 
isolated from the medium as previously described. Briefly, the conditioned medium 
was subjected to two consecutive centrifugations; the first at 300 g for 10 minutes to 
pellet down floating cells, while the second at 12,000 g for 20 minutes to pellet down 
cell debris. The supernatant was then subjected to the third centrifugation at 100,000 g 
for 1.5 hours and the resulting pellet was washed with PBS and then lysed in cell lysis 
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 buffer. To generate intact MVs for anchorage-independent growth assay, the 
supernatant after the first two spins (medium cleared of cells and cell debris) was then 
filtered though a Millipore Steriflip PVDF-filter with a 0.22 µm pore size. The MVs 
trapped on top of the PVDF membrane were resuspended in serum-free medium, and 
then mixed with NIH3T3 cell suspension supplemented with serum and agarose as 
indicated below. 
 
Immunoblot Analysis. Cells were lysed with lysis buffer (25 mM Tris, 100 mM NaCl, 
1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM -glycerol 
phosphate, and 1 g/mL aprotinin), and the lysate proteins were resolved by SDS-
PAGE and then transferred to PDVF membranes. The membranes were first incubated 
with various primary antibodies diluted in TBST (20 mM Tris, 135 mM NaCl, and 
0.05% Tween 20), and then with horseradish peroxidase-conjugated secondary 
antibodies followed by exposure to ECL reagent.  
 
RBD Binding Assay. Equal amount of whole cell lysates collected from MDAMB231 
cells or HeLa cells stimulated without or with EGF for 24 hours were incubated with 
agarose beads conjugated with the Rho-binding domain of Rhotekin. After an hour 
incubation, the beads were pelleted down and washed for three times. The precipitates 
were then subjected to Western blot analysis by using anti-RhoA antibody, to detect 
the amount of activated RhoA that interacted with the Rho-binding domain of 
Rhotekin. 
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 Immunofluorescence. Cells overexpressing various constructs or treated with different 
reagents as indicated were fixed using 3.7% formaldehyde in PBS for 20 min, 
permeabilized by 0.2% Triton X-100 for 20 min, and then blocked by 10% BSA in 
PBS for half an hour. Following that cells were incubated with either tTG, HA, Myc 
or V5 antibodies as indicated for 1.5 hours, washed by PBS for 3 times and then 
incubated with fluorophore-conjugated secondary antibody for a hour. Sometimes in 
this step rhodamine-conjugated phalloidin was applied to stain actin filaments and 
DAPI was used to stain the cell nuclei. The samples were visualized by Zeiss 
fluorescent microscope and the images were captured using IPlab software. 
 
Anchorage-independent Growth Assays. Parental NIH3T3 cells incubated without or 
with MVs derived from 5.0 x 106 MDAMB231 cells, U87 cells, or HeLa cells 
simulated without or with EGF were plated in a density of 7,000 cells/mL in the 
medium containing 0.3% agarose and 10% calf serum, onto underlays composed of 
10% calf serum and 0.6% agarose in six-well dishes. The soft agar cultures were re-
fed (including the addition of freshly prepared MVs and calf serum) every fourth day 
for 12 days, at which time the colonies that formed were counted. Each of the assays 
was performed three times and the results were averaged. 
 
Scanning Electron Microscopy (SEM). MDAMB231 cells grown on Lab-Tek chamber 
slides (Nunc/Lab Vision) were preliminarily fixed for 1 hour with 2% EM-grade 
glutaraldehyde diluted in 0.05 M cacodylic acid buffer solution (PH=7.4). The 
samples were then deeply fixed for 1 hour by 1% osmium tetroxide in PBS and 
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 dehydrated in gradient solutions of 25%, 50%, 70%, 95%, and 100% ethanol. After 
that, the slides were further dehydrated in a CPD-30 critical point drying machine 
(BAL-TEC SCD050). The samples were then sputter-coated by thin-layered platinum, 
before being observed under a Leica 440 Scanning Electron Microscope.  
 
Mouse Studies. 1 x 106 mitotically arrested (using mitomycin-C) MDAMB231 cells 
stably expressing control or LIMK siRNAs were combined with 1 x 106 NIH3T3 
fibroblasts and growth factor-reduced Matrigel (BD Biosciences) to achieve 30% 
Matrigel in the final solution. The cell preparations were subcutaneously injected into 
the flanks of 6-8 weeks-old female NIH-III nude mice. As controls, parental 
MDAMB231 cells and NIH3T3 cells (1 x 106 cells of each cell line) were singly 
combined with growth factor-reduced Matrigel (to a final concentration of 30% 
Matrigel) and then were injected into mice as well. After a month, the animals were 
sacrificed and the resulting tumors that formed for each experimental condition were 
excised and weighed. The experiments involving mice were performed in accordance 
with the protocols approved by The Cornell Center for Animal Resources and 
Education (CARE). 
176 
 REFERENCES 
 
1. Sherer NM, Mothes W (2008) Cytonemes and tunneling nanotubules in cell-
cell communication and viral pathogenesis. Trends Cell Biol 18:414-420. 
2. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ 
(2006) Membrane-derived microvesicles: important and underappreciated 
mediators of cell-to-cell communication. Leukemia 20:1487-1495. 
3. Al-Nedawi K, et al. (2008) Intercellular transfer of the oncogenic receptor 
EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10:619-
624. 
4. Skog J, et al. (2008) Glioblastoma microvesicles transport RNA and proteins 
that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 
10:1470-1476. 
5. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J (2009) Endothelial 
expression of autocrine VEGF upon the uptake of tumor-derived microvesicles 
containing oncogenic EGFR. Proc Natl Acad Sci U S A 106:3794-3799. 
6. Antonyak MA, et al. (2011) Cancer cell-derived microvesicles induce 
transformation by transferring tissue transglutaminase and fibronectin to 
recipient cells. Proc Natl Acad Sci U S A 108:4852-4857. 
7. Balaj L, et al. (2011) Tumour microvesicles contain retrotransposon elements 
and amplified oncogene sequences. Nat Commun 2:180. 
8. George JN, Thoi LL, McManus LM, Reimann TA (1982) Isolation of human 
platelet membrane microparticles from plasma and serum. Blood 60:834-840. 
9. Hess C, Sadallah S, Hefti A, Landmann R, Schifferli JA (1999) Ectosomes 
released by human neutrophils are specialized functional units. J Immunol 
163:4564-4573. 
10. Greco V, Hannus M, Eaton S (2001) Argosomes: a potential vehicle for the 
spread of morphogens through epithelia. Cell 106:633-645. 
11. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R (2005) Shed membrane 
microparticles from circulating and vascular cells in regulating vascular 
function. Am J Physiol Heart Circ Physiol 288:H1004-1009. 
12. Iero M, et al. (2008) Tumour-released exosomes and their implications in 
cancer immunity. Cell Death Differ 15:80-88. 
177 
 13. Al-Nedawi K, Meehan B, Rak J (2009) Microvesicles: messengers and 
mediators of tumor progression. Cell Cycle 8:2014-2018. 
14. Rak J (2010) Microparticles in cancer. Semin Thromb Hemost 36:888-906. 
15. Lee TH, et al. (2011) Microvesicles as mediators of intercellular 
communication in cancer-the emerging science of cellular 'debris'. Semin 
Immunopathol. 
16. Keller S, Sanderson MP, Stoeck A, Altevogt P (2006) Exosomes: from 
biogenesis and secretion to biological function. Immunol Lett 107:102-108. 
17. Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts 
no more. Trends Cell Biol 19:43-51. 
18. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA (2005) Tissue-factor-
bearing microvesicles arise from lipid rafts and fuse with activated platelets to 
initiate coagulation. Blood 106:1604-1611. 
19. Bianco F, et al. (2009) Acid sphingomyelinase activity triggers microparticle 
release from glial cells. EMBO J 28:1043-1054. 
20. Ratajczak J, et al. (2006) Embryonic stem cell-derived microvesicles 
reprogram hematopoietic progenitors: evidence for horizontal transfer of 
mRNA and protein delivery. Leukemia 20:847-856. 
21. Muralidharan-Chari V, et al. (2009) ARF6-regulated shedding of tumor cell-
derived plasma membrane microvesicles. Curr Biol 19:1875-1885. 
22. Di Vizio D, et al. (2009) Oncosome formation in prostate cancer: association 
with a region of frequent chromosomal deletion in metastatic disease. Cancer 
Res 69:5601-5609. 
23. Yu X, Harris SL, Levine AJ (2006) The regulation of exosome secretion: a 
novel function of the p53 protein. Cancer Res 66:4795-4801. 
24. Janowska-Wieczorek A, et al. (2005) Microvesicles derived from activated 
platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 
113:752-760. 
25. Hong BS, et al. (2009) Colorectal cancer cell-derived microvesicles are 
enriched in cell cycle-related mRNAs that promote proliferation of endothelial 
cells. BMC Genomics 10:556. 
26. Hao S, et al. (2006) Epigenetic transfer of metastatic activity by uptake of 
highly metastatic B16 melanoma cell-released exosomes. Exp Oncol 28:126-
131. 
178 
 27. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA (2009) 
Tumor-derived microvesicles modulate the establishment of metastatic 
melanoma in a phosphatidylserine-dependent manner. Cancer Lett 283:168-
175. 
28. Jung T, et al. (2009) CD44v6 dependence of premetastatic niche preparation 
by exosomes. Neoplasia 11:1093-1105. 
29. Castellana D, et al. (2009) Membrane microvesicles as actors in the 
establishment of a favorable prostatic tumoral niche: a role for activated 
fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 69:785-793. 
30. Wysoczynski M, Ratajczak MZ (2009) Lung cancer secreted microvesicles: 
underappreciated modulators of microenvironment in expanding tumors. Int J 
Cancer 125:1595-1603. 
31. Narumiya S, Tanji M, Ishizaki T (2009) Rho signaling, ROCK and mDia1, in 
transformation, metastasis and invasion. Cancer Metastasis Rev 28:65-76. 
32. Li B, et al. (2010) EGF potentiated oncogenesis requires a tissue 
transglutaminase-dependent signaling pathway leading to Src activation. Proc 
Natl Acad Sci U S A 107:1408-1413. 
33. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2006) Tissue 
transglutaminase expression promotes cell attachment, invasion and survival in 
breast cancer cells. Oncogene 26:2459-2470. 
34. Mann AP, et al. (2006) Overexpression of tissue transglutaminase leads to 
constitutive activation of nuclear factor-kappaB in cancer cells: delineation of 
a novel pathway. Cancer Res 66:8788-8795. 
35. Yuan L, et al. (2007) Transglutaminase 2 inhibitor, KCC009, disrupts 
fibronectin assembly in the extracellular matrix and sensitizes orthotopic 
glioblastomas to chemotherapy. Oncogene 26:2563-2573. 
36. Akimov SS, Krylov D, Fleischman LF, Belkin AM (2000) Tissue 
transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J 
Cell Biol 148:825-838. 
37. Teis D, Saksena S, Emr SD (2009) SnapShot: the ESCRT machinery. Cell 
137:182-182 e181. 
38. Heasman SJ, Ridley AJ (2008) Mammalian Rho GTPases: new insights into 
their functions from in vivo studies. Nat Rev Mol Cell Biol 9:690-701. 
39. Karlsson R, Pedersen ED, Wang Z, Brakebusch C (2009) Rho GTPase 
function in tumorigenesis. Biochim Biophys Acta 1796:91-98. 
179 
 180 
40. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated 
protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. 
41. Cerione RA, Zheng Y (1996) The Dbl family of oncogenes. Current opinion in 
cell biology. 8:216-222. 
42. Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular 
physiology and pathophysiology. Circ Res 98:322-334. 
43. Narumiya S, Ishizaki T, Uehata M (2000) Use and properties of ROCK-
specific inhibitor Y-27632. Methods Enzymol 325:273-284. 
44. Maekawa M, et al. (1999) Signaling from Rho to the actin cytoskeleton 
through protein kinases ROCK and LIM-kinase. Science 285:895-898. 
45. Yang N, et al. (1998) Cofilin phosphorylation by LIM-kinase 1 and its role in 
Rac-mediated actin reorganization. Nature 393:809-812. 
46. Kawano Y, et al. (1999) Phosphorylation of myosin-binding subunit (MBS) of 
myosin phosphatase by Rho-kinase in vivo. J Cell Biol 147:1023-1038. 
47. Petrache I, et al. (2003) Caspase-dependent cleavage of myosin light chain 
kinase (MLCK) is involved in TNF-alpha-mediated bovine pulmonary 
endothelial cell apoptosis. FASEB J 17:407-416. 
48. Mbeunkui F, Johann DJ, Jr. (2009) Cancer and the tumor microenvironment: a 
review of an essential relationship. Cancer Chemother Pharmacol 63:571-582. 
49. Fackler OT, Grosse R (2008) Cell motility through plasma membrane blebbing. 
J Cell Biol 181:879-884. 
50. Charras GT, Hu CK, Coughlin M, Mitchison TJ (2006) Reassembly of 
contractile actin cortex in cell blebs. J Cell Biol 175:477-490. 
51. Charras G, Paluch E (2008) Blebs lead the way: how to migrate without 
lamellipodia. Nat Rev Mol Cell Biol 9:730-736. 
52. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of 
metastasis reveals an essential role for RhoC. Nature 406:532-535. 
 
 
 CHAPTER 5 
 
Conclusions 
 
The regulation and function of tTG in EGF-promoted oncogenesis 
The critical role of tTG in EGF-stimulated cancer cell survival and migration, 
which was demonstrated in a number of cancer cell lines (1-5), prompted me to 
consider the possibility that tTG might also be essential for EGF-stimulated cancer 
cell growth. To investigate this issue, I took advantage of the fact that exposing 
SKBR3 breast cancer cells to EGF not only augmented their proliferative capacity and 
ability to form colonies in soft agar, but also resulted in the induction of tTG 
expression and activation. I found that suppressing tTG expression using tTG-specific 
siRNAs, or blocking its transamidation activity using the competitive inhibitor MDC, 
potently inhibited the growth-promoting effects afforded to SKBR3 cells by EGF 
stimulation. Moreover, overexpressing tTG in SKBR3 cells was sufficient to mimic 
the actions of EGF and strongly stimulate the growth of these cells in monolayer and 
under anchorage-independent conditions.  
These results prompted two follow-up questions: How is tTG expression up-
regulated by EGF stimulation and how does it enhance cell proliferation? To answer 
the first question, I continued using the SKBR3 cell line as my model system and 
delineated the EGF-mediated signaling pathways that were responsible for inducing 
tTG expression. I found that individually activating signaling pathways known to be 
coupled to EGF stimulation by ectopically expressing activated forms of a variety of 
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 signaling proteins including Ras, Rac, RhoA and Cdc42 (6) in SKBR3 cells did not 
result in the induction of tTG expression. Surprisingly, co-expression of activated 
forms of Ras and Cdc42 in these cells was able to successfully induce tTG expression. 
The fact that the up-regulation of tTG was caused by a combination of Ras and Cdc42 
led to the conclusion that common effector(s) acting downstream of these two 
GTPases might be involved. PI3K (7) turned out to be one such effector protein. 
Interestingly, I found that expressing a constitutively active form of PI3K alone in 
SKBR3 cells did not lead to increases in tTG expression. This finding argued that 
while PI3K functioned as an essential signaling component in the induction of tTG 
expression by the co-activation of Ras and Cdc42, additional Ras- and/or Cdc42-
dependent signaling events were also needed. In fact, another downstream participant 
that contributed to the up-regulation of tTG expression was NFB (8). Blocking NFB 
activity in SKBR3 cells using the small molecule inhibitor BAY 11-7082 completely 
abolished the up-regulation of tTG expression by EGF treatment. Taken together, co-
signaling events from multiple small GTPases, such as Ras and Cdc42, leading to the 
activation of PI3K and NFB, provide a mechanism by which EGF up-regulates tTG 
in breast cancer cells.  
The fact that tTG up-regulation is crucial for EGF-mediated cell growth 
enhancement suggests that the signaling pathway(s) activated by tTG to promote 
SKBR3 cell growth very likely overlaps EGF-coupled signaling cascades. While I 
checked the tyrosine phosphorylation profile for lysates collected from SKBR3 cells 
overexpressing tTG or vector, a unique 60 kD protein exhibited a two-fold increase in 
its tyrosine phosphorylation, which led me to consider whether tTG promoted the 
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 phosphorylation and subsequent activation of Src (9), a well-established non-receptor 
tyrosine kinase of Mr ~60 kDa. Indeed, I was able to show that SKBR3 cells 
overexpressing wild-type tTG exhibited a significant increase in Src activity compared 
to cells overexpressing vector or the transamidation-deficient tTG (C277V) mutant, 
which further raised the question of how tTG activates Src in breast cancer cells. The 
classical model for Src activation starts with the recruitment of a phosphatase upon 
receiving upstream signals, which dephosphorylates a C-terminal tyrosine residue of 
Src (Tyr527) that normally forms an auto-inhibitory loop with the SH2 domain of Src 
(10). However, this classical model is unable to provide a straightforward explanation 
of how tTG activates Src because tTG neither exhibits phosphatase activity, nor has it 
been reported to activate a phosphatase.  
Several groups recently provided an unconventional mechanism for activating 
Src, namely through Src-binding proteins that displace the inhibitory loop away from 
the catalytic domain of Src, thereby driving it to assume its active conformation (10, 
11). I suspect that tTG activates Src though this type of mechanism because the 
association of tTG with Src was observed in multiple breast cancer cell lines. However, 
this association seems likely to be indirect due to the fact that recombinant tTG did not 
exhibit any binding affinity toward GST-tagged Src, as demonstrated by in vitro GST-
pull-down assays. Given that wild-type tTG, but not the transamidation-deficient 
mutant (C277V), is capable of activating Src, the formation of a proposed Src-
activating complex seems to require the transamidation-competent tTG. Efforts to 
search for candidate transamidation substrates of tTG led me to the intermediate 
filament protein K19. As a component of cytoskeleton-building blocks, the main 
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 functions of the keratins are believed to provide the mechanical support to maintain 
the desired cell shape (12, 13). However, recent studies revealed that keratins were 
also able to bind and regulate the activities of signaling effectors, thereby functioning 
as scaffold proteins to modulate a number of cellular events including metabolic 
responses, cell migration and cell growth (12-15). These findings prompted me to 
consider the possibility of K19 as the mediator for tTG-Src interactions in breast 
cancer cells. This in fact turned out to be the case, as shown by the result that 
knocking-down K19 expression seriously impaired the interaction between tTG and 
Src in SKBR3 cells. Furthermore, suppressing K19 expression greatly compromised 
the ability of tTG to activate Src and its ability to promote the anchorage-independent 
growth of SKBR3 cells. Thus, my findings showing that K19 bridges the interaction 
between tTG and Src, depict a novel signaling pathway that is used by cancer cells to 
obtain a growth advantage.  
However, many of the molecular details about how K19 mediates the 
interaction between tTG and Src remain to be determined. For instance, which part of 
K19 interacts with tTG and Src respectively? How does the catalytic site of tTG 
contribute to the activation of Src? Are there any additional components involved in 
this signaling complex? If so, what are their specific functions? Future works and 
efforts are needed to answer these follow-up questions.  
 
Cancer cell-derived microvesicles require tTG and fibronectin to induce the 
transformation of normal cells 
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 Microvesicles (MVs) are one type of unconventional cellular secretion 
structures that directly bud off from the plasma membrane (16, 17). It was frequently 
observed that several malignant cancer cell lines exhibited the phenotype of 
membrane-bound MVs (18-23), however, the cellular function associated with these 
cancer cell-derived MVs are poorly understood. In a recent report by Al-Nedawi, K et 
al., the authors showed that human glioblastoma cell line U373 transfected by EGFR 
VIII, an in-frame truncation of the EGFR that is constitutively active, shed MVs that 
contained this specific variant type of the EGFR (18). Interestingly, the secreted MVs, 
when collected from the conditioned medium, were capable of fusing to the recipient 
U373 cells that did not express EGFR VIII, thus conferring upon the recipient cells 
EGFR VIII-signaling capability. Building upon this finding, I hypothesized that cancer 
cell-derived MVs are not only able to dock to the same type of cancer cells from 
which they originated, thereby enhancing their oncogenic potential, but MVs are also 
able to interact and stimulate the oncogenic signaling in recipient normal (non-
transformed) cells, such as those that exist in the tumor microenvironment.  
To test this idea, MVs were collected from the conditioned medium of 
MDAMB231 breast cancer cells or U87 glioblastoma cells, the two human cancer cell 
lines that constitutively generate and shed MVs, and then added to normal NIH3T3 
fibroblasts. Surprisingly, it appeared that MDAMB231 and U87 cell-derived MVs 
were able to cause the recipient fibroblasts to acquire transformed phenotypes, as 
indicated by their enhanced survival rate under serum starvation and their abilities to 
form colonies in anchorage-independent culturing conditions. The fact that cancer 
cell-derived MVs are capable of inducing the transformation of normal fibroblasts 
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 highlights the necessity to identify the critical protein cargo that is responsible for this 
effect. 
Efforts to address this issue led me to perform the proteomic screening on the 
collected MV preps, with approximately 40 proteins being eventually identified as the 
common protein cargo shared by MDAMB231 and U87 cell-derived MVs. 
Interestingly, tTG was highlighted as one such cargo. My earlier findings showing that 
overexpression and activation of tTG is sufficient to promote the oncogenesis of 
human breast cancer cells raised the possibility that tTG might be one of the critical 
cargo used by MVs to confer the transforming properties onto NIH3T3 fibroblasts. To 
test this hypothesis, I took advantage of a commercially-available tTG inhibitor T101, 
a small-molecule that covalently modifies the active site of tTG. The fact that T101 
covalently modifies tTG allowed me to treat tTG-containing MVs during the 
purification steps, with MV-associated tTG remaining inactivated even after MVs 
were transferred to recipient cells, which provided me a great tool to examine the 
importance of tTG for MVs. Interestingly, the abilities of both types of MVs to induce 
cellular transformation were found to be severely inhibited after incubation with T101, 
suggesting that tTG is in fact a critical component for the transforming capabilities of 
cancer cell-derived MVs. At the same time, tTG expression was knocked down from 
MDAMB231 cells using two specific siRNAs, and the tTG-depleted MVs collected 
from these cells exhibited much less potency at inducing the transformation of 
NIH3T3 fibroblasts, which was consistent with the results obtained by using T101 
inhibitor.  
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 Although tTG is essential for the ability of cancer cell-derived MVs to 
transform normal cells, the ectopic expression of tTG in normal cells is not sufficient 
to trigger their cellular transformation. Efforts to identify additional MV cargo that 
cooperate with tTG to fully transform normal cells led me to fibronectin, another 
protein cargo contained in both MDAMB231 and U87-derived MVs. As one of the 
best-studied tTG substrates, fibronectin can be cross-linked into oligomers by tTG on 
the cell surface (24, 25), resulting in the recruitment and assembly of fibronectin-
bound 1-integrins whose clustering events would lead to the activation of Focal 
Adhesion Kinase (FAK) (26, 27).  
As one of the most-studied signaling “hubs” in cancer cells, activated FAK has 
been shown to be able to stimulate cell proliferation, migration and survival (28, 29), 
all of which are associated with a more transformed phenotype. To examine the 
possibility that tTG may cross-link fibronectin in MVs, Western blot analyses of 
fibronectin were performed on lysates collected from MDAMB231 cells and 
MDAMB231 cell-derived MVs. Surprisingly, the fibronectin dimer was only found to 
be present in MV lysates. Moreover, I was able to show that the amount of fibronectin 
dimer was sensitive to T101 treatment, suggesting that tTG is the particular enzyme 
that catalyzes the formation of fibronectin dimer in MVs. In line with this finding, 
FAK signaling is significantly enhanced within MV-treated NIH3T3 cells, while such 
a signaling increase can be potently inhibited by pre-treating MVs with the tTG 
inhibitor T101. This signaling profile was successfully mimicked by pre-treating MVs 
with RGD, a small peptide inhibitor that specifically disrupts the fibronectin-integrin 
interaction. All of these results suggested that tTG was functioning through the 
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 fibronectin-integrin-FAK-signaling pathway to help MVs confer the transforming 
properties onto normal cells. 
Although tTG and fibronectin were suggested to be the critical cargo involved 
in MV-mediated transformation, additional MV components may also contribute to 
this effect. For example, pyruvate kinase M2, one of the mitochondrial enzymes that 
participate in the metabolic reprogramming of cancer cells, is also present in MVs 
collected from MDAMB231 cells and U87 cells. In addition, MVs not only contain 
protein cargo but also carry mRNA transcripts, which may add another dimension to 
the cellular functions of MVs. Future studies focused on these issues will shed more 
light on the molecular mechanisms underlying the various biological outcomes 
triggered by MVs.  
 
RhoA-ROCK-LIMK signaling controls the biogenesis of MVs in cancer cells 
The newly-discovered importance of MVs in cancer progression underscores 
the demand to understand how they are generated from cancer cells. However, thus far, 
the molecular mechanism underlying this process is poorly understood. It was found 
that activated EGFR signaling is capable of inducing MV formation in several cancer 
cell lines including U373 glioblastoma cells, DU145 prostate cancer cells and HeLa 
cervical carcinoma cells (18, 19, 21). Although how the EGFR stimulates MV 
formation was unclear, several lines of evidence seemed to implicate signaling 
pathways that influence the cytoskeletal reorganization or actomyosin regulation (19, 
21). Among the many downstream effectors of the EGFR, the group of small GTPases 
including Ras, Rho, Rac and Cdc42 (30, 31), are best known for their ability to 
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 reorganize cytoskeletal structure. In order to determine whether any of these GTPases 
were linked to MV formation, I individually overexpressed the dominant-active forms 
of Rac, Cdc42, Ras or RhoA in HeLa cells and examined their ability to induce MV 
formation. Interestingly, overexpression of the dominant-active form of RhoA, but not 
Rac, Cdc42 or Ras, dramatically stimulated the formation and secretion of MVs. Since 
active RhoA is sufficient to induce MV formation, I then asked whether RhoA is also 
essential for the ability of EGF to trigger the MV production. By using two siRNAs 
specifically targeting RhoA, I found that knocking-down RhoA expression from HeLa 
cells completely abolished EGF-stimulated MV formation, suggesting that RhoA is 
both necessary and sufficient for controlling the biogenesis of MVs in cancer cells. 
The essential role of RhoA in regulating MV formation prompted me to search 
for its critical downstream effector(s) that is involved in this process. It was known 
that several protein targets can be activated by RhoA, including Rhotekin, Rhophilin, 
mDia, ROCK and PKN (32, 33). Among them, ROCK represents a highly attractive 
candidate because of its established function in cytoskeletal remodeling and 
actomyosin contraction (34). To examine the possible role of ROCK in MV formation, 
I took advantage of the ROCK-specific inhibitor Y-27632. Interestingly, treatment of 
MDAMB231 cells, U87 cells, or EGF-stimulated HeLa cells, with Y-27632 
completely eliminated the formation of MVs. Although attempts to knock-down 
ROCK expression had failed, overexpression of wild-type ROCK in HeLa cells, which 
is sufficient to activate ROCK signaling, dramatically stimulated MV formation.  
As the next step, I tried to further delineate the downstream pathways of 
ROCK that linked to MV production. There are two well-studied signaling targets of 
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 ROCK, namely Lim kinase (LIMK) and Myosin light chain phosphatase (MYLP) (33), 
both of which are able to regulate the cytoskeleton dynamics. Activated ROCK 
phosphorylates LIMK and MYLP, which respectively stimulates LIMK and inhibits 
MYLP activity (34, 35). Surprisingly, I found that either activating the LIMK pathway 
by overexpressing wild-type LIMK, or attenuating the effect of MYLP by 
overexpressing wild-type Myosin light chain kinase (MYLK), is sufficient to induce 
MV formation in HeLa cells. The fact that cancer cells have two signaling pathways 
that are capable of generating microvesicles then raised the question of whether cells 
prefer to use one pathway over the other, or a combination of both. To answer this 
question, I introduced the dominant-negative form of LIMK or MYLK into HeLa cells 
overexpressing the activated form of RhoA. While dominant-negative MYLK did not 
interfere the ability of RhoA to generate MVs, overexpression of dominant-negative 
LIMK significantly reduced the number of MV-producing cells triggered by activated 
RhoA. I went on to show that the preference of using LIMK as a MV-inducing 
pathway is not restricted to HeLa cells, because introducing the dominant-negative 
LIMK mutant also compromised the formation of 231 cell-derived MVs, while the 
MYLK mutant again exhibited little effect. To further confirm the importance of 
LIMK pathway to MV formation, LIMK expression was knocked down in 
MDAMB231 cells using two specific LIMK siRNAs, and I was able to show that the 
amount of MVs secreted from MDAMB231 cells dramatically decreased while LIMK 
expression was suppressed. As a conclusion, RhoA-ROCK signaling, one of the 
signature downstream pathways of EGFR that leads to LIMK activation, appears to be 
predominantly responsible for the biogenesis of MVs in cancer cells. 
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 Although the major driving force for MV formation has been attributed to 
RhoA-ROCK-LIMK signaling pathway, little is known about the cargo-sorting 
mechanism that accompanies with this process. Our proteomic screenings as well as 
studies from other groups (19, 21) suggest that MVs prefer to enrich specific types of 
cargo. Two follow-up questions are truly prompted by these findings: How is MV 
cargo selectively grouped and transported to the budding site? What signaling 
pathways are responsible to direct and package MV cargo? Understanding the 
molecular details of these processes will not only shed more light on the mechanism of 
MV formation, but should also provide potentially new targets for chemical 
intervention to block the biogenesis of MVs in cancer cells.  
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